Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
NOVEL 2,3-DIHYDRO-1H-IMIDAZO{1,2-a}PYRIMIDIN-5-ONE and this1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2013/190510
Kind Code:
A2
Abstract:
The invention relates to the novel products of formula (I) with p, q = 0, 1 or 2; R1 = phenyl, pyridyl; -(CH2) m -Ra; alkylene; cycloalkyl; heterocycloalkyl; alkyl; -SO2 -Rb; -CO-Re; m = 1 or 2; Ra = aryl, heteroaryl, -CO-cycloalkyl, -CO-heterocycloalkyl, -CO-Rb, -C(Rb)=N-ORc, -CO 2 Rd, -CONRxRy; Rb = alkyl, aryl, heteroaryl; Rc = H, alkyl; Rd = alkyl, cycloalkyl; Re = alkyl, cycloalkyl, aryl, heteroaryl; NRxRy with Rx,Ry = H, alkyl, cycloalkyl, alkoxy, phenyl, or form with N a ring with optionally O, N; R2, R3 = H, alkyl, CF 3, or form with C a ring with optionally O, S and N; R4 = H, F, Cl, CH3 or CN; the morpholine is substituted with Me, and optionally substituted with F, OH; or is (Formula 1a) and the isomer of configuration R,R (Formula 1b) these products being in all the isomer forms and the salts, as medicaments, in particular as anticancer medicaments.

Inventors:
EL-AHMAD YOUSSEF (FR)
FILOCHE-ROMME BRUNO (FR)
LETALLEC JEAN-PHILIPPE (FR)
MARCINIAK GILBERT (FR)
RONAN BAPTISTE (FR)
VIVET BERTRAND (FR)
Application Number:
IB2013/055099
Publication Date:
December 27, 2013
Filing Date:
June 21, 2013
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SANOFI SA (FR)
International Classes:
C07D233/46
Domestic Patent References:
WO2008148074A22008-12-04
WO2008064244A22008-05-29
WO2004016607A12004-02-26
WO2001053266A12001-07-26
WO2006109081A12006-10-19
WO2006109084A12006-10-19
WO2006126010A22006-11-30
WO2003024949A12003-03-27
WO2005058908A12005-06-30
WO2011001112A12011-01-06
WO2011001113A22011-01-06
WO2011001112A12011-01-06
WO2007097981A22007-08-30
Foreign References:
EP1460076A12004-09-22
EP1340761A12003-09-03
EP1454909A12004-09-08
Other References:
B. VANHAESEBROECK ET AL., NAT REV MOL CELL BIOL, 2010
X. ZHOU ET AL., PLOS ONE, 2011
N. JABER ET AL., PNAS, 2011
MS YOON ET AL., J CELL BIOL, 2011
EE JOHNSON ET AL., J CELL SCIENCE, 2005
N. JABER ET AL., PNAS, 2012
F. JANKU ET AL., NAT REV CLINICAL ONCOL, 2011
Y. MOSESSON, NAT REV CANCER, 2008
I. VERGNE, FEBS LETT, 2010
N. TAGUCHI-ATARASHI ET AL., TRAFFIC, 2010
S. TOOZE ET AL., NAT CELL BIOL, 2010
Z YANG ET AL., NAT CELL BIOL, 2010
QW. FAN ET AL., SINCE SIGNALING, 2010
A. GUPTA ET AL., PNAS, 2010
X LI ET AL., CANCER RES, 2010
A VAZQUEZ-MARTIN ET AL., PLOS ONE, 2009
Z. WU ET AL., GENES CANCER, 2010
B. VANHAESEBROEC ET AL., NAT REV MOL CELL BIOL, 2010
AP SAGONA ET AL., NAT CELL BIOL, 2010
P. STAHL; C. WERMUTH: "Handbook of pharmaceutical salts", WILEY
BRIGAUD, T. ET AL., J. ORG. CHEM., vol. 71, no. 18, 2006, pages 7075 - 7078
ROBERT M. WILLIAMS: "Synthesis of Optically Active a-Amino Acids", PERGAMON PRESS
P. PERLMUTTER: "Tetrahedron Organic Chemistry", vol. 9, PERGAMON PRESS, article "Conjugate Addition Reactions in Organic Synthesis"
LAROCK; RICHARD, C. ET AL.: "Comprehensive Organic Transformations A Guide to Functional Group Preparations", VCH
THEODORA W. GREENE; PETER G. M. WUTS: "Protective Groups in Organic Synthesis", WILEY-INTERSCIENCE
LAROCK, RICHARD, C. ET AL.: "Comprehensive Organic Transformations A Guide to Functional Group Preparations", VCH
THEODORA W. GREENE; PETER G. M. WUTS: "Protective Groups in Organic Synthesis Third Edition", WILEY- INTERSCIENCE
BADAWEY E.-S.A.M. ET AL., EUR J MED CHEM, vol. 33, no. 5, 1998, pages 349 - 361
YAMASHITA, A. ET AL., SYN. COMMUN., vol. 34, no. 5, 2004, pages 795 - 803
ALIABIEV S.B., LETT. ORG. CHEM., vol. 4, no. 4, 2007, pages 273 - 280
ULMANN, CHEM. BER., vol. 36, 1903, pages 2389
MITSUNOBU, O.: "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products", SYNTHESIS, 1981, pages 1 - 28
FAN ET AL., SINCE SIGNALING, 2010
JS SAMADDAR ET AL., MOL CANCER THER, 2008
B; HOANG ET AL., MOL CANCER THER, 2009
JS CAREW ET AL., BLOOD, 2007
J LI ET AL., EUR J OF CANCER, 2010
A. APPEL ET AL., CANCER RES, 2008
N. RABEN ET AL., AUTOPHAGY, 2010
B LEVINE ET AL., CELL, 2008
N. MIZUSHIMA ET AL., NATURE, 2008
I. VERGNE ET AL., FEBS LETT, 2010
Attorney, Agent or Firm:
BOURGOUIN-MULLER, Alessandra (Patent Department54 rue La Boétie, Paris, FR)
Download PDF:
Claims:
1 ) Products of formula (I):

in which: p and q are the integers 0 or 1 or 2 such that, if p = 0, then q = 1 or 2 and, if p = 1 or 2, then q = 0;

R1 is chosen from the following values a) to e): a) R1 is a phenyl or pyridyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cycloalkyl, alkyl and alkoxy radicals, the latter alkyl and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms; b) R1 is a -(CH2)m-Ra radical with m being the integer 1 or 2 and Ra an optionally substituted aryl or heteroaryl radical, or a -CO-cycloalkyl, -CO- heterocycloalkyl, -CO-Rb, -C(Rb)=N-ORc, -CO2Rd or -CONRxRy radical; c) R1 is an alkylene radical; cycloalkyl radical; heterocycloalkyl radical; or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, cycloalkyl, heterocycloalkyl, phenyl, pyridine and alkoxy radicals, the latter phenyl, pyridine and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms; d) R1 is an -SO2-Rb radical; e) R1 is a -CO-Re radical; Rb is an optionally substituted alkyl, cycloalkyl, aryl or heteroaryl radical; Rc is a hydrogen atom or an alkyl radical; Rd is an alkyl or cycloalkyl radical;

Re is an optionally substituted alkyl, cycloalkyle, heterocycloalkyi, aryl or heteroaryl radical;

NRxRy being such that Rx and Ry, which may be identical or different, are chosen from a hydrogen atom and alkyl, cycloalkyl, alkoxy and phenyl radicals; or Rx and Ry form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 7 ring members and optionally one or more other heteroatoms chosen from O, NH and N-alkyl;

R2 and R3, which may be identical or different, are chosen from a hydrogen atom and an alkyl radical optionally substituted with one or more fluorine atoms, it being understood that R2 and R3 are not both CF3 and R2 and R3 are not both hydrogen; or else R2 and R3 form, together with the carbon atom to which they are bonded, a cyclic radical containing from 3 to 6 ring members and optionally one or more other heteroatoms chosen from O, S and -NRz, this cyclic radical being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and oxo, Rz, -ORz and -NRzRz' radicals; with Rz and Rz', which may be identical or different, being a hydrogen atom or an alkyl, cycloalkyl or heterocycloalkyi radical;

R4 is a hydrogen atom, a fluorine or chlorine atom, a methyl radical or a CN radical; the morpholine residue is substituted with the radicals R5 to R12, which may be identical or different, chosen from a hydrogen atom and methyl and ethyl radicals optionally substituted with a fluorine atom or a hydroxyl radical, it being understood that, either at least one of R5 to R12 is not a hydrogen atom, or this morpholine residue contains a bridge defined as follows: R7 or R8 can form an ethylene bridge with R9 or R10, or else R7 or R8 can form a methylene bridge of absolute configuration R,R with R1 1 or R12, or else R5 or R6 can form a methylene bridge of absolute configuration R,R with R9 or R10 so as to give the following radicals: and the isomer of configuration R,R the aryl and heteroaryl radicals that Ra, Rb and Re may represent, and also the alkyl radicals that Rb and Re may represent, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cycloalkyl, heterocycloalkyl, heteroaryl and alkoxy radicals, the latter heteroaryl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals; the aryl and heteroaryl radicals that Ra, Rb and Re may represent being, in addition, optionally substituted with one or more alkyl radicals themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl and alkoxy radicals; all the cycloalkyl radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from a fluorine atom and alkyl radicals themselves optionally substituted with one or more fluorine atoms; all the heterocycloalkyl radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from a fluorine atom and alkyl radicals themselves optionally substituted with one or more fluorine atoms; all the heterocycloalkyl radicals being, in addition, optionally substituted with a CO2alk radical, where appropriate on a nitrogen atom; all the alkyl (alk), alkylene and alkoxy radicals above being linear or branched and containing at most 7 carbon atoms, it being understood that one or more of the hydrogen atoms of said products of formula (I) can be a deuterium atom; it being understood that, when p = 0 and one of R2 and R3 is an alkyl radical and the other an alkyl radical substituted with one or more fluorine atoms, then R1 is not a phenyl or pyridyl radical as defined in a) above, said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

2) Products of formula (I) as defined in Claim 1 , in which the morpholine residue is chosen from the following radicals:

,R

the radicals p, q, R1 , R2, R3 and R4 having the meanings indicated in Claim 1 , said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

3) Products of formula (I) as defined in Claim 1 or 2, in which p is the integer 0 and q is the integer 2 or else p is the integer 2 and q is the integer 0; the radicals R1 , R2, R3 and R4 and the morpholine residue having the meanings indicated in Claim 1 , said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

4) Products of formula (I) as defined in Claim 1 or 2, in which p is the integer 0 and q is the integer 1 or else p is the integer 1 and q is the integer 0; the radicals R1 , R2, R3 and R4 and the morpholine residue having the meanings indicated in Claim 1 , said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

5) Products of formula (I) as defined in Claim 1 or 2, in which: p and q are the integers 0 or 1 or 2 such that, if p = 0, then q = 1 or 2 and, if p = 1 or 2, then q = 0; R1 is a phenyl or pyridyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine atoms and cycloalkyi, alkyl and alkoxy radicals, the latter alkyl and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms; a -(CH2)m-Ra radical; an -SO2-phenyl radical optionally substituted with an alkyl radical; a -CO-alkyl radical; an alkylene radical; or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetane, tetrahydrofuran, tetrahydropyran, alkoxy, phenyl and pyridine radicals, the latter three radicals all being optionally substituted with one or more fluorine atoms; m is the integer 1 or 2;

Ra is a radical -CO-Rb; -C(cycloalkyl)=N-ORc; CO2Rd; -CONRxRy; a -CO- cyclopropyl, -CO-cyclobutyl, -CO-cyclopentyl or -CO-cyclohexyl radical, all optionally substituted with one or more alkyl radicals; a -CO-morpholine, -CO- piperidyl, -CO-tetrahydrofuran, -CO-tetrahydropyran or -CO-pyrrolidine radical, all optionally substituted with one or more alkyl radicals or a CO2alk radical, where appropriate on a nitrogen atom; or else a phenyl, pyridine, oxazole, isoxazole, oxadiazole, pyrazole, thiophene, thiazole, thiadiazole, pyridazine, benzimidazole, imidazopyridine or triazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cycloalkyi, heterocycloalkyl, heteroaryl, alkyl and alkoxy radicals, the latter heteroaryl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

Rb is an alkyl, phenyl, pyridyl, thiazole, isoxazole, oxazole or oxadiazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cycloalkyi, heterocycloalkyi, phenyl, heteroaryl, alkyl and alkoxy radicals, the latter phenyl, heteroaryl, heterocyloalkyl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

Rc is in particular a hydrogen atom or an alkyl radical;

Rd is an alkyl or cycloalkyi radical;

NRxRy are such that Rx and Ry, which may be identical or different, are a hydrogen atom or an alkyl, alkoxy or phenyl radical or else together form a piperidyl, morpholinyl, azetidine, oxaazaspiro[3.3]heptane, isoxazolidine or {1 ,2}oxazinane radical;

R2 and R3 are such that: either R2 is a hydrogen atom and R3 is the trifluoromethyl radical CF3; or R2 is a methyl radical and R3 is the trifluoromethyl radical CF3; or R2 and R3 are both a methyl radical;

R4 is a hydrogen atom, a fluorine or chlorine atom, a methyl radical or a CN radical; the morpholine residue is chosen from the following radicals:

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

6) Products of formula (I) as defined in any one of the other claims, corresponding to the following formulae:

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-3-Fluoro-9-(2-fluoropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-((S)-2-hydroxypropyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-5-ylmethyl-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(2-Chloropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetic acid ethyl ester

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3- ylmethyl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one - (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-[1 ,2,4]oxadiazol-5-ylmethyl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4- yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pynmidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-[1 ,2,4]oxadiazol-5- ylmethyl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-methoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3- ylmethyl)-6-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 2-[(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4- dihydro-2H,6H-pyrimido[1 ,2-a]pynmidin-1 -yl]-N-methoxy-N-methylacetamide

- (S)-9-(6-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(2-Fluoropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)- 6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-9-(3- tnfluoromethyl-[1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one - (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl- 6,7,8,9-tetrahydropynmido[1 ,2-a]pynmidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(5-methyl-

[1 ,2,4]oxadiazol-3-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2- a]pyrinnidin-5-one

- (S)-1 -(2-Cyclopropyl-2-oxoethyl)-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2- trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-(1 -Difluoromethyl-1 H-pyrazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-9-lsoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8- tnfluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-one, single stereoisomer - (S)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-isoxazol-5-ylmethyl-2-((R)-3-nnethylnnorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2,2,2-trifluoroethoxy)- ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(6-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one - (S)-9-(6-Chloropyridin-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-tert-Butyl-[1 ,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-[2-(3-fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin- 4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(3-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(2-Methoxypyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(6-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-9-lmidazo[1 ,2-a]pyridin-2-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(4-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-3-pyridin-2-ylpropyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-thiazol-2-ylethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-4-ylmethyl-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(5-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- 3-Fluoro-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2- ylethyl)-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8,8-dimethyl-2-((R)-3- methylnnorpholin-4-yl)-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- 3-Fluoro-9-isoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-8,8-dimethyl-2-((R)-3- methylnnorpholin-4-yl)-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Fluorophenyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one - (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-4-ylmethyl-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(6- tnfluoromethylpyndin-3-yl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(2,2,2-trifluoroethoxy)ethyl]-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(6-methylpyridin-3-yl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(6-lsopropoxypyridin-3-yl)-2-((R)-3-methylnnorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-5-ylmethyl-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one - (S)-9-(6-Cyclobutylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Cyclopropylpyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Methoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(5-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2,5-Dimethyloxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,3,4]oxadiazol-2-ylmethyl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one - (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Methylisoxazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(toluene-4-sulfonyl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-lsoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-lsoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-6-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one - (R)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-lsopropoxypyridin-4-yl)-2-((R)-3-methylnnorpholin-4-yl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(6-lsopropoxypyridin-3-yl)-2-((R)-3-methylnnorpholin-4-yl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-6-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (R)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)- 6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,3,4]thiadiazol-2-ylmethyl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-9-(6-Difluoromethoxypyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-[1 ,2,3]thiadiazol-5-ylmethyl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-9-(6-Difluoromethoxypyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4- yl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-6-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4- yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pynmidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxetan-3-ylmethyl-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 9-(6-Difluoromethylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydrofuran-2-yl)methyl]-8- tnfluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydrofuran-2-yl)methyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydropyran-2-yl)methyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydropyran-2-yl)methyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(5-trifluoromethyl- [1 ,3,4]oxadiazol-2-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1 ,3,4]oxadiazol-2-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-6-trifluoromethyl-9-(3-trifluoromethyl- [1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-6-trifluoromethyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)- 6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (R)-9-(3-Cyclopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-6-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-[1 ,2,4]oxadiazol-5- ylmethyl)-6-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(3,3-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5R)-3,5-dimethylmorpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one,

- single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5S)-3,5-dimethylmorpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((3S,5S)-3,5-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((3R,5R)-3,5- dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ^ a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-(3-methylisoxazol-5-ylmethyl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one - (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Chloropyndin-4-yl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-pyridin-3-yl-8-tnfluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(3,5-Difluorophenyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-9-(2-oxo-2-phenylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-5-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza- bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(1 -Difluoromethyl-1 H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza- bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-9-lsoxazol-3-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

- single stereoisomer

- (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(3,5-Difluorophenyl)-2-(3-hydroxymethylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(3-hydroxymethylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((S)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-2-ylethyl)-2- trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one - (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-3-ylethyl)-2- trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-1 -(2-Chloropyridin-4-ylmethyl)-2-methyl-7-((R)-3-methylmorpholin-4-yl)- 2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -oxazol-5-ylmethyl-2- trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -oxazol-4-ylmethyl-2- trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-1 -(2-Chloropyridin-4-ylmethyl)-6-fluoro-2-methyl-7-((R)-3- methylmorpholin-4-yl)-2-tnfluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2- a]pyrinnidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-2- oxobutyl)-2-trifluoronnethyl-2,3-dihydro-1 H-innidazo[1 ,2-a]pyrinnidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -[2-0X0-2- (tetrahydropyran-4-yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2- a]pyrinnidin-5-one

- (S)-1 -(2-Cyclopropyl-2-oxoethyl)-6-fluoro-2-methyl-7-((R)-3- methylmorpholin-4-yl)-2-tnfluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2- a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-2-oxobutyl)-2- trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-3- ylethyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -[2-oxo-2-(tetrahydropyran-4- yl)ethyl]-2-trifluoronnethyl-2,3-dihydro-1 H-innidazo[1 ,2-a]pyrinnidin-5-one - (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- N-Methoxy-N-methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2- trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1 ,2-a]pyrimidin-1 -yl]acetamide

- N-Methoxy-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4- dihydro-2H,6H-pyrimido[1 ,2-a]pyrimidin-1 -yl]acetamide

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8-trifluoromethyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-2- ylethyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-lsopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-9-(5-tert-Butyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-((S)-2-Hydroxypropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-(1 R,5S)-8-oxa-3-aza- bicyclo[3.2.1 ]oct-3-yl-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-

[1 ,2,4]oxadiazol-5-ylnnethyl)-2-tnfluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2- a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-[1 ,2,4]oxadiazol-5- ylmethyl)-2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8- tnfluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3- ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer - (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8-methyl-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-9-lsoxazol-3-ylmethyl-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-4-ylmethyl-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-ylmethyl-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-2-ylmethyl-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-[2-(4-Fluorophenyl)ethyl]-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-pyridin-2-ylethyl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- N,N-Dimethyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl- 3,4-dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetamide

- N-Methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4- dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetamide

- (S)-9-(6-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-9-(2-lsopropoxypyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-lsopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Cyclopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-tert-Butyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-lsopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-lsopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-2-ylmethyl-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-2-ylmethyl-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-1 -ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-(2-morpholin-4-yl-2-oxoethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(2-morpholin-4-yl-2-oxoethyl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]-N-phenylacetamide - (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-1 -ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-Acetyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(5-methyl-[1 ,2,4]oxadiazol-3- ylmethyl)-2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-thiazol-2-ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pynnnidin-1 -yl]acetic acid cyclopentyl ester

- (S)-9-(2-Cyclopentyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(5-isopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(5-Cyclopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one - (S)-3-Fluoro-9-(3-isopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(3-Cyclopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(3-tert-Butyl-[1 ,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-9-(3- tnfluoromethyl-[1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(1 -Methylcyclopentyl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pynnnidin-1 -yl]acetic acid isopropyl ester

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Fluoropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Cyclohexyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridazin-4-ylmethyl-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetic acid tert-butyl ester

- 2-{2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetyl}pyrrolidine-1 -carboxylic acid tert- butyl ester

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pyrinnidin-1 -yl]acetic acid methyl ester

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro- 2H,6H-pyrimido[1 ,2-a]pyrimidin-1 -yl]acetamide

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4H-[1 ,2,4]triazol-3-ylmethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-4-ylethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(3-Methylbut-2-enyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-[2-(3-Methylisoxazol-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydrofuran-3-yl)ethyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one - (S)-9-(5-Methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza- bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(3-methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza- bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-2-oxopentyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((S)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-2-((S)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-2-oxohexyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(4-methyl-2-oxopentyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-9-(3-Ethyl-2-oxopentyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(3-Ethyl-2-oxopentyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- [(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4- dihydro-2H,6H-pyrinnido[1 ,2-a]pynnnidin-1 -yl]acetic acid methyl ester

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one, single stereoisomer

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-2-oxohexyl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxopentyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(3-trifluoromethyl- [1 ,2,4]oxadiazol-5-ylrinethyl)-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2-oxa-6-azaspiro[3.3]hept- 6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin- 4-one

- (S)-3-Fluoro-9-[2-(5-methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrimidin-4-one

- (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-isoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- 9-lsoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-lsopropoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-2-((R)-3-Methylmorpholin-4-yl)-9-{2-[2-((R)-3-methylmorpholin-4-yl)- pyndin-4-yl]-2-oxoethyl}-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-9-{2-Cyclopropyl-2-[(Z)-hydroxyimino]ethyl}-2-((R)-3-methylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one, isomer

1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-hydroxyimino]ethyl}-2-((R)-3-methylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, isomer

2 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-methoxyimino]ethyl}-2-((R)-3-methylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, isomer

1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(Z)-methoxyimino]ethyl}-2-((R)-3-methylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, isomer

2 of undetermined configuration Z or E

- (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(4-methyltetrahydropyran-4-yl)-2- oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-[2-(5-Methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8^ trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-3-ylmethyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(6-oxa-1 -azaspiro[3.3]hept- 1 -yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrim 4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-[1 ,2]oxazinan-2-yl-2- oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-[1 ,2]oxazinan-2-yl-2-oxoethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-lsoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(2-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one, diastereoisomer 1 of undeternnined absolute configuration on the asymmetric carbon of the morpholine

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((S)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(2-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine - (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one,

diastereoisonner 1 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylnnorpholin-4-yl)-8- thfluoromethyl-6,7,8,9-tetrahydropyhmido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 2 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin-4-yl)-8- thfluoromethyl-6,7,8,9-tetrahydropyhmido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 1 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin-4-yl)-8- thfluoromethyl-6,7,8,9-tetrahydropyhmido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 2 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-8- thfluoromethyl-6,7,8,9-tetrahydropyhmido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-nnethylnnorpholin-4-yl)-8- thfluoromethyl-6,7,8,9-tetrahydropyhmido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 1 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-nnethylnnorpholin-4-yl)-8- thfluoromethyl-6,7,8,9-tetrahydropyhmido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 2 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(1 -oxa-6-azaspiro[3.3]hept-6-yl)-2- oxoethyl]-8-thfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyhmidin-4-one - (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one,

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain - (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(1 -oxa-6-azaspiro[3.3]hept- 6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-

4-one and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

7) Process for preparing the products of formula (I) as defined in any one of the other claims, according to scheme 2 as defined hereinafter:

Scheme 2:

in which the substituents n, p, q, PG, R1 , R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 , R12 and alkyl have the meanings indicated for the products of formula (I) in any one of Claims 1 to 5.

8) As medicaments, the products of formula (I) as defined in any one of Claims 1 to 6, and also the pharmaceutically acceptable addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

9) As medicaments, the products of formula (I) as defined in Claim 6, and also the pharmaceutically acceptable addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

10) Pharmaceutical compositions containing, as active ingredient, at least one of the products of formula (I) as defined in any one of Claims 1 to 6, or a pharmaceutically acceptable salt of this product or a prodrug of this product and a pharmaceutically acceptable carrier.

1 1 ) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment or prevention of a disease chosen from the following group: blood vessel proliferation disorders, fibrotic disorders, "mesangial" cell proliferation disorders, metabolic disorders, allergies, asthma, thrombosis, nervous system diseases, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration and cancers.

12) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of cancers. 13) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of solid or liquid tumours.

14) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of cancers resistant to cytotoxic agents.

15) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of primary tumours and/or of metastases, in particular in gastric, hepatic, renal, ovarian, colon, prostate and lung (NSCLC and SCLC) cancers, glioblastomas, thyroid, bladder and breast cancers, in melanoma, in lymphoid or myeloid haematopoietic tumours, in sarcomas, in brain, larynx and lymphatic system cancers, bone and pancreatic cancers, and in hamartomas.

16) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in cancer chemotherapy.

17) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in cancer chemotherapy alone or in combination.

18) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of lysosomal diseases such as glycogenosis type II (or Pompe's disease) or Danon disease. 19) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of X-linked myotubular myopathies and Charcot- Marie-Tooth disease.

20) As novel industrial products, the starting products or synthesis

intermediates as defined in Claim 7 as follows:

- of formulae A, B, G and N:

A B a in which n = 1 , one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and PG is a protective group for amine;

- of formulae E, F, I and J:

in which q = 0, one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and the substituents p, PG, R1 and R4 have the definitions indicated in any one of Claims 1 to 5;

- of formulae P and H: in which the substituents n, p, q, PG, R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 and R12 have the definitions indicated in any one of Claims 1 to 5;

- of formula Q:

in which either q = 0, one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and the substituents p, PG, R1 and R4 have the definitions indicated in any one of Claims 1 to 5, or R1 is - (CH2)m-Ra with Ra being -CO-cycloalkyl, -CO-heterocycloalkyl, -CO-Rb, - C(Rb)=N-ORc, -CO2Rd or -CONRxRy, and the substituents p, q, R2, R3 and R4 have the definitions indicated in any one of Claims 1 to 5.

Description:
NOVEL 2.3-DIHYDRO-1 H-IMIDAZOI1 .2-a)PYRIMIDIN-5-ONE and thisl ,2,3,4-TETRAHYDROPYRIMIDOH ,2-a)PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF The present invention relates to novel 2,3-dihydro-1 H-imidazo{1 ,2-a} pyrimidin-5-one and 1 ,2,3,4-tetrahydropyrinnido{1 ,2-a}pyhmidin-6-one chemical compounds comprising a substituted morpholine, to pyrimidinone derivatives, to the process for preparing same, to the novel intermediates obtained, to the use thereof as medicaments, to the pharmaceutical compositions containing them and to the novel use of such derivatives.

The present invention thus also relates to the use of said derivatives for preparing a medicament intended for treating humans.

More particularly, the invention relates to novel pyrimidinone derivatives and to the pharmaceutical use thereof for preventing and treating conditions capable of being modulated by inhibiting the Vps34/PIK3C3 pathway. Vps34/PIK3C3 is a key contributor in autophagy. Vps34/PIK3C3 is also involved in phenomena of vesicular trafficking such as endocytosis and phagocytosis (B. Vanhaesebroeck et al. Nat Rev Mol Cell Biol 2010). Vps34 also has a role in the signalling of the mTOR protein (X. Zhou et al. Plos One 201 1 , N. Jaber et al . PNAS 201 1 , MS Yoon et al. J Cell Biol 201 1 ). Finally, Vps34 has been shown to be involved in cell proliferation (EE Johnson et al. J Cell Science 2005, X. Zhou et al. Plos One 201 1 , N. Jaber et al. PNAS 2012).

Inhibition and regulation of the Vps34/PIK3C3 pathway constitutes in particular a new mechanism of action for treating a large number of cancer diseases including solid and liquid tumours.

Role of the VPS34/PI K3C3 pathway

The Vps34/PIK3C3 signalling pathway is a complex network which regulates multiple cell functions summarised under the name vesicular trafficking (B. Vanhaesebroeck et al. Nat Rev Mol Cell Biol 2010). This signalling pathway is an important target in the treatment of cancer, since vesicular trafficking phenomena such as autophagy, endocytosis and phagocytosis are modified in human tumours (F. Janku et al. Nat Rev Clinical Oncol 201 1 , Y. Mosesson Nat Rev Cancer 2008).

The class III PI3K lipid kinase (Vps34/PIK3C3) forms a heterodimer with the Vps15 protein. Vps15 is a protein which is myristoylated, thus enabling the Vps34/Vps15 complex to be anchored in membranes. This heterodimer is found in various multiprotein complexes, thus underlining its various biological functions (B. Vanhaesebroeck et al. Nat Rev Mol Cell Biol 2010). Vps34/PIK3C3 phosphorylates phosphatidylinositol (PI) on the position 3 of the inositol, so as to give phosphatidylinositol 3 phosphate (PI3P). PI3P is a secondary messenger. Myotubularin (MTM) phosphatase lipids dephosphorylate PI3P on position 3. Among the 16 MTMs described, the MTMR3, 6, 7 and 14 (JUMPY) proteins are thought to be involved in the inhibition of autophagosome formation and therefore of autophagy (I. Vergne FEBS Lett 2010, N. Taguchi-Atarashi et al . Traffic 2010).

Role of Vps34/PIK3C3 in autophagy

The PI3P formed by Vps34/PIK3C3 is a key secondary messenger in autophagosome formation by the recruitment of proteins such as WIPI, DFCP1 and Alfy (S. Tooze et al, Nat Cell Biol 2010). The autophagosomes formed will then fuse with lysosomes, making it possible to degrade constituents of the cytoplasm (organelles, long-lived proteins, etc.) (Z Yang et al. Nat Cell Biol 2010).

Autophagy is a mechanism of cell survival which enables the cell to survive in a situation of stress, for instance faced with a metabolic stress. In the case of cancer, autophagy is implicated in the resistance of tumour cells faced with environmental stresses, such as: hypoxia, oxidative stresses, nutrient deficiency, but also faced with therapeutic stresses: treatments with anticancer agents, ionizing radiation. Furthermore, this signalling pathway is a major factor of resistance to chemotherapy, to radiotherapy and to targeted therapies such as inhibitors of EGFR, HER2 or Bcr-Abl for example (QW. Fan et al., Since signaling 2010, A. Gupta et al. PNAS 2010, X Li et al. Cancer Res 2010, A Vazquez-Martin et al. PLos One 2009, Z. Wu et al. Genes Cancer 2010).

Role of Vps34/PIK3C3 in endocytosis At the endosome level, PI3P makes it possible to recruit molecules bearing FYVE (Fab1 YOTB, Vac1 and EEA1 ) or PX (Phox-homology) motifs, such as EEA1 , HRS or SNXs, thus resulting in the fusion of endocytic vesicles. The Vps34/PIK3C3 protein has been described as being involved in the endosomal trafficking of certain transmembrane receptors such as receptor tyrosine kinases (EGF receptor, PDGF receptor) or the transferrin receptor, for example (B. Vanhaesebroeck et al . Nat Rev Mol Cell Biol 2010). Finally, Vps34, via the regulation of endosomes, has been shown to participate in the cytokinesis phenomenon during cell division (AP Sagona et al. Nat Cell Biol 2010). Role of Vps34/PIK3C3 in phagocytosis

PI3P is also generated at the membranes of phagosomes. The role of the Vps34/PIK3C3 protein does not appear to be involved in phagosome membrane initiation, but in phagosome maturation. Finally, the PI3P formed by the Vps34/PIK3C3 protein is thought to be involved in the activation of NADPH oxidase at the phagosome level (B. Vanhaesebroeck et al. Nat Rev Mol Cell Biol 2010).

Kinase-inhibiting morpholinopyrimidinone derivatives are known to those skilled in the art.

Application WO2008/148074 describes products which have an mTOR-inhibiting activity. These products are pyrido[1 ,2-a]pyrimidin-4-ones which differ from the products of the present invention owing to their entirely aromatic nature and to their substitutions.

Application WO2008/064244 describes the application of the ΡΙ3Κβ- inhibiting products TGX-221 and TGX-155 which are of use in the treatment of cancer, and in particular in breast cancer. These products are pyrido[1 ,2- a]pyrimidin-4-ones previously described in applications WO2004/016607 and WO2001 /053266, which differ from the products of the present invention owing to their entirely aromatic nature and to their substitutions.

Applications WO2006/109081 , WO2006/109084 and WO2006/126010 describe DNA-PK-inhibiting products which are of use in the treatment of ATM deficient cancers. These products are pyrido[1 ,2-a]pyrimidin-4-ones which differ from the products of the present invention owing to their entirely aromatic nature and to their substitutions.

Application WO2003/024949 describes DNA-PK-inhibiting products which are of use in the treatment of ATM deficient cancers. These products are pyrido[1 ,2-a]pyrimidin-4-ones which differ from the products of the present invention owing to their entirely aromatic nature and to their substitutions.

The subject of the present invention is the products of formula (I):

in which: p and q are the integers 0 or 1 or 2 such that, if p = 0, then q = 1 or 2 and, if p = 1 or 2, then q = 0;

R1 is chosen from the following values a) to e): a) R1 is a phenyl or pyridyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cycloalkyl, alkyl and alkoxy radicals, the latter alkyl and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms; b) R1 is a -(CH 2 ) m -Ra radical with m being the integer 1 or 2 and Ra an optionally substituted aryl or heteroaryl radical, or a -CO-cycloalkyl, -CO- heterocycloalkyl, -CO-Rb, -C(Rb)=N-ORc, -CO2Rd or -CONRxRy radical; c) R1 is an alkylene radical; cycloalkyl radical; heterocycloalkyi radical; or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, cycloalkyl, heterocycloalkyi, phenyl, pyridine and alkoxy radicals, the latter phenyl, pyridine and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms; d) R1 is an -SO 2 -Rb radical; e) R1 is a -CO-Re radical;

Rb is an optionally substituted alkyl, cycloalkyl, aryl or heteroaryl radical; Rc is a hydrogen atom or an alkyl radical; Rd is an alkyl or cycloalkyl radical;

Re is an optionally substituted alkyl, cycloalkyle, heterocycloalkyi, aryl or heteroaryl radical;

NRxRy being such that Rx and Ry, which may be identical or different, are chosen from a hydrogen atom and alkyl, cycloalkyl, alkoxy and phenyl radicals; or Rx and Ry form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 7 ring members and optionally one or more other heteroatoms chosen from O, NH and N-alkyl;

R2 and R3, which may be identical or different, are chosen from a hydrogen atom and an alkyl radical optionally substituted with one or more fluorine atoms, it being understood that R2 and R3 are not both CF 3 and R2 and R3 are not both hydrogen; or else R2 and R3 form, together with the carbon atom to which they are bonded, a cyclic radical containing from 3 to 6 ring members and optionally one or more other heteroatoms chosen from O, S and -NRz, this cyclic radical being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and oxo, Rz, -ORz and -NRzRz' radicals; with Rz and Rz', which may be identical or different, being a hydrogen atom or an alkyl, cycloalkyl or heterocycloalkyi radical; R4 is a hydrogen atom, a fluorine or chlorine atom, a methyl radical or a CN radical; the morpholine residue is substituted with the radicals R5 to R12, which may be identical or different, chosen from a hydrogen atom and methyl and ethyl radicals optionally substituted with a fluorine atom or a hydroxyl radical, it being understood that, either at least one of R5 to R12 is not a hydrogen atom, or this morpholine residue contains a bridge defined as follows: R7 or R8 can form an ethylene bridge with R9 or R10, or else R7 or R8 can form a methylene bridge of absolute configuration R,R with R1 1 or R12, or else R5 or R6 can form a methylene bridge of absolute configuration R,R with R9 or R10 so as to give the following radicals: and the isomer of configuration R,R the aryl and heteroaryl radicals that Ra, Rb and Re may represent, and also the alkyl radicals that Rb and Re may represent, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cycloalkyl, heterocycloalkyl, heteroaryl and alkoxy radicals, the latter heteroaryl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals; the aryl and heteroaryl radicals that Ra, Rb and Re may represent being, in addition, optionally substituted with one or more alkyl radicals themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl and alkoxy radicals; all the cycloalkyl radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from a fluorine atom and alkyl radicals themselves optionally substituted with one or more fluorine atoms; all the heterocycloalkyl radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from a fluorine atom and alkyl radicals themselves optionally substituted with one or more fluorine atoms; all the heterocycloalkyl radicals being, in addition, optionally substituted with a CO2alk radical, where appropriate on a nitrogen atom; all the alkyl (alk), alkylene and alkoxy radicals above being linear or branched and containing at most 7 carbon atoms, it being understood that one or more of the hydrogen atoms of said products of formula (I) can be a deuterium atom; it being understood that, when p = 0 and one of R2 and R3 is an alkyl radical and the other an alkyl radical substituted with one or more fluorine atoms, then R1 is not a phenyl or pyridyl radical as defined in a) above, said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

Thus, in the products of formula (I) as defined above, R2 and R3, which may be identical or different, are such that R2 is a hydrogen atom or an alkyl radical optionally substituted with one or more fluorine atoms and R3 is an alkyl radical optionally substituted with one or more fluorine atoms, it being understood that R2 and R3 are not both CF 3 ; or else R2 and R3 form, together with the carbon atom to which they are bonded, a cyclic radical as defined above.

A subject of the present invention is the products of formula (I) as defined above, in which the morpholine residue is chosen from the following radicals: .

the radicals p, q, R1 , R2, R3 and R4 having the meanings indicated above, said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

A subject of the present invention is thus the products of formula (I) as defined above, in which p is the integer 0 and q is the integer 2 or else p is the integer 2 and q is the integer 0; the radicals R1 , R2, R3 and R4 and the morpholine residue having the meanings indicated above, said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

A subject of the present invention is thus the products of formula (I) as defined above, in which p is the integer 0 and q is the integer 1 or else p is the integer 1 and q is the integer 0; the radicals R1 , R2, R3 and R4 and the morpholine residue having the meanings indicated above, said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

In the products of formula (I) according to the present invention,

- the term alkyl (or alk) radical denotes linear and branched radicals containing from 1 to 10 carbon atoms, such as: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl and also heptyl, octyl, nonyl and decyl, and also the linear or branched positional isomers thereof: preference is given to the alkyl radicals containing from 1 to 6 carbon atoms and more particularly the alkyl radicals containing from 1 to 4 carbon atoms of the list above; - the term alkenyl radical denotes linear and branched radicals containing from 2 to 10 carbon atoms, chosen from the alkyl radicals defined above containing one or more double bonds, such as allyl, but-3-enyl or pent- 4-enyl, and also the linear or branched positional isomers thereof: preference is given to the allyl and but-3-enyl radicals; -the term alkoxy radical denotes the linear and branched radicals, containing from 1 to 10 carbon atoms, methoxy, ethoxy, propoxy, isopropoxy, linear, secondary or tertiary butoxy, pentoxy or hexoxy, and also the linear or branched positional isomers thereof: preference is given to the alkoxy radicals containing from 1 to 4 carbon atoms of the list above; -the term alkythio or -S(O)x alkyl denotes the linear, and where appropriate branched, radicals in which the alkyl residue has the definition indicated above for the alkyl radical; -S(O)x alkyl thus in particular represents -S(O)x methyl, -S(O)x ethyl, -S(O)x propyl, -S(O)x isopropyl, linear, secondary or tertiary -S(O)x butyl, -S(O)x pentyl or -S(O)x hexyl and also the linear or branched positional isomers thereof: preference is given to the -S(O)x alkyl radicals containing from 1 to 4 carbon atoms of the list above;

-the term halogen atom denotes chlorine, bromine, iodine or fluorine atoms and preferably the chlorine, bromine or fluorine atom; -the term cycloalkyl radical denotes a saturated carbocyclic radical containing from 3 to 10 carbon atoms, and thus denotes in particular the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals and quite particularly the cyclopropyl, cyclopentyl and cyclohexyl radicals;

- in the -O-cycloalkyl radical, the cycloalkyl radical is as defined above; -the term heterocycloalkyl radical thus denotes a monocyclic or bicyclic carbocyclic radical containing from 3 to 10 ring members, interrupted by one or more heteroatoms, which may be identical or different, chosen from oxygen, nitrogen or sulfur atoms: mention may, for example, be made of morpholinyl, thiomorpholinyl, homomorpholinyl, aziridyl, azetidyl, piperazinyl, piperidyl, homopiperazinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuryl, tetrahydrothienyl, tetrahydropyran, oxodihydropyridazinyl, or else oxetanyl radicals, all these radicals being optionally substituted; mention may in particular be made of morpholinyl, thiomorpholinyl, homomorpholinyl, piperazinyl, piperidyl, homopiperazinyl or else pyrrolidinyl radicals; -the terms aryl and heteroaryl denote monocyclic or bicyclic, respectively, carbocyclic and heterocyclic, unsaturated or partially unsaturated radicals containing at most 12 ring members, which can optionally contain a -C(O) ring member, the heterocyclic radicals containing one or more heteroatoms, which may be identical or different, chosen from O, N or S with N, where appropriate, optionally substituted;

-the term aryl radical thus denotes monocyclic or bicyclic radicals containing from 6 to 12 ring members, such as, for example, phenyl, naphthyl, biphenyl, indenyl, fluorenyl and anthracenyl radicals, more particularly phenyl and naphthyl radicals and even more particularly the phenyl radical. It may be noted that a carbocyclic radical containing a -C(O) ring member is, for example, the tetralone radical;

- the term heteroaryl radical thus denotes monocyclic or bicyclic radicals containing from 5 to 12 ring members: monocyclic heteroaryl radicals such as, for example, the radicals: thienyl such as 2-thienyl and 3-thienyl, furyl such as 2-furyl or 3-furyl, pyrannyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, pyridyl such as 2-pyridyl, 3-pyridyl and 4-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, isothiazolyl, diazolyl, thiadiazolyl, triazolyl, thiatriazolyl, oxadiazolyl, isoxazolyl such as 3- or 4-isoxazolyl, furazanyl, free or salified tetrazolyl, all these radicals being optionally substituted, among which are more particularly the radicals: thienyl such as 2-thienyl and 3-thienyl, thiazolyl, furyl such as 2-furyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, pyridazinyl, these radicals being optionally substituted; bicyclic heteroaryl radicals such as, for example, the radicals: benzothienyl (benzothiophene) such as 3- benzothienyl, benzothiazolyl, quinolyl, isoquinolyl, dihydroquinolyl, quinolone, tetralone, adamentyl, benzofuryl, isobenzofuryl, dihydrobenzofuran, ethylenedioxyphenyl, thianthrenyl, benzopyrrolyl, benzimidazolyl, imidazopyridine, benzoxazinyl, benzoxazolyl, thionaphthyl, indolyl, dihydroindolyl, azaindolyl, indazolyl, purinyl, thienopyrazolyl, tetrahydroindazolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, dihydropyrrolopyridyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, tetrahydropyridinopyrazolyl or oxodihydropyridinopyrazolyl, all these radicals being optionally substituted.

As examples of heteroaryl or bicyclic radicals, mention may be made more particularly of pyrimidinyl, pyridyl, pyrrolyl, azaindolyl, indazolyl or pyrazolyl, benzothiazolyl or benzimidazolyl radicals optionally substituted with one or more substituents, which may be identical or different, as indicated above. The carboxy radical(s) of the products of formula (I) may be salified or esterified with the various groups known to those skilled in the art, among which mention may be made, for example, of:

-among the salification compounds, inorganic bases such as, for example, an equivalent of sodium, of potassium, of lithium, of calcium, of magnesium or of ammonium, or organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N,N- dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine or N-methylglucamine,

-among the esterification compounds, the alkyl radicals for forming alkoxycarbonyl groups, such as, for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl or benzyloxycarbonyl, it being possible for these alkyl radicals to be substituted with radicals chosen, for example, from halogen atoms, and hydroxyl, alkoxy, acyl, acyloxy, alkylthio, amino or aryl radicals, for instance in the chloromethyl, hydroxypropyl, methoxymethyl, propionyloxymethyl, methylthiomethyl, dimethylaminoethyl, benzyl or phenethyl groups.

The compounds of formula (I) can exist in the salt form, such salts being part of the invention; these salts can be prepared with pharmaceutically acceptable acids or bases (P. Stahl, C. Wermuth; Handbook of pharmaceutical salts; Wiley Ed.), but other salts, obtained, for example, for the purification or isolation of the compounds of formula (I), are part of the invention. The compounds of formula (I) can comprise one or more asymmetric centres. They can therefore exist in the form of enantiomers or diastereoisomers. These enantiomers, diastereoisomers and also mixtures thereof, including racemic mixtures, are part of the invention.

It may be recalled that the stereoisomerism can be defined in its broad sense as the isomerism of compounds having the same structural formula, but the various groups of which are arranged differently in space, such as, in particular, in monosubstituted cyclohexanes, the substituent of which can be in the axial or equatorial position, and the various possible rotational conformations of ethane derivatives. However, there is another type of stereoisomerism, owing to the different spatial arrangements of substituents attached either on double bonds or on rings, which is often referred to as geometric isomerism or cis-trans isomerism. The term stereoisomers is used in the present application in its broadest sense and therefore relates to all of the compounds indicated above. In the products of formula (I) according to the present invention, when R1 is an optionally substituted phenyl or pyridyl radical, then in particular R1 is a phenyl or pyridyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine atoms and cycloalkyl, alkyl and alkoxy radicals, the latter alkyl and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms, the other substituents R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 , R12, p and q of said products of formula (I) having the meanings indicated above.

In the products of formula (I) according to the present invention, when R1 is a -(CH 2 )m-Ra radical, then m is the integer 1 or 2 and in particular Ra is a radical -CO-Rb; -C(cycloalkyl)=N-ORc; CO 2 Rd; -CONRxRy; a -CO- cyclopropyl, -CO-cyclobutyl, -CO-cyclopentyl or -CO-cyclohexyl radical, all optionally substituted with one or more alkyl radicals; a -CO-morpholine, -CO- piperidyl, -CO-tetrahydrofuran, -CO-tetrahydropyran or -CO-pyrrolidine radical, all optionally substituted with one or more alkyl radicals or a CO 2 alk radical, where appropriate on a nitrogen atom; or else a phenyl, pyridine, oxazole, isoxazole, oxadiazole, pyrazole, thiophene, thiazole, thiadiazole, pyridazine, benzimidazole, imidazopyridine or triazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cycloalkyl, heterocycloalkyl, heteroaryl, alkyl and alkoxy radicals, the latter heteroaryl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

Rb is an alkyl, phenyl, pyridyl, thiazole, isoxazole, oxazole or oxadiazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cycloalkyl, heterocycloalkyl, phenyl, heteroaryl, alkyl and alkoxy radicals, the latter phenyl, heteroaryl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals; Rc is in particular a hydrogen atom or an alkyl radical;

Rd is an alkyl or cycloalkyl radical; and NRxRy being as defined above or hereinafter; the other substituents R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 , R12, p and q of said products of formula (I) having the meanings indicated above. In the products of formula (I) according to the present invention, when NRxRy forms a ring as defined above, such an aminated ring can be chosen in particular from piperidyl, morpholinyl, homomorpholinyl, azetidine, oxaazaspiro[3.3]heptane, isoxazolidine, {1 ,2}oxazinane, pyrrolidinyl, pyrazolidinyl, pyrazolinyl, azepinyl, piperazinyl or homopiperazinyl radicals, these radicals being themselves optionally substituted as indicated above or hereinafter.

More particularly, when NRxRy forms a ring as defined above, such an aminated ring can be chosen in particular from piperidyl, morpholinyl, azetidine, oxaazaspiro[3.3]heptane, isoxazolidine or {1 ,2}oxazinane radicals. In the products of formula (I) according to the present invention, when R1 is the SO 2 Rb radical, then R1 is in particular the -SO 2 -phenyl radical optionally substituted with an alkyl radical or a halogen atom, the other substituents R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 , R12, p and q of said products of formula (I) having the meanings indicated above. In the products of formula (I) according to the present invention, when R1 is an alkyl radical, then in particular R1 is an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetane, tetrahydrofuran, tetrahydropyran, alkoxy, phenyl and pyridine radicals, the latter three radicals all being optionally substituted with one or more fluorine atoms, the other substituents R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 , R12, p and q of said products of formula (I) having the meanings indicated above. In the products of formula (I) according to the present invention, when R1 is a cycloalkyl radical, then R1 is in particular a cyclobutyl, cyclopentyl or cyclohexyl radical, the other substituents R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 , R12, p and q of said products of formula (I) having the meanings indicated above. In the products of formula (I) according to the present invention, when R1 is a heterocycloalkyl radical, then R1 is in particular an oxetane, tetrahydrofuran or tetrahydropyran radical, the other substituents R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 , R12, p and q of said products of formula (I) having the meanings indicated above. In the products of formula (I) according to the present invention, in particular R2 and R3 may be such that R2 is a hydrogen atom and R3 is the trifluoromethyl radical CF 3 , the other substituents R1 , R4, R5, R6, R7, R8, R9, R10, R1 1 , R12, p and q of said products of formula (I) having the meanings indicated above. In the products of formula (I) according to the present invention, in particular R2 and R3 may be such that R2 is a methyl radical and R3 is the trifluoromethyl radical CF 3 , the other substituents R1 , R4, R5, R6, R7, R8, R9, R10, R1 1 , R12, p and q of said products of formula (I) having the meanings indicated above. In the products of formula (I) according to the present invention, in particular R2 and R3 may be such that R2 and R3 are both a methyl radical, the other substituents R1 , R4, R5, R6, R7, R8, R9, R10, R1 1 , R12, p and q of said products of formula (I) having the meanings indicated above. In the products of formula (I) according to the present invention, one or more of the hydrogen atoms that R4, R5, R6, R7, R8, R9, R10, R1 1 and R12 of said products of formula (I) may represent can be a deuterium atom.

In the products of formula (I) according to the present invention, the cyclic radical that R2 and R3 may optionally form with the carbon atom to which they are bonded, as defined above, can thus be a carbocyclic (spirocycloalkyl) radical such as the spirocyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl radical, or else be a heterocyclic radical such as, for example, the oxetane radical, all these radicals being optionally substituted as defined above. In the products of formula (I) according to the present invention, when NRxRy forms a ring as defined above, such an aminated ring can be chosen in particular from pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, azepinyl, morpholinyl, homomorpholinyl, piperazinyl or homopiperazinyl radicals, these radicals being themselves optionally substituted as indicated above or hereinafter.

A subject of the present invention is the products of formula (I) as defined above, in which: p and q are the integers 0 or 1 or 2 such that, if p = 0, then q = 1 or 2 and, if p = 1 or 2, then q = 0; R1 is a phenyl or pyridyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine atoms and cycloalkyi, alkyi and alkoxy radicals, the latter alkyi and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms; a -(CH 2 ) m -Ra radical; an -SO 2 -phenyl radical optionally substituted with an alkyi radical; a -CO-alkyl radical; an alkylene radical; or an alkyi radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetane, tetrahydrofuran, tetrahydropyran, alkoxy, phenyl and pyridine radicals, the latter three radicals all being optionally substituted with one or more fluorine atoms; m is the integer 1 or 2;

Ra is a radical -CO-Rb; -C(cycloalkyl)=N-ORc; CO 2 Rd; -CONRxRy; a -CO- cyclopropyl, -CO-cyclobutyl, -CO-cyclopentyl or -CO-cyclohexyl radical, all optionally substituted with one or more alkyl radicals; a -CO-morpholine, -CO- piperidyl, -CO-tetrahydrofuran, -CO-tetrahydropyran or -CO-pyrrolidine radical, all optionally substituted with one or more alkyl radicals or a CO2alk radical, where appropriate on a nitrogen atom; or else a phenyl, pyridine, oxazole, isoxazole, oxadiazole, pyrazole, thiophene, thiazole, thiadiazole, pyridazine, benzimidazole, imidazopyridine or triazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cycloalkyl, heterocycloalkyl, heteroaryl, alkyl and alkoxy radicals, the latter heteroaryl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

Rb is an alkyl, phenyl, pyridyl, thiazole, isoxazole, oxazole or oxadiazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cycloalkyl, heterocycloalkyl, phenyl, heteroaryl, alkyl and alkoxy radicals, the latter phenyl, heteroaryl, heterocyloalkyl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

Rc is in particular a hydrogen atom or an alkyl radical; Rd is an alkyl or cycloalkyl radical; NRxRy are such that Rx and Ry, which may be identical or different, are a hydrogen atom or an alkyl, alkoxy or phenyl radical or else together form a piperidyl, morpholinyl, azetidine, oxaazaspiro[3.3]heptane, isoxazolidine or {1 ,2}oxazinane radical;

R2 and R3 are such that: either R2 is a hydrogen atom and R3 is the trifluoromethyl radical CF 3 ; or R2 is a methyl radical and R3 is the trifluoromethyl radical CF 3 ; or R2 and R3 are both a methyl radical;

R4 is a hydrogen atom, a fluorine or chlorine atom, a methyl radical or a CN radical; the morpholine residue is chosen from the following radicals:

.

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I). A subject of the present invention is thus the products of formula (I) as defined above, in which the morpholine residue is chosen from the following radicals:

the other substituents R1 , R2, R3, R4, p and q of said products of formula (I) having the meanings indicated above, said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

A subject of the present invention is thus the products of formula (I) as defined above, in which the morpholine residue is chosen from the following radicals:

the other substituents R1 , R2, R3, R4, p and q of said products of formula (I) having the meanings indicated above, said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I). In the products of formula (I) according to the present invention, Rb can in particular be one of the following radicals as defined above: alkyl, such as, for example, methyl, ethyl or isopropyl; phenyl, pyridyl, thiazole, isoxazole, oxazole and oxadiazole; all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, piperidyl, morpholinyle, phenyl, pyridyl, alkyl and alkoxy radicals, the latter phenyl, pyridyl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals. In particular, Rd can be an alkyl or cyclopentyl radical.

In the products of formula (I) according to the present invention, R4 can be a hydrogen atom or a fluorine atom.

In the products of formula (I) according to the present invention, when R1 is a -(CH 2 ) m -Ra radical with m being the integer 1 or 2 and Ra being -CO- cycloalkyl or -CO-heterocycloalkyl, then these cycloalkyl and heterocycloalkyl radicals are chosen, for example, from cyclopropyl, cyclopentyl, cyclohexyl, morpholinyl, piperidyl, tetrahydrofuran, tetrahydropyran and pyrrolidine radicals, all optionally substituted with one or more alkyl radicals and, in addition, optionally with CO 2 alk on the nitrogen of the pyrrolidine. In the products of formula (I) according to the present invention, when R1 is a -(CH 2 ) m -Ra radical with m being the integer 1 or 2 and Ra being -CO-Rb, then Rb can be, for example, an alkyl radical such as, in particular, methyl, ethyl, propyl, butyl or pentyl, all linear or branched, such as, for example isopropyl, terf-butyl, linear or branched butyl, linear or branched pentyl, which are optionally substituted as indicated above. A subject of the present invention is most particularly the products of formula (I) as defined above, corresponding to the following formulae:

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-ox obutyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoropyridin-4-ylmethyl)-2-((R)-3-methylm orpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmor pholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)- 8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-((S)-2-hydroxypropyl)-2-((R)-3-methylmorpholi n-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-5-ylme thyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-[2-(2-Chloropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylm orpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylet hyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin -4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6-tri fluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl- 3,4-dihydro- 2H,6H-pyrimido[1 ,2-a]pyrimidin-1 -yl]acetic acid ethyl ester - (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3- ylmethyl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluor omethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-[1 ,2,4]oxadiazol-5-ylmethyl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetr ahydropyran-4- yl)ethyl]-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-[1 ,2,4]oxadiazol-5- ylmethyl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-methoxyethyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3- ylmethyl)-6-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 2-[(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifl uoromethyl-3,4- dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]-N-methoxy-N-nnethylacetannide

- (S)-9-(6-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(2-Fluoropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylm orpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluor omethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)- 6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethy l-9-(3- tnfluoromethyl-[1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-6 -trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(5-methyl-

[1 ,2,4]oxadiazol-3-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2- a]pyrinnidin-5-one

- (S)-1 -(2-Cyclopropyl-2-oxoethyl)-2-methyl-7-((R)-3-methylmorpholi n-4-yl)-2- trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-(1 -Difluoromethyl-1 H-pyrazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-t rifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-t rifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((R)-3-meth ylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyrid in-2-ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl )-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one, single stereoisomer - (S)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-3-fluoro-2-((R)-3-methylm orpholin-4-yl)-8 trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmet hyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmo rpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-4-ylmet hyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorphol in-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-isoxazol-5-ylmethyl-2-((R)-3-nnethylnnorpholi n-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-3-yl-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2,2,2-trif luoroethoxy)- ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-hydroxy-2-methylpropyl)-2-((R)-3-methylmor pholin-4-yl)-8 trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyrid in-3-ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(6-fluoropyridin-3-ylmethyl)-2-((R)-3-methylm orpholin-4-yl)-8 trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-3-fluoro-2-((R)-3-methylm orpholin-4-yl)-8 trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methy lmorpholin-4-yl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-9-(5-tert-Butyl-[1 ,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-2-ylmethyl)-2-((R)-3-methylm orpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-3-ylmethyl)-2-((R)-3-methylm orpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-fluoropyridin-3-ylmethyl)-2-((R)-3-methylm orpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-[2-(3-fluoropyridin-2-yl)-2-oxoethyl]-2-((R)- 3-methylmorpholin- 4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-9-[2-(3-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylm orpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(2-Methoxypyridin-4-yl)-2-oxoethyl]-2-((R)-3-methyl morpholin-4-yl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methyl morpholin-4-yl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(6-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylm orpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lmidazo[1 ,2-a]pyridin-2-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(4-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-3-pyridin-2-ylpr opyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-thiaz ol-2-ylethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-4-ylme thyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(5-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylm orpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- 3-Fluoro-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-ox o-2-pyridin-2- ylethyl)-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8,8-dimethyl-2-(( R)-3- methylmorpholin-4-yl)-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-one

- 3-Fluoro-9-isoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylm orpholin-4-yl)- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-8,8-dime thyl-2-((R)-3- methylmorpholin-4-yl)-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-one

- (S)-9-(3-Fluorophenyl)-2-((R)-3-methylmorpholin-4-yl)-8-trif luoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-4-ylmethyl-8-tr ifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)- 8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl) -8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(6- tnfluoromethylpyndin-3-yl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(2,2,2-trifluoroetho xy)ethyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(6-methylpyridin-3-yl)- 8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4- yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-lsopropoxypyridin-3-yl)-2-((R)-3-methylnnorpholin-4 -yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-5-ylmethyl-8-tr ifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(6-Cyclobutylpyridin-3-yl)-2-((R)-3-methylmorpholin-4- yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Cyclopropylpyridin-4-yl)-2-((R)-3-methylmorpholin-4 -yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Methoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trif luoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-8-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(5-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2,5-Dimethyloxazol-4-ylmethyl)-2-((R)-3-methylmorphol in-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-9-(5-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,3,4]oxadiazol-2-ylmethyl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-3-fluoro-2-((R)-3-methylmorp holin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((R)-3-methylmorpholin -4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8 -trifluoromethyl 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-((R)-3-methylmorpholin -4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Methylisoxazol-5-ylmethyl)-2-((R)-3-methylmorpholin -4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylet hyl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-8-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(toluene-4-sulfonyl)-8- trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-lsoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-t rifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-lsoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-t rifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4 -yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)- 6-trifluoromethyl 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one - (R)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl) -6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-6-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-5-ylmet hyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4- yl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-lsopropoxypyridin-4-yl)-2-((R)-3-methylnnorpholin-4 -yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(6-lsopropoxypyridin-3-yl)-2-((R)-3-methylnnorpholin-4 -yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-6-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4- yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpho lin-4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmor pholin-4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methy lmorpholin-4-yl)- 6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorphol in-4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,3,4]thiadiazol-2-ylmethyl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Difluoromethoxypyridin-3-yl)-2-((R)-3-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-[1 ,2,3]thiadiazol-5-ylmethyl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyrid in-3-ylethyl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(6-Difluoromethoxypyridin-3-yl)-3-fluoro-2-((R)-3-meth ylmorpholin-4- yl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-ox obutyl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmet hyl-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-6 -trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyr an-4-yl)ethyl]-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetr ahydropyran-4- yl)ethyl]-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxetan-3-ylmethyl-8-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 9-(6-Difluoromethylpyridin-3-yl)-2-((R)-3-methylmorpholin-4- yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyrid in-2-ylethyl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydrofuran-2-yl)methyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydrofuran-2-yl)methyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydropyran-2-yl)methyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydropyran-2-yl)methyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(5-tr ifluoromethyl- [1 ,3,4]oxadiazol-2-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylet hyl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1 ,3,4]oxadiazol-2-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin -4-yl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-6-trifluoromethyl-9-(3-tr ifluoromethyl- [1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-6-trifluo romethyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methyl morpholin-4-yl)- 6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (R)-9-(3-Cyclopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-6-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)- 6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-[1 ,2,4]oxadiazol-5- ylmethyl)-6-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(3,3-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8 -trifluoromethyl 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5R)-3,5-dimethylm orpholin-4-yl) 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- single stereoisomer.

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5S)-3,5-dimethylm orpholin-4-yl) 8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((3S,5S)-3,5-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenyl ethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((3R,5R)-3, 5- dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro pyrimido[1 ^ a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-(3-methylisoxaz ol-5-ylmethyl) 8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((3R,5R)-3,5-dimethylmo rpholin-4-yl)-8 trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((3R,5R)-3,5-dimethylmo rpholin-4-yl)-8 trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-oxazol-2-ylmeth yl-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one - (S)-9-(2-Chloropyndin-4-yl)-2-((3R,5R)-3,5-dimethylmorpholin -4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-pyridin-3-yl-8- tnfluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(3,5-Difluorophenyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct- 3-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3 .2.1 ]oct-3-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-9-(2-oxo-2-phenylethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-5-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3. 2.1]oct-3-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-(8-oxa-3-az a- bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(1 -Difluoromethyl-1 H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza- bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3. 2.1 ]oct-3-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-3-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)- 8-trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

- single stereoisomer

- (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)- 8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl) -8-trifluoromethyl 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl) -8-trifluoromethyl 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(3,5-Difluorophenyl)-2-(3-hydroxymethylmorpholin-4-yl) -8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(3-hydroxymethylmorpho lin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((S)-3-methylmorpholin -4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-Methyl-7-((R)-3-Methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-2-ylethyl)-2- trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-3-ylethyl)-2- trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one

- (S)-1 -(2-Chloropyridin-4-ylmethyl)-2-methyl-7-((R)-3-methylmorpho lin-4-yl)- 2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -oxazol-5-ylmethyl-2- trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -oxazol-4-ylmethyl-2- trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one - (S)-1 -(2-Chloropyridin-4-ylmethyl)-6-fluoro-2-methyl-7-((R)-3- methylmorpholin-4-yl)-2-tnfluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2- a]pyrinnidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-2- oxobutyl)-2-trifluoronnethyl-2,3-dihydro-1 H-innidazo[1 ,2-a]pyrinnidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -[2-oxo-2-(tetrahydro pyran-4-yl)ethyl]-2-tnfluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5- one

- (S)-1 -(2-Cyclopropyl-2-oxoethyl)-6-fluoro-2-methyl-7-((R)-3- methylmorpholin-4-yl)-2-tnfluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2- a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-2-oxobutyl)-2- trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-3- ylethyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -[2-oxo-2-(tetrahydropyran-4- yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6, 7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6, 7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromet hyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromet hyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromet hyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer - N-Methoxy-N-methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-o xo-2- tnfluoromethyl-3,4-dihydro-2H,6H-pynmido[1 ,2-a]pyrinnidin-1 -yl]acetannide

- N-Methoxy-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trif luoromethyl-3,4 dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetamide

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8-trifluor omethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-2- ylethyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-8-methyl-2-((R)-3-methylmor pholin-4-yl)-8 trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-lsopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Cyclopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-tert-Butyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-hydroxyethyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-((S)-2-Hydroxypropyl)-2-((R)-3-methylmorpholin-4-yl)-8 -trifluoromethyl 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-(1 R,5S)-8-oxa-3-aza- bicyclo[3.2.1 ]oct-3-yl-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-

[1 ,2,4]oxadiazol-5-ylnnethyl)-2-tnfluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2- a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-[1 ,2,4]oxadiazol-5- ylmethyl)-2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one - (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3- ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8-methyl-2-(( R)-3- methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropy rimido[1 ,2- a]pyrimidin-4-one

- (S)-9-lsoxazol-3-ylmethyl-8-methyl-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-4-ylmethyl-8-tr ifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-ylmethyl-8-tr ifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-2-ylmethyl-8-tr ifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-[2-(4-Fluorophenyl)ethyl]-2-((R)-3-methylmorpholin-4-y l)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-pyridin-2-ylethyl)-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-9-(2-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- N,N-Dimethyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-t rifluoromethyl- 3,4-dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetamide

- N-Methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifl uoromethyl-3,4- dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetamide

- (S)-9-(6-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-lsopropoxypyridin-4-ylmethyl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-lsopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Cyclopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-tert-Butyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-lsopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-lsopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-2-ylmethyl-8-tr ifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-2-ylme thyl-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-1 -ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-(2-morpholin-4-yl-2-oxo ethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-morpholin-4 -yl-2-oxoethyl)- 8-tnfluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethy l-3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]-N-phenylacetamide

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-piper idin-1 -ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-Acetyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethy l-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmet hyl-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(5-methyl-[1 ,2,4]oxadiazol-3- ylmethyl)-2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4- yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-thiazol-2-ylet hyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl- 3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pynnnidin-1 -yl]acetic acid cyclopentyl ester

- (S)-9-(2-Cyclopentyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4- yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyr an-4-yl)ethyl]-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(5-isopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(5-Cyclopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one - (S)-3-Fluoro-9-(3-isopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(3-Cyclopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(3-tert-Butyl-[1 ,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethy l-9-(3- tnfluoromethyl-[1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-ox obutyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(1 -Methylcyclopentyl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-y l)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl- 3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pynnnidin-1 -yl]acetic acid isopropyl ester

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluo romethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Fluoropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Cyclohexyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridazin-4-ylmethyl-8- trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one - [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl- 3,4-dihydro- 2H,6H-pyrimido[1 ,2-a]pyrimidin-1 -yl]acetic acid tert-butyl ester

- 2-{2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluorome thyl-3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetyl}pyrrolidine-1 -carboxylic acid tert- butyl ester

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl- 3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pyrinnidin-1 -yl]acetic acid methyl ester

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethy l-3,4-dihydro- 2H,6H-pyrimido[1 ,2-a]pyrimidin-1 -yl]acetamide

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4H-[1 ,2,4]triazol-3-ylmethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-4-yl ethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(3-Methylbut-2-enyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl )-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-[2-(3-Methylisoxazol-4-yl)-2-oxoethyl]-2-((R)-3-methyl morpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydrofur an-3-yl)ethyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-Methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza- bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-(8-oxa-3-aza-bicyclo[3.2. 1 ]oct-3-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(3-Methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one - (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(8-oxa-3-aza-bic yclo[3.2.1 ]oct-3- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(3-methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[ 3.2.1 ]oct-3-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza- bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-2-oxopentyl)- 8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((S)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((S)-3-methylmorpholin-4-yl)-9-(3-methyl-2-ox obutyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-2-ox ohexyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(4-methyl-2-ox opentyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Ethyl-2-oxopentyl)-2-((R)-3-methylmorpholin-4-yl)-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(3-Ethyl-2-oxopentyl)-3-fluoro-2-((R)-3-methylmorpholi n-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- [(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluo romethyl-3,4- dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetic acid methyl ester

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluorome thyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one, single stereoisomer

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluorome thyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer - (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-2-oxohexyl)-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxopentyl)- 8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(3-tr ifluoromethyl- [1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2-oxa-6-az aspiro[3.3]hept- 6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimi do[1 ,2-a]pyrimidin- 4-one

- (S)-3-Fluoro-9-[2-(5-methylisoxazol-3-yl)-2-oxoethyl]-2-((R) -3- methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropy rimido[1 ,2- a]pyrimidin-4-one

- (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl )-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-isoxazol-3-ylmethyl-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-2-(( R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- 9-lsoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylmorpholin- 4-yl)-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-5-ylmethyl)-2-((R)-3-methyl morpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-lsopropoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-t rifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluor omethyl-^ tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4 -yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-{2-[2-((R)-3-methylmorp holin-4-yl)^ pyndin-4-yl]-2-oxoethyl}-8-tnfluoromethyl-6,7,8,9-tetrahydro pyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-9-{2-Cyclopropyl-2-[(Z)-hydroxyimino]ethyl}-2-((R)-3-met hylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pynmidin-4-one, isomer

1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-hydroxyimino]ethyl}-2-((R)-3-met hylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, isomer

2 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-methoxyimino]ethyl}-2-((R)-3-met hylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, isomer

1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(Z)-methoxyimino]ethyl}-2-((R)-3-met hylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, isomer

2 of undetermined configuration Z or E - (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-on

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(4-methyltetrahydrop yran-4-yl)-2- oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-[2-(5-Methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3-methyl morpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((3R,5R)-3,5-dimethylmo rpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-3-ylme thyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-met hylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trif luoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(6-oxa-1 -azaspiro[3.3]hept- 1 -yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimid o[1 ,2-a]pyrimidin- 4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-[1 ,2]oxazinan-2-yl-2- oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-[1 ,2]oxazinan-2-yl-2-oxoethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-9-(2-lsoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(2-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one, diastereoisonner 1 of undeternnined absolute configuration on the asynnnnetric carbon of the morpholine

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((S)-3-methylmor pholin-4-yl)-8- thfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyhmidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(2-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 1 of undeternnined absolute configuration on the asynnnnetric carbon of the morpholine

- (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl )-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl )-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin -4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain - (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin -4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)- 8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methylmorph olin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-on

diastereoisonner 1 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-fluoro-3-methyl butyl chain - (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methylnnorp holin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 2 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(1 -oxa-6-azaspiro[3.3]hept-6-yl)-2- oxoethyl]-8-thfluoromethyl-6,7,8,9-tetrahydropyhmido[1 ,2-a]pyhmidin-4-one

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methyl morpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 1 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-cyclopropyl-2-fluoroethyl chain - (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methyl morpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 2 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(1 -oxa-6-azaspiro[3.3]hept- 6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimi do[1 ,2-a]pyrimidin-

4-one and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

A subject of the present invention is also any process for preparing the products of formula (I) as defined above.

The products according to the invention can be prepared using conventional organic chemistry methods. A subject of the present invention is thus in particular a process for synthesis of the products of formula (I) as defined above, described in scheme 1 or scheme 2.

Preparation of compounds of formula (I) The products of formula (I) according to the present invention, as defined above, can be prepared according to the usual methods known to those skilled in the art, and in particular according to the process described in scheme 1 below.

Scheme 1 below illustrates the methods used for preparing the products of formula (I). In this respect, they could not constitute a limitation of the scope of the invention, with regard to the methods for preparing the compounds claimed.

A subject of the present invention is thus also the process for preparing products of formula (I) according to scheme 1 as defined hereinafter. A subject of the present invention is thus also the process for preparing products of formula (I) according to scheme 2 as defined hereinafter.

The products of formula (I) as defined above according to the present invention can thus in particular be prepared according to the process described in scheme 3 as defined hereinafter.

Scheme 1 :

Ainldation n = 0 or 1 in which the substituents n, p, q, PG, R1 , R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 , R12 and alkyl have the meanings indicated above for the products of formula (I).

In particular, when n = 1 , the intermediate L can be prepared according to the following scheme under the conditions indicated hereinafter:

K L (n = 1 ) in which the substituents R2 and R3 have the meanings indicated above for the products of formula (I).

Scheme 2:

R3 R2 R3 R2

Deprotection Reduction

Reductive HN

A Η,Ν' " amination PG

n = 0 or 1

in which the substituents n, p, q, PG, R1 , R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 , R12 and alkyl have the meanings indicated above for the products of formula (I). Scheme 3:

in which the substituents n, p, q, R1 , R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 and R12 have the meanings indicated above for the products of formula (I).

In schemes 1 , 2 and 3 as defined above, the procedure can be carried out according to the usual methods known to those skilled in the art and in particular according to the conditions described hereinafter.

The diamines A are either commercially available, or prepared, in the achiral, chiral or racemic version, according to the methods known to those skilled in the art, such as, in particular, by analogy and homologation with the process described by Brigaud, T. et al. in J. Org. Chem. 2006, 71 (18), 7075- 7078, for the values of n, R2 and R3 as defined above.

Alternatively, the diamines A can be obtained according to the methods known to those skilled in the art, such as in particular from the amino esters L (alpha-amino esters n = 0, or beta-amino esters n = 1 ), which are either commercially available or prepared respectively as described, for example, by Robert M. Williams in Synthesis of Optically Active a-Amino Acids from Pergamon Press or, for example (n = 1 ), by 1 ,4 Michael addition of an amine such as aqueous ammonia, for example, on the corresponding acrylates K as described, for example, by P. Perlmutter in Tetrahedron Organic Chemistry Series Volume 9 Conjugate Addition Reactions in Organic Synthesis from Pergamon Press, by stringing together the conventional sequences of hydrolysis of the ester function L to give the acid M, followed by an N amidation in the presence of an amine such as, for example, benzylamine, para-methoxybenzylamine, dimethoxybenzylamine or 4- methoxyphenylethylamine, followed by reduction of the amide function N to give the amine G in the presence, for example, of lithium aluminium tetrahydride, then by deprotection of the amine G, if necessary, given that all of the sequences can be carried out by conventional methods as described, for example, by Larock, Richard, C. et al. in Comprehensive Organic Transformations A Guide to Functional Group Preparations from VCH and by Theodora W. Greene and Peter G. M. Wuts in Protective Groups in Organic Synthesis Third Edition from Wiley-lnterscience, for the values of R2, R3, PG and n as defined above.

Alternatively, the diamines G can be obtained in particular by means of a reductive amination reaction of the commercially available diamines A via a conventional method as described, for example, by Larock, Richard, C. et al. in Comprehensive Organic Transformations A Guide to Functional Group Preparations from VCH and by Theodora W. Greene and Peter G. M. Wuts in Protective Groups in Organic Synthesis Third Edition from Wiley-lnterscience, for the values of R2, R3, PG and n as defined above.

The guanidines B (n = 1 ) are either commercially available or prepared from C according to the methods known to those skilled in the art, such as, in particular, according to the processes described in Lochead, A.W. et al. (EP1460076 2002), Lochead, A.W. et al. (EP1340761 2003), Lochead, A.W. et al. (EP1454909 2004), Lochead, A.W. et al. (WO2005058908 2005), and Bacque, Eric et al . (WO201 1001 1 12A1 and WO201 1001 1 13A2) or by analogy with this same reference in the other cases, for the values of n, R2 and R3 as defined above.

The guanidines B can be obtained in particular by reacting a diamine A and cyanogen bromide in a solvent such as water or acetonitrile, at a temperature between 0°C and the boiling point of the solvent, according to the conditions described, for example, by Gallet, T. et al. (EP1340761 2003) and Bacque, Eric et al . (WO201 1001 1 12A1 and WO201 1001 1 13A2), for the values of n, R2 and R3 as defined above.

Alternatively, the guanidines B can be obtained by deprotection of the guanidines H according to the conventional methods known to those skilled in the art as described, for example, by Theodora W. Greene and Peter G. M. Wuts in Protective Groups in Organic Synthesis Third Edition from Wiley- Interscience, for the values of n, R2, R3 and PG as defined above.

The guanidines H can be obtained in particular by reacting a diamine G and cyanogen bromide in a solvent such as water or acetonitrile, at a temperature between 0°C and the boiling point of the solvent, according to the conditions described, for example, by Gallet, T. et al. (EP1340761 2003) and Bacque, Eric et al . (WO201 1001 1 12A1 and WO201 1001 1 13A2), for the values of n, R2, R3 and PG as defined above. The compounds E can be obtained in particular by condensation of the guanidines B with a dialkyi malonate (preferably dimethyl or diethyl malonate) D, in the presence of a base such as sodium methoxide, at a temperature between 0°C and 150°C, as described, for example, by Badawey E.-S.A.M. et al. (Eur J Med Chem, 1998, 33(5), 349-361 ) and Bacque, Eric et al. (WO201 1001 1 12A1 and WO201 1001 1 13A2), for the values of n, p, q, R2, R3 and R4 as defined above.

Alternatively, the compound E can be obtained by deprotection of the compound I according to the conventional methods known to those skilled in the art as described, for example, by Theodora W. Greene and Peter G. M. Wuts in Protective Groups in Organic Synthesis Third Edition from Wiley- Interscience, for the values of p, q, R2, R3, R4 and PG as defined above.

The compounds I can be obtained in particular by condensation of the guanidines H with a dialkyi malonate (preferably dimethyl or diethyl malonate) D, in the presence of a base such as sodium methoxide, at a temperature between 0°C and 150°C, as described, for example, by Badawey E.-S.A.M. et al. (Eur J Med Chem, 1998, 33(5), 349-361 ) and Bacque, Eric et al. (WO201 1001 1 12A1 and WO201 1001 1 13A2), for the values of n, p, q, R2, R3, R4 and PG as defined above.

The compounds F can be obtained in particular from the compounds E by treatment with a chlorinating agent such as phosphorus oxychloride, in the absence of solvent, at a temperature between 20°C and 150°C, or in the presence of a solvent such as dichloroethane, at a temperature between 20°C and the boiling point of the solvent, for instance under the conditions described by Yamashita, A. et al . (Syn. Commun. (2004), 34(5), 795-803) and Bacque, Eric et al . (WO201 1001 1 12A1 and WO201 1001 1 13A2), for the values of p, q, R2, R3 and R4 as defined above.

Alternatively, the compound F can be obtained by deprotection of the compound J according to the conventional methods known to those skilled in the art as described, for example, by Theodora W. Greene and Peter G. M. Wuts in Protective Groups in Organic Synthesis Third Edition from Wiley- Interscience, for the values of R2, R3, R4, p and q as defined above.

The compounds J can be obtained in particular from the compounds I by treatment with a chlorinating agent such as phosphorus oxychloride, in the absence of solvent, at a temperature between 20°C and 150°C, or in the presence of a solvent such as dichloroethane, at a temperature between 20°C and the boiling point of the solvent, for instance under the conditions described by Yamashita, A. et al. (Syn. Commun. (2004), 34(5), 795-803) and Bacque, Eric et al . (WO201 1001 1 12A1 and WO201 1001 1 13A2), for the values of p, q, R2, R3, R4 and PG as defined above. The compounds P can be obtained from the compounds F by reacting with a substituted morpholine, in the absence or in the presence of a solvent such as acetonitrile, at a temperature between 20°C and 200°C, in the presence or absence of a base such as triethylamine or sodium carbonate for example, by analogy as described, for example, by Aliabiev S.B. (Lett. Org. Chem. (2007), 4(4), 273-280) and Bacque, Eric et al. (WO201 1001 1 12A1 and WO201 1001 1 13A2), for the values of p, q, R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 and R12 as defined above.

The products of formulae (I) can be obtained from the compounds Q by reacting with a substituted morpholine, in the absence or in the presence of a solvent such as acetonitrile, at a temperature between 20°C and 200°C, in the presence or absence of a base such as triethylamine or sodium carbonate for example, by analogy as described, for example, by Aliabiev S.B. (Lett. Org. Chem . (2007), 4(4), 273-280) and Bacque, Eric et al. (WO201 1001 1 12A1 and WO201 1001 1 13A2), for the values of p, q, R1 , R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 and R12 as defined above.

The compounds Q or alternatively the products of formulae (I), as indicated on the schemes above, can be obtained respectively from the compounds F and P, for example by reacting with an electrophile by addition of a compound T1 , T2 or T3 as defined above and as follows: · T1 is R1 '-X in which R1 ' represents values of R1 as defined above for the products of formula (I): when R1 ' represents the values of R1 with the exception of the aryl and heteroaryl values, then the addition reaction of R1 'X in which X is in particular CI, Br, I, OMs, OTs or OTf, respectively with the compounds F and P, can be carried out, for example, in the presence of a base such as caesium carbonate, potassium phosphate or sodium hydride in excess, in a solvent such as acetonitrile, tetrahydrofuran, Ν,Ν-dimethylformamide or dimethyl sulfoxide, at a temperature between ambient temperature and 200°C, as described, for example, by Larock, Richard, C. et al. in Comprehensive Organic Transformations A Guide to Functional Group Preparations from VCH in the case of the alkylation reaction. When R1 ' represents the aryl and heteroaryl values of R1 , then the addition reaction of R1 'X, in which X is in particular I or Br, respectively with the compounds P, can be carried out, for example, by a reaction or a coupling of Ullmann type in the presence of a base such as potassium phosphate in excess with cuprous iodide, in a solvent such as Ν,Ν-dimethylformamide, at a temperature between 100 and 200°C, as described, for example, by Ulmann, F. in Chem. Ber. 1903, 36, 2389 and Bacque, Eric et al. (WO201 1001 1 12A1 and WO201 1001 1 13A2) in the case of the Ullmann-type reaction.

T2 is R1 "-OH in which R1 " represents values of R1 with the exception of the aryl and heteroaryl values as defined above for the products of formula (I): the addition reaction of T2, respectively with the compounds F and P, can be carried out, for example, in the presence of supported or nonsupported triphenylphosphine and of diethyl azodicarboxylate and of a base such as diisopropylethylamine, in a solvent such as tetrahydrofuran, at a temperature between ambient temperature and 100°C, as described, for example, by Mitsunobu, O. in "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products" Synthesis 1981 (1 ) 1 -28 in the case of the Mitsunobu reaction.

T3 is an epoxyethylene radical disubstituted in position 1 with substituents Y,Z, which may be identical or different, chosen from a hydrogen atom and alkyl (such as, for example, methyl or ethyl), aryl or heteroaryl radicals, all optionally substituted as indicated for R1 in the products of formula (I) as defined above: the addition reaction of T3, respectively with the compounds F and P, can be carried out, for example, in the presence of a base such as sodium hydride, sodium hydroxide, potassium phosphate or caesium carbonate in excess, in the absence of solvent or in a solvent such as tetrahydrofuran, dimethyl sulfoxide, Ν,Ν-dimethylformamide, N,N-dimethylacetamide, acetonitrile, or an acetone and water mixture with a phase- transfer agent such as, for example, benzyltriethylammonium chloride, at a temperature between 20°C and 200°C, as described, for example, by Hepperle, Michael E. et al., PCT Int. Appl., 2007097981 , 30 Aug 2007 and Bacque, Eric et al. (WO201 1001 1 12A1 and WO201 1001 1 13A2).

In general schemes 2 and 3 above:

• The compound B can be obtained according to the 3 routes indicated in scheme 1 from the compounds A, C and H as defined above and according to the steps also defined above.

• The compound E can be obtained according to the 2 routes indicated in scheme 1 from the compounds I and B as defined above and according to the steps also defined above.

• The compound F can be obtained according to the 2 routes indicated in scheme 1 from the compounds E and J as defined above and according to the steps also defined above.

• The products of formula (I) can be obtained according to the 2 routes indicated in scheme 1 from the compounds P and Q as defined above and according to the steps also defined above.

When R2 is different from R3 and if the synthesis is not stereoselective, the enantiomers or the possible diastereoisomers of the synthesis intermediates or of the compounds (I) can be separated by chromatography on a chiral support.

The following examples of products of formula (I) illustrate the invention without, however, limiting it.

Among the starting products of formulae A, B, C, D, G, H, K, L, M, N, O and T, some are known and can be obtained either commercially, or according to the usual methods known to those skilled in the art as described, for example, by Larock, Richard, C. et al., in Comprehensive Organic Transformations A Guide to Functional Group Preparations from VCH, for example starting from commercial products.

It is understood by those skilled in the art that, in order to implement the processes according to the invention previously described, it may be necessary to introduce function-protective groups, such as, for example, the PG protective group, as described in particular by Theodora W. Greene and Peter G. M. Wuts in Protective Groups in Organic Synthesis Third Edition from Wiley-lnterscience. Thus, the amine group protected by PG may be, for example, a benzylamine, para-methoxybenzylamine, 2,4- dimethoxybenzylamine or 4-methoxyphenylethylamine.

It may be noted that, if desired and if necessary, it is possible to subject intermediate products or products of formula (I) thus obtained by means of the processes indicated above, in order to obtain other

intermediates or other products of formula (I), to one or more conversion reactions known to those skilled in the art, as described, for example, by Larock, Richard, C. et al. in Comprehensive Organic Transformations A Guide to Functional Group Preparations from VCH.

The products of formula (I) as defined above and also the addition salts thereof with acids exhibit advantageous pharmacological properties, in particular owing to their kinase-inhibiting properties as is indicated above.

The products of the present invention are in particular of use for antitumour therapies.

The products of the invention can thus also increase the therapeutic effects of commonly used antitumour agents. The products of the invention can thus also increase the therapeutic effects of commonly used radiotherapies.

These properties justify the therapeutic application thereof, and the subject of the invention is in particular, as medicaments, the products of formula (I) as defined above, said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the pharmaceutically acceptable addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

A subject of the invention is quite particularly, as medicaments, the products corresponding to the following formulae:

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-ox obutyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoropyridin-4-ylmethyl)-2-((R)-3-methylm orpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmor pholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)- 8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-((S)-2-hydroxypropyl)-2-((R)-3-methylmorpholi n-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-5-ylme thyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-[2-(2-Chloropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylm orpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylet hyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin -4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6-tri fluoromethyl- 6,7,8,9-tetrahydropynnnido[1 ,2-a]pynnnidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl- 3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetic acid ethyl ester

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3- ylmethyl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluor omethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-[1 ,2,4]oxadiazol-5-ylmethyl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetr ahydropyran-4- yl)ethyl]-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-[1 ,2,4]oxadiazol-5- ylmethyl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-methoxyethyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3- ylmethyl)-6-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 2-[(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifl uoromethyl-3,4- dihydro-2H,6H-pyrinnido[1 ,2-a]pynmidin-1 -yl]-N-methoxy-N-methylacetamide

- (S)-9-(6-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(2-Fluoropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylm orpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluor omethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one - (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)- 6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethy l-9-(3- tnfluoromethyl-[1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-6 -trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(5-methyl-

[1 ,2,4]oxadiazol-3-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2- a]pyrinnidin-5-one

- (S)-1 -(2-Cyclopropyl-2-oxoethyl)-2-methyl-7-((R)-3-methylmorpholi n-4-yl)-2- trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-(1 -Difluoromethyl-1 H-pyrazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-t rifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-t rifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((R)-3-meth ylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyrid in-2-ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl )-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one, single stereoisomer

- (S)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-3-fluoro-2-((R)-3-methylm orpholin-4-yl)-8 trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmet hyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmo rpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-4-ylmet hyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-isoxazol-5-ylmethyl-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-3-yl-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2,2,2-trif luoroethoxy)- ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-hydroxy-2-methylpropyl)-2-((R)-3-methylmor pholin-4-yl)-8 trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyrid in-3-ylethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(6-fluoropyridin-3-ylmethyl)-2-((R)-3-methylm orpholin-4-yl)-8 trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one - (S)-9-(6-Chloropyridin-3-ylmethyl)-3-fluoro-2-((R)-3-methylm orpholin-4-yl)-8 trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methy lmorpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-tert-Butyl-[1 ,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-2-ylmethyl)-2-((R)-3-methylm orpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-3-ylmethyl)-2-((R)-3-methylm orpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-fluoropyridin-3-ylmethyl)-2-((R)-3-methylm orpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-[2-(3-fluoropyridin-2-yl)-2-oxoethyl]-2-((R)- 3-methylmorpholin 4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(3-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylm orpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(2-Methoxypyridin-4-yl)-2-oxoethyl]-2-((R)-3-methyl morpholin-4-yl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methyl morpholin-4-yl) 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(6-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylm orpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lmidazo[1 ,2-a]pyridin-2-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-9-(4-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-3-pyridin-2-ylpr opyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-thiaz ol-2-ylethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-4-ylme thyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(5-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylm orpholin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- 3-Fluoro-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-ox o-2-pyridin-2- ylethyl)-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8,8-dimethyl-2-(( R)-3- methylmorpholin-4-yl)-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-one

- 3-Fluoro-9-isoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylm orpholin-4-yl)- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-8,8-dime thyl-2-((R)-3- methylmorpholin-4-yl)-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-one

- (S)-9-(3-Fluorophenyl)-2-((R)-3-methylmorpholin-4-yl)-8-trif luoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-4-ylmethyl-8-tr ifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one - (S)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)- 8-trifluoromethyl 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl) -8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(6- tnfluoromethylpyndin-3-yl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(2,2,2-trifluoroetho xy)ethyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(6-methylpyridin-3-yl)- 8-trifluoromethyl 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4- yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-lsopropoxypyridin-3-yl)-2-((R)-3-methylnnorpholin-4 -yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-5-ylmethyl-8-tr ifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(6-Cyclobutylpyridin-3-yl)-2-((R)-3-methylmorpholin-4- yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Cyclopropylpyridin-4-yl)-2-((R)-3-methylmorpholin-4 -yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Methoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trif luoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-8-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(5-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-9-(2,5-Dimethyloxazol-4-ylmethyl)-2-((R)-3-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,3,4]oxadiazol-2-ylmethyl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-3-fluoro-2-((R)-3-methylmorp holin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((R)-3-methylmorpholin -4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-((R)-3-methylmorpholin -4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Methylisoxazol-5-ylmethyl)-2-((R)-3-methylmorpholin -4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylet hyl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-8-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(toluene-4-sulfonyl)-8- trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-lsoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-t rifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-lsoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-t rifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one - (R)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4 -yl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)- 6-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl) -6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-6-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-5-ylmet hyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4- yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-lsopropoxypyridin-4-yl)-2-((R)-3-methylnnorpholin-4 -yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(6-lsopropoxypyridin-3-yl)-2-((R)-3-methylnnorpholin-4 -yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-6-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4- yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpho lin-4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmor pholin-4-yl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (R)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methy lmorpholin-4-yl)- 6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorphol in-4-yl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,3,4]thiadiazol-2-ylmethyl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Difluoromethoxypyridin-3-yl)-2-((R)-3-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-[1 ,2,3]thiadiazol-5-ylmethyl)- 8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyrid in-3-ylethyl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(6-Difluoromethoxypyridin-3-yl)-3-fluoro-2-((R)-3-meth ylmorpholin-4- yl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-ox obutyl)-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmet hyl-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-6 -trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyr an-4-yl)ethyl]-6- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetr ahydropyran-4- yl)ethyl]-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxetan-3-ylmethyl-8-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 9-(6-Difluoromethylpyridin-3-yl)-2-((R)-3-methylmorpholin-4- yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyrid in-2-ylethyl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydrofuran-2-yl)methyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydrofuran-2-yl)methyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydropyran-2-yl)methyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydropyran-2-yl)methyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(5-tr ifluoromethyl- [1 ,3,4]oxadiazol-2-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylet hyl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1 ,3,4]oxadiazol-2-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin -4-yl)-6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-6-trifluoromethyl-9-(3-tr ifluoromethyl- [1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-6-trifluo romethyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methyl morpholin-4-yl)- 6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (R)-9-(3-Cyclopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-6-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)- 6- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-[1 ,2,4]oxadiazol-5- ylmethyl)-6-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(3,3-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8 -trifluoromethyl 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5R)-3,5-dimethylm orpholin-4-yl) 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- single stereoisomer.

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5S)-3,5-dimethylm orpholin-4-yl) 8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((3S,5S)-3,5-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenyl ethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((3R,5R)-3, 5- dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro pyrimido[1 ^ a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-(3-methylisoxaz ol-5-ylmethyl) 8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((3R,5R)-3,5-dimethylmo rpholin-4-yl)-8 trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((3R,5R)-3,5-dimethylmo rpholin-4-yl)-8 trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-oxazol-2-ylmeth yl-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one - (S)-9-(2-Chloropyndin-4-yl)-2-((3R,5R)-3,5-dimethylmorpholin -4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-pyridin-3-yl-8- tnfluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(3,5-Difluorophenyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct- 3-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3 .2.1 ]oct-3-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-9-(2-oxo-2-phenylethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-5-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3. 2.1]oct-3-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-(8-oxa-3-az a- bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(1 -Difluoromethyl-1 H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza- bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3. 2.1 ]oct-3-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-3-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)- 8-trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

- single stereoisomer

- (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)- 8-trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl) -8-trifluoromethyl 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl) -8-trifluoromethyl 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(3,5-Difluorophenyl)-2-(3-hydroxymethylmorpholin-4-yl) -8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(3-hydroxymethylmorpho lin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((S)-3-methylmorpholin -4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-Methyl-7-((R)-3-ethylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-2-ylethyl)-2- trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-3-ylethyl)-2- trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one

- (S)-1 -(2-Chloropyridin-4-ylmethyl)-2-methyl-7-((R)-3-methylmorpho lin-4-yl)- 2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -oxazol-5-ylmethyl-2- trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -oxazol-4-ylmethyl-2- trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one - (S)-1 -(2-Chloropyridin-4-ylmethyl)-6-fluoro-2-methyl-7-((R)-3- methylmorpholin-4-yl)-2-tnfluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2- a]pyrinnidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-2- oxobutyl)-2-trifluoronnethyl-2,3-dihydro-1 H-innidazo[1 ,2-a]pyrinnidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -[2-oxo-2-(tetrahydro pyran-4-yl)ethyl]-2-tnfluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5- one

- (S)-1 -(2-Cyclopropyl-2-oxoethyl)-6-fluoro-2-methyl-7-((R)-3- methylmorpholin-4-yl)-2-tnfluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2- a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-Methylmorpholin-4-yl)-1 -(3-methyl-2-oxobutyl)-2- trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-3- ylethyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -[2-oxo-2-(tetrahydropyran-4- yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6, 7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6, 7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromet hyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromet hyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromet hyl-6,7,8,9- terahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer - N-Methoxy-N-methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-o xo-2- tnfluoromethyl-3,4-dihydro-2H,6H-pynmido[1 ,2-a]pyrinnidin-1 -yl]acetannide

- N-Methoxy-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trif luoromethyl-3,4 dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetamide

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8-trifluor omethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-2- ylethyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-8-methyl-2-((R)-3-methylmor pholin-4-yl)-8 trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-lsopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Cyclopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-tert-Butyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-hydroxyethyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-((S)-2-Hydroxypropyl)-2-((R)-3-methylmorpholin-4-yl)-8 -trifluoromethyl 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-(1 R,5S)-8-oxa-3-aza- bicyclo[3.2.1 ]oct-3-yl-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-

[1 ,2,4]oxadiazol-5-ylnnethyl)-2-tnfluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2- a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-[1 ,2,4]oxadiazol-5- ylmethyl)-2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one - (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3- ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8-methyl-2-(( R)-3- methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropy rimido[1 ,2- a]pyrimidin-4-one

- (S)-9-lsoxazol-3-ylmethyl-8-methyl-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-4-ylmethyl-8-tr ifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-ylmethyl-8-tr ifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-2-ylmethyl-8-tr ifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-[2-(4-Fluorophenyl)ethyl]-2-((R)-3-methylmorpholin-4-y l)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-pyridin-2-ylethyl)-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-9-(2-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- N,N-Dimethyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-t rifluoromethyl- 3,4-dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetamide

- N-Methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifl uoromethyl-3,4- dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetamide

- (S)-9-(6-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-lsopropoxypyridin-4-ylmethyl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-lsopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Cyclopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-tert-Butyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4- yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-lsopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-lsopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-2-ylmethyl-8-tr ifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-2-ylme thyl-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-1 -ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-(2-morpholin-4-yl-2-oxo ethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one - (S)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(2-morpholin-4 -yl-2-oxoethyl)- 8-tnfluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethy l-3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]-N-phenylacetamide

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-piper idin-1 -ylethyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-Acetyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethy l-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmet hyl-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(5-methyl-[1 ,2,4]oxadiazol-3- ylmethyl)-2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4- yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-thiazol-2-ylet hyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl- 3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pynnnidin-1 -yl]acetic acid cyclopentyl ester

- (S)-9-(2-Cyclopentyl-2-oxoethyl)-2-((R)-3-Methylmorpholin-4- yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyr an-4-yl)ethyl]-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(5-isopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(5-Cyclopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one - (S)-3-Fluoro-9-(3-isopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(3-Cyclopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- (S)-9-(3-tert-Butyl-[1 ,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethy l-9-(3- tnfluoromethyl-[1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-ox obutyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(1 -Methylcyclopentyl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-y l)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl- 3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pynnnidin-1 -yl]acetic acid isopropyl ester

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluo romethyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Fluoropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Cyclohexyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridazin-4-ylmethyl-8- trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one - [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl- 3,4-dihydro- 2H,6H-pyrimido[1 ,2-a]pyrimidin-1 -yl]acetic acid tert-butyl ester

- 2-{2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluorome thyl-3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetyl}pyrrolidine-1 -carboxylic acid tert- butyl ester

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl- 3,4-dihydro- 2H,6H-pyrinnido[1 ,2-a]pyrinnidin-1 -yl]acetic acid methyl ester

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethy l-3,4-dihydro- 2H,6H-pyrimido[1 ,2-a]pyrimidin-1 -yl]acetamide

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4H-[1 ,2,4]triazol-3-ylmethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-4-yl ethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(3-Methylbut-2-enyl)-2-((R)-3-methylmorpholin-4-yl)-8- trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl )-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-[2-(3-Methylisoxazol-4-yl)-2-oxoethyl]-2-((R)-3-methyl morpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydrofur an-3-yl)ethyl]-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-Methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza- bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-(8-oxa-3-aza-bicyclo[3.2. 1 ]oct-3-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(3-Methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one - (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(8-oxa-3-aza-bic yclo[3.2.1 ]oct-3- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(3-methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[ 3.2.1 ]oct-3-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza- bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2- a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-2-oxopentyl)- 8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((S)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((S)-3-methylmorpholin-4-yl)-9-(3-methyl-2-ox obutyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-2-ox ohexyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(4-methyl-2-ox opentyl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-ethyl-2-oxopentyl)-2-((R)-3-methylmorpholin-4-yl)-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(3-ethyl-2-oxopentyl)-3-fluoro-2-((R)-3-methylmorpholi n-4-yl)-8- trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- [(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluo romethyl-3,4- dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetic acid methyl ester

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluorome thyl-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one, single stereoisomer

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluorome thyl-6,7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer - (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-y l)-8- trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-2-oxohexyl)-8 -trifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxopentyl)- 8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(3-tr ifluoromethyl- [1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2-oxa-6-az aspiro[3.3]hept- 6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimi do[1 ,2-a]pyrimidin- 4-one

- (S)-3-Fluoro-9-[2-(5-methylisoxazol-3-yl)-2-oxoethyl]-2-((R) -3- methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropy rimido[1 ,2- a]pyrimidin-4-one

- (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl )-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-isoxazol-3-ylmethyl-2-((R)-3-methylmorpholin- 4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-2-(( R)-3- methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyr imido[1 ,2- a]pyrinnidin-4-one

- 9-lsoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylmorpholin- 4-yl)-6,7,8,9- tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-5-ylmethyl)-2-((R)-3-methyl morpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-lsopropoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-t rifluoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluor omethyl-^ tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4 -yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-{2-[2-((R)-3-methylmorp holin-4-yl)^ pyndin-4-yl]-2-oxoethyl}-8-tnfluoromethyl-6,7,8,9-tetrahydro pyrimido[1 ,2- a]pyrinnidin-4-one

- (S)-9-{2-Cyclopropyl-2-[(Z)-hydroxyimino]ethyl}-2-((R)-3-met hylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pynmidin-4-one, isomer

1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-hydroxyimino]ethyl}-2-((R)-3-met hylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, isomer

2 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-methoxyimino]ethyl}-2-((R)-3-met hylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, isomer

1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(Z)-methoxyimino]ethyl}-2-((R)-3-met hylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, isomer

2 of undetermined configuration Z or E - (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-on

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(4-methyltetrahydrop yran-4-yl)-2- oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-[2-(5-Methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3-methyl morpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((3R,5R)-3,5-dimethylmo rpholin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-3-ylme thyl-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-met hylmorpholin-4- yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trif luoromethyl- 6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(6-oxa-1 -azaspiro[3.3]hept- 1 -yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimid o[1 ,2-a]pyrimidin- 4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-[1 ,2]oxazinan-2-yl-2- oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-[1 ,2]oxazinan-2-yl-2-oxoethyl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-9-(2-lsoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpho lin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(2-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-tri fluoromethyl- 6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one, diastereoisonner 1 of undeternnined absolute configuration on the asynnnnetric carbon of the morpholine

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((S)-3-methylmor pholin-4-yl)-8- thfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyhmidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(2-methylmorphol in-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 1 of undeternnined absolute configuration on the asynnnnetric carbon of the morpholine

- (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl )-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl )-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin -4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain - (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin -4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)- 8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methylmorph olin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-on

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain - (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methylmorph olin-4-yl)-8- trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(1 -oxa-6-azaspiro[3.3]hept-6-yl)-2- oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methyl morpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain - (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methyl morpholin-4-yl)- 8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(1 -oxa-6-azaspiro[3.3]hept- 6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimi do[1 ,2-a]pyrimidin-

4-one and also the pharmaceutically acceptable addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I). The invention also relates to pharmaceutical compositions containing, as active ingredient, at least one of the products of formula (I) as defined above or a pharmaceutically acceptable salt of this product or a prodrug of this product and, where appropriate, a pharmaceutically acceptable carrier. The invention also extends to the pharmaceutical compositions containing, as active ingredient, at least one of the medicaments as defined above.

Such pharmaceutical compositions of the present invention can also, where appropriate, contain active ingredients of other anti-mitotic medicaments, such as, in particular, those based on taxol, cisplatin, DNA- intercalating agents, and the like.

These pharmaceutical compositions can be administered orally, parenterally or locally by topical application to the skin and the mucous membranes or by intravenous or intramuscular injection.

These compositions may be solid or liquid and be in any of the pharmaceutical forms commonly used in human medicine, for instance simple or sugar-coated tablets, pills, lozenges, gel capsules, drops, granules, injectable preparations, ointments, creams or gels; they are prepared according to the usual methods. The active ingredient may be incorporated therein with excipients normally used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or nonaqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting agents, dispersants or emulsifiers, or preservatives.

The usual dosage, which is variable according to the product used, the individual treated and the condition in question, can be, for example, from 0.05 to 5 g per day in adults, or preferably from 0.1 to 2 g per day.

A subject of the present invention is also the use of products of formula (I) as defined above, for preparing a medicament intended for the treatment or prevention of a disease characterized by the dysregulation of the activity of a protein or lipid kinase.

Such a medicament can in particular be intended for the treatment or prevention of a disease in a mammal. A subject of the present invention is in particular the use of a product of formula (I) as defined above, for preparing a medicament intended for the prevention or treatment of diseases associated with an uncontrolled proliferation. A subject of the present invention is thus quite particularly the use of a product of formula (I) as defined above, for preparing a medicament intended for the treatment or prevention of diseases in oncology, and in particular intended for the treatment of cancers. A subject of the present invention is the products of formula (I) as defined above, for use thereof in the treatment of solid or liquid tumours.

The cited products of the present invention can in particular be used for the treatment of primary tumours and/or of metastases, in particular in gastric, hepatic, renal, ovarian, colon, prostate, endometrial and lung (NSCLC and SCLC) cancers, glioblastomas, thyroid, bladder and breast cancers, in melanoma, in lymphoid or myeloid haematopoietic tumours, in sarcomas, in brain, larynx and lymphatic system cancers, bone and pancreatic cancers, and in hamartomas.

A subject of the present invention is also the use of the products of formula (I) as defined above, for preparing medicaments intended for cancer chemotherapy. A subject of the present invention is therefore the products of formula (I) as defined above, for use thereof in cancer chemotherapy, alone or in combination. The products of the present application can in particular be administered alone or in combination with chemotherapy or radiotherapy or else in combination, for example, with other therapeutic agents. Such therapeutic agents may be commonly used antitumour agents.

A therapeutic benefit can in particular be expected when administering the products of the present application in combinations with varied targeted therapies. These targeted therapies are in particular the following: i) targeted therapies which inhibit kinases or pseudo-kinases such as EGFR, HER2, HER3, PI3K, AKT, mTOR, Bcr-Abl, Kit, PDGFR or Src (QW. Fan et al., Since signaling 2010, A. Gupta et al. PNAS 2010, X Li et al. Cancer Res 2010, A Vazquez-Martin et al. PLos One 2009, Z. Wu et al . Genes Cancer 2010) ii) targeted therapies which inhibit the oestrogen receptor, the proteasome, the HDAC protein (JS Samaddar et al . Mol Cancer Ther 2008, B; Hoang et al. Mol Cancer Ther 2009, JS Carew et al. Blood 2007). A therapeutic effect can also be expected when combining the products of the present application with chemotherapy agents such as camptothecin, taxotere or 5-FU, for example; or else when combining them with radiotherapy (J Li et al. Eur J of Cancer 2010, A. Appel et al. Cancer Res 2008).

A subject of the present invention is in particular the use of a product of formula (I) as defined above, for preparing a medicament intended for the prevention or treatment of lysosomal diseases such as glycogenosis type II (or Pompe's disease) or Danon disease, for example (N. Raben et al., Autophagy 2010, B Levine et al. Cell 2008, N . Mizushima et al. Nature 2008). Such medicaments intended for the treatment of lysosomal diseases can be used alone or in combination, for example, with other therapeutic agents.

A subject of the present invention is also the use of a product of formula (I) as defined above, for preparing a medicament intended for the prevention or treatment of X-linked myotubular myopathies, Charcot-Marie- Tooth disease; where mutations of the proteins of the myotubularin family have been described (I. Vergne et al ., FEBS Lett, 2010). A subject of the present invention is thus the use as defined above, in which said products of formula (I) are alone or in combination. Among the cancers, the treatment of solid or liquid tumours, and the treatment of cancers resistant to cytotoxic agents are of interest.

The products of the present application can in particular be administered alone or in combination with chemotherapy or radiotherapy or else in combination, for example, with other therapeutic agents. Such therapeutic agents may be commonly used antitumour agents. As kinase inhibitors, mention may be made of butyrolactone, flavopiridol, 2(2-hydroxyethylamino)-6-benzylamino-9-methylpurine known as olomucine, sorafenib, imatinib, erlotinib, gefitinib and lapatinib. Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof as a VPS34 inhibitor.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in the treatment of cancers.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in the treatment of solid or liquid tumours.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in the treatment of cancers resistant to cytotoxic agents.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in the treatment of primary tumours and/or of metastases, in particular in gastric, hepatic, renal, ovarian, colon, prostate and lung (NSCLC and SCLC) cancers, glioblastomas, thyroid, bladder and breast cancers, in melanoma, in lymphoid or myeloid haematopoietic tumours, in sarcomas, in brain, larynx and lymphatic system cancers, bone and pancreatic cancers, and in hamartomas.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in cancer chemotherapy.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in cancer chemotherapy, alone or in combination.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in the treatment of lysosomal diseases such as glycogenosis type II (or Pompe's disease) or Danon disease. Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in the treatment of X-linked myotubular myopathies and Charcot-Marie-Tooth disease.

A subject of the present invention is also, as novel industrial products, certain starting products or synthesis intermediates of formulae A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, T1 , T2 and T3 as defined above.

A subject of the present invention is thus in particular, as novel industrial products, the starting products or synthesis intermediates as defined above and hereinafter: - of formulae A, B, G and N:

in which n = 1 , one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and PG is a protective group for amine; - of formulae E, F, I and J:

in which q = 0, one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and the substituents p, PG, R1 and R4 have the definitions indicated above and hereinafter; - of formulae P and H: in which the substituents n, p, q, PG, R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 and R12 have the definitions indicated above and hereinafter;

- of formula Q:

in which either q = 0, one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and the substituents p, PG, R1 and R4 have the definitions indicated above and hereinafter, or R1 is -(CH 2 ) m - Ra with Ra being -CO-cycloalkyl, -CO-heterocycloalkyl, -CO-Rb, -C(Rb)=N- ORc, -CO 2 Rd or -CONRxRy, and the substituents p, q, R2, R3 and R4 have the definitions indicated above and hereinafter.

The following examples which are products of formula (I) illustrate the invention without, however, limiting it.

The following examples which are products of formula (I) according to the present invention can be prepared according to the usual methods known to those skilled in the art, and in particular as indicated above or below, and in the schemes and Tables 1 to 10.

Experimental section

The nomenclature of the compounds of this present invention was performed with the ACDLABS version 10.0 software.

The microwave oven used is a Biotage, Initiator™ Eight, 400W max, 2450 MHz apparatus. The 1 H NMR spectra at 400 MHz and 1 H NMR spectra at 500 MHz were carried out on a Bruker Avance 250 or Bruker Avance DRX-400 or Bruker Avance DPX-500 spectrometer with the chemical shifts (δ in ppm) in the solvent dimethyl sulfoxide^ (DMSO-d6) referenced at 2.5 ppm at the temperature of 303K.

The mass spectra (MS) were obtained either by method A or by method B.

Method A:

Waters UPLC-SQD apparatus; Ionization: positive and/or negative mode electrospray (ES+/-); Chromatographic conditions: Column: Acquity BEH C18 1 .7 pm - 2.1 x 50 mm; Solvents: A: H 2 O (0.1 % formic acid) B: CH 3 CN (0.1 % formic acid); Column temperature: 50°C; Flow rate: 1 ml/min; Gradient (2 min): from 5% to 50% of B in 0.8 min; 1 .2 min: 100% of B; 1 .85 min: 100% of B; 1 .95 min: 5% of B; Retention time = Tr (min). Method B:

Waters ZQ apparatus; Ionization: positive and/or negative mode electrospray (ES+/-); Chromatographic conditions: Column: XBridge C18 2.5 Mm - 3 x 50 mm; Solvents: A: H 2 O (0.1 % formic acid) B: CH 3 CN (0.1 % formic acid); Column temperature: 70°C; Flow rate: 0.9 ml/min; Gradient (7 min): from 5% to 100% of B in 5.3 min; 5.5 min: 100% of B; 6.3 min: 5% of B; Retention time = Tr (min).

The optical rotations (ORs) were measured on a model 341 polarimeter from Perkin Elmer. Wavelength: sodium a line (589 nm).

The intermediates of type F as defined in the schemes above, i.e. F1 to F9 defined in Table 1 below, resulting in Examples 1 to 295, can be prepared in the following way:

Intermediate F1

(S)-2-Chloro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-py rimido[1 ,2- a]pyrimidin-4-one can be prepared in the following way.

The separation of the two enantiomers of (8R,8S)-2-chloro-8- (trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one (17 g) is carried out by chiral chromatography: stationary phase: Chiralpak AD; mobile phase: EtOH (20%) / Heptane (80%). The laevorotatory enantiomer is concentrated so as to give 8.52 g of (R)-2-chloro-8-(trifluoromethyl)-6, 7,8,9- tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one, in the form of a white powder. The dextrorotatory enantiomer is concentrated so as to obtain 8.21 g of (S)-2- chloro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4- one, in the form of a white powder, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.51

[a] D 25 at 589 nm = + 21 .3 +/- 0.5 (MeOH) (8R, 8S)-2-Chloro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrim ido[1 ,2-a] pyrimidin-4-one can be prepared in the following way.

60 ml of phosphorus oxychloride are added, at ambient temperature and under an argon atmosphere, to a suspension of 34 g of (8R,8S)-2- hydroxy-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4- one in 500 ml of 1 ,2-dichloroethane. The mixture obtained is then heated to 65°C. After three hours of stirring at 65°C, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 100 ml of cold water and 400 ml of ethyl acetate. 32% sodium hydroxide is added to the mixture obtained, to pH = 6. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure, so as to give an orange residue. This residue is purified by chromatography on silica (eluent: CH 2 Cl2/MeOH: 97/03) so as to give 20 g of (8R,8S)-2-chloro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-p yrimido[1 ,2- a]pyrimidin-4-one, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.51

(8R,8S)-2-Hydroxy-8-(trifluoromethyl)-6,7,8,9-tetrahydro- 4H- pyrimido[1 ,2-a]pyrimidin-4-one can be prepared in the following way.

10 g of (4R,4S)-4-(trifluoromethyl)-1 ,4,5,6-tetrahydropyrimidin-2- ylamine hydrochloride and 10 g of sodium methoxide are added to 50 ml of diethyl malonate. The mixture obtained is brought to 100°C for 75 minutes. The heterogeneous mixture thickens and becomes yellow, with a slight release of gas. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is triturated with ethyl ether. The solid formed is filtered off through a sintered glass funnel and then taken up with 20 ml of cold water. 12N hydrochloric acid is added to the thick suspension obtained, to pH = 5-6. The suspension obtained is filtered through a sintered glass funnel and the insoluble matter is rinsed with ethyl ether so as to give 1 1 .5 g of (8R,8S)-2-hydroxy-8-(trifluoromethyl)-6,7,8,9-tetrahydro- 4H-pyrimido[1 ,2-a]pyrimidin-4-one, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 236; [M-H]-: m/z 234; Tr (min) = 0.26

(4R,4S)-4-(Trifluoromethyl)-1 ,4,5,6-tetrahydropyrimidin-2-ylamine hydrochloride can be prepared in the following way.

A mixture of 1 .1 g of 10% Pd/C, 22 g of 2-amino-4- (trifluoromethyl)pyrimidine dissolved in 200 ml of water, 50 ml of methanol and 50 ml of 12N HCI is hydrogenated at 3 bar, at 22°C, for 24 hours in an autoclave. The resulting mixture is then filtered and the filtrate is concentrated under reduced pressure. The residue obtained is oven-dried, in the presence of P 2 O 5 , so as to give 27 g of (4R,4S)-4-(trifluoromethyl)-1 ,4,5,6- tetrahydropyrimidin-2-ylamine hydrochloride, in the form of a grey solid, the characteristics of which are the following: Mass spectrum (method A), ES+/-: [M+H]+: m/z 168; Tr (min) = 0.17

Intermediate F2

(8S)-2-chloro-3-fluoro-8-(trifluoromethyl)-6,7,8,9-tetrah ydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one can be prepared in the following way.

The separation of the enantiomers of (8R,8S)-2-chloro-3-fluoro-8- (trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one is carried out by chiral chromatography (Chiralpak AD 20μηη 80x350 mm 250 ml/min 254 nm; 5% EtOH 5% MeOH 90% Heptane +0.1 % TEA), using 6.8 g of a racemic mixture. The dextrorotatory enantiomer is concentrated so as to obtain 3.13 g of (8S)-2-chloro-3-fluoro-8-(trifluoromethyl)-6,7,8,9-tetrahydr o- 4H-pyrimido[1 ,2-a]pyrimidin-4-one, in the form of a white solid, the characteristics of which are the following:

[CX] D 25 at 589 nm= + 19.6 +/- 0.6 (c = 2.488 mg / 0.5 ml MeOH)

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 272; [M-H]-: m/z 270; Tr (min) = 0.62 (8R, 8S)-2-Chloro-3-fluoro-8-(trifluoromethyl)-6,7,8,9-tetrahydro -4H- pyrimido[1 ,2-a]pyrinnidin-4-one can be prepared in the following way.

8 ml of phosphorus oxychloride are added to a solution of 6.5 g of (8R, 8S)-3-fluoro-2-hydroxy-8-(trifluoromethyl)-6,7,8,9-tetrahydr o-4H-pyrimido[1 ,2- a]pyrimidin-4-one in 80 ml of 1 ,2-dichloroethane. After stirring for 4 hours at a temperature of 65°C and returning to a temperature of about 20°C, the reaction mixture is concentrated to dryness under reduced pressure. The residue is diluted in 150 ml of ethyl acetate and 10 ml of ice-cold water. At a temperature between 0°C and 10°C, a concentrated sodium hydroxide solution is added until a pH between 6 and 7 is obtained. The solid form is filtered off so as to give 3.5 g of a beige solid S1 . The filtrate is separated by settling out, and the organic phase is dried over anhydrous magnesium sulfate, filtered, and concentrated to dryness under reduced pressure. After purification of the residue on a silica column (eluent: 97/03 CH2CI2 / MeOH), 3.3 g of a pale yellow solid S2 are obtained. The two solids S1 and S2 are combined so as to give 6.8 g of (8R, 8S)-2-chloro-3-fluoro-8-(trifluoromethyl)- 6,7,8,9-tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one, in the form of a pale yellow powder, the characteristics of which are the following: Mass spectrum (method B) (ES+/-) [M+H]+: m/z 272; [M-H]-: m/z 270;

Tr (min) = 2.9

(8R, 8S)-3-Fluoro-2-hydroxy-8-(trifluoromethyl)-6,7,8,9-tetrahydr o-4H- pyrimido[1 ,2-a]pyrimidin-4-one can be prepared in the following way. 5.6 g of sodium methoxide are added to a suspension of 7 g of

(4R,4S)-4-(trifluoromethyl)-1 ,4,5,6-tetrahydropyrimidin-2-ylamine hydrochloride in 35 ml of dimethyl fluoropropanedioate. After stirring the suspension for 3 hours at a temperature of 100°C, the medium obtained is concentrated to dryness under reduced pressure. The residue is taken up in diethyl ether and then dried with suction under vacuum. The solid obtained is taken up in 14 ml of water, and the resulting mixture is cooled in ice, before acidification to pH 5-6 by addition of concentrated hydrochloric acid (25%). After 2 hours of stirring at a temperature of 0°C and then overnight at a temperature of about 20°C, the suspension is filtered and then the solid is dried with suction and dried under vacuum over P2O 5 . 6.5 g of (8R, 8S)-3- fluoro-2-hydroxy-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-p yrimido[1 ,2- a]pyrimidin-4-one are obtained in the form of a yellow powder, the characteristics of which are the following:

Mass spectrum (method A) (ES +/-) [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.28 Intermediate F3

(R)-8-chloro-4-(trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2- a]pyrimidin-6(2H)-one can be prepared in the following way.

H and H

The separation of the two enantiomers of (4R,4S)-chloro-4- (trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2-a]pyrimidin-6(2H)-one (4.5 g) is carried out by chiral chromatography: stationary phase: AS 20μηη; mobile phase: 5% MeOH; 10% EtOH; 85% Heptane; 0.1 % TEA. The laevorotatory enantiomer is concentrated so as to give 2.07 g of (R)-8-chloro-4- (trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2-a]pyrimidin-6(2H)-one, in the form of a white powder, [a] D 25 at 589 nm = -32.7 +/- 0.7 (DMSO). The dextrorotatory enantiomer is concentrated so as to obtain 2.19 g of (S)-8- chloro-4-(trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2-a]pyrimidin-6(2H)-one, in the form of a cream powder, [a] D 25 at 589 nm = +29.2 +/- 0.8 (DMSO). 8-Chloro-4-(trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2-a]pyrimidin- 6(2H)-one can be prepared in the following way.

16 ml of trifluoromethanesulfonic acid are added, at ambient temperature and under an argon atmosphere, to a solution of 8.1 g of 2- chloro-9-(2,4-dimethoxybenzyl)-6-trifluoromethyl-6, 7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one in 200 ml of 1 ,2-dichloromethane. The mixture obtained is then stirred at ambient temperature for one hour. The reaction is complete according to the verification by LC/MS. The reaction medium is cooled in an ice bath. 32% sodium hydroxide is added dropwise to pH = 10. The white solid formed is filtered off so as to give 7 g of the solid S1 . After separation of the filtrate by settling out, the organic phase is dried over magnesium sulfate, filtered, and concentrated under reduced pressure, so as to give 0.9 g of the solid S2. The solid S1 is taken up with water and ethyl acetate. After separation by settling out, the organic phase is dried over magnesium sulfate, filtered, and concentrated under reduced pressure, so as to give 3.5 g of the solid S3. The two solids S2 and S3 are combined for purification by chromatography on silica (eluent: Ch C^/EtOAc: 90/10) so as to give 4.08 g of 8-chloro-4-(trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2- a]pyrimidin-6(2H)-one, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.56

2-Chloro-9-(2,4-dimethoxybenzyl)-6-trifluoromethyl-6,7,8, 9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one can be prepared in the following way.

14 ml of phosphorus oxychloride are added, at ambient temperature and under an argon atmosphere, to a suspension of 1 1 .5 g of 9-(2,4- dimethoxybenzyl)-2-hydroxy-6-trifluoromethyl-6,7,8,9-tetrahy dropyrimido[1 ,2- a]pyrimidin-4-one in 140 ml of 1 ,2-dichloroethane. The mixture obtained is then heated to 65°C. After one hour of stirring at 60°C, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 30 ml of cold water and 200 ml of ethyl acetate. 32% sodium hydroxide is added to the mixture obtained, to pH = 8. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica, eluents: dichloromethane/EtOAc: 97/03, so as to give 8.2 g of 2-chloro-9-(2,4- dimethoxybenzyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimid o[1 ,2-a]pyrimidin- 4-one, the characteristics of which are the following:

Mass spectrum (method B): ES+/-: [M+H]+: m/z 404; Tr (min) = 4.54 then CH 2 CI 2 /EtOAc: 85/15, so as to give 0.64 g of 8-chloro-4- (trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2-a]pyrimidin-6(2H)-one, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.56

9-(2,4-Dimethoxybenzyl)-2-hydroxy-6-trifluoromethyl-6, 7,8,9- tetrahydropyrimido[1 ,2-a]pyrimidin-4-one can be prepared in the following way.

35 ml of methyl malonate and 13 g of anhydrous sodium methoxide are added, at ambient temperature and under an argon atmosphere, to a suspension of 19.1 g of 1 -(2,4-dimethoxybenzyl)-4-trifluoromethyl-1 ,4,5,6- tetrahydropyrimidin-2-ylamine in 175 ml of methanol. The mixture obtained is then heated at reflux. After six hours of stirring at reflux, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 20 ml of cold water and 400 ml of ethyl acetate. 36% HCI is added dropwise to pH = 5-6. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica, eluents: dichloromethane/MeOH : 98/02, so as to give 1 1 .6 g of 9-(2,4- dimethoxybenzyl)-2-hydroxy-6-trifluoromethyl-6,7,8,9-tetrahy dropyrimido[1 ,2- a]pyrimidin-4-one, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 386; [M-H]-: m/z 384; Tr (min) = 0.78

1 -(2,4-Dimethoxybenzyl)-4-trifluoromethyl-1 ,4,5,6-tetrahydropyrimidin- 2-ylamine can be prepared in the following way.

5.7 g of cyanogen bromide are added, in small amounts, at ambient temperature and under an argon atmosphere, to a solution of 14.2 g of N1 - (2,4-dimethoxybenzyl)-4,4,4-trifluorobutane-1 ,3-diamine in 150 ml of acetonitrile. At the end of the addition, the mixture obtained is then heated at reflux for three hours in an oil bath preheated to 100°C. After cooling, the reaction mixture is evaporated to dryness under reduced pressure, so as to give 19.1 1 g of 1 -(2,4-dimethoxybenzyl)-4-trifluoromethyl-1 ,4,5,6- tetrahydropyrimidin-2-ylamine in the form of a pale yellow foam, which will be used as it is in the next step and the characteristics of which are the following: Mass spectrum (method B): ES+/-: [M+H]+: m/z 318; Tr (min) = 2.67

N1 -(2,4-Dimethoxybenzyl)-4,4,4-trifluorobutane-1 ,3-diamine can be prepared in the following way.

8 g of LiAIH are added, in small portions, at ambient temperature and under an argon atmosphere, to a solution of 10.6 g of 3-amino-N-(2,4- dimethoxybenzyl)-4,4,4-trifluorobutyramide in 500 ml of anhydrous ethyl ether. At the end of the addition, the reaction medium, a suspension, is stirred at ambient temperature for 48 hours. The reaction medium is cooled to 4°C in an ice bath, and then 1 1 ml of water, followed by 1 1 ml of 4N NaOH and then 22 ml of water are added dropwise. The white precipitate formed is filtered off. The filtrate is dried over magnesium sulfate and then concentrated under reduced pressure, so as to give 9.5 g of N1 -(2,4-dimethoxybenzyl)-4,4,4- trifluorobutane-1 ,3-diamine, in the form of a colourless oil, which is used as it is in the next step. Mass spectrum (method A): ES+/-: [M+H]+: m/z 293; ES+ base peak: m/z 151 ; Tr (min) = 0.33

3-Amino-N-(2,4-dimethoxybenzyl)-4,4,4-trifluorobutyramide can be prepared in the following way.

23.4 g of 2,4-dimethoxybenzylamine are added in one step to a suspension of 20 g of 3-amino-4-trifluorobutyric acid in 120 ml of DMF, followed, dropwise, by 41 g of phenylsilane, said additions being carried out while maintaining the temperature of the reaction medium between 20 and 28°C. At the end of the addition, the reaction medium, a suspension, is stirred at ambient temperature for 48 hours. The reaction medium is cooled to 4°C in an ice bath, and then 200 ml of water, followed by 300 ml of ethyl acetate, are added dropwise. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is taken up with 500 ml of methanol. The white solid formed is filtered off. The filtrate is concentrated under reduced pressure. The residue obtained is purified by chromatography on silica, eluents: dichloromethane/MeOH: 95/05, so as to give 25 g of 3-amino-N-(2,4- dimethoxybenzyl)-4,4,4-trifluorobutyramide, in the form of a pasty white solid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 307; ES+ base peak: m/z 151 ; Tr (min) = 2.38 Alternative intermediate F3: Alternatively, (R)-8-chloro-4-

(trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2-a]pyrimidin-6(2H)-one can be prepared in the following way.

3.7 ml of phosphorus oxychloride are added, at ambient temperature and under an argon atmosphere, to a suspension of 3.2 g of (R)-8-hydroxy-4- (trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2-a]pyrimidin-6(2H)-one in 37 ml of 1 ,2-dichloroethane. The mixture obtained is then heated to 65°C. After 4 hours of stirring at 60°C, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 50 ml of cold water and 200 ml of ethyl acetate. 32% sodium hydroxide is added to the mixture obtained, to pH = 10. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica, eluents: CH 2 CI 2 /MeOH: 96/04), so as to give 2.53 g of (R)-8-chloro-4-(trifluoromethyl)- 3,4-dihydro-1 H-pyrimido[1 ,2-a]pyrimidin-6(2H)-one, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.56 (R)-8-Hydroxy-4-(trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2- a]pyrimidin-6(2H)-one can be prepared in the following way.

50 ml of trifluoroacetic acid are added, at ambient temperature and under an argon atmosphere, to a suspension of 7.5 g of (R)-8-hydroxy-1 -((S)- 1 -(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2- a]pyrimidin-6(2H)-one in 50 ml of 1 ,2-dichloromethane. The reaction medium is stirred at ambient temperature for 18 hours. After a verification by LC/MS, 51 % of the starting product remains. 25 ml of trifluoroacetic acid are added. After 40 hours of stirring, the reaction is complete according to the verification by LC/MS. The reaction medium is concentrated to dryness under reduced pressure. The residue obtained is taken up with 1 0 ml of ice-cold water. 32% sodium hydroxide is added dropwise to pH = 6. The mixture is concentrated to dryness under reduced pressure. The residue obtained is taken up with an 80/20 dichloromethane/MeOH mixture and filtered, and then the filtrate is concentrated to dryness under reduced pressure. The residue obtained is purified by chromatography on silica (eluent: Ch C^/MeOH: 75/25), so as to give 2.4 g of (R)-8-hydroxy-7-fluoro-4-(trifluoromethyl)-3,4-dihydro-1 H- pyrimido[1 ,2-a]pyrimidin-6(2H)-one, in the form of a white solid, the characteristics of which are the following:

OR= -22.5+/-0.6. C=2.702mg/0.5ml DMSO. On 589 nm.

(R)-8-hydroxy-1 -((S)-1 -(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4- dihydro-1 H-pyrimido[1 ,2-a]pyrimidin-6(2H)-one can be prepared in the following way.

29 g of methyl malonate and 10 g of anhydrous sodium methoxide are added, at ambient temperature and under an argon atmosphere, to a suspension of 1 1 g of (S)-1 -[(S)-1 -(4-methoxyphenyl)ethyl]-4-trifluoromethyl- 1 ,4,5,6-tetrahydropyrimidin-2-ylamine in 150 ml of methanol. The mixture obtained is then heated at reflux. After 4 hours of stirring at reflux, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is purified by chromatography on silica, eluents: dichloromethane/MeOH : 95/05, so as to give 1 1 .6 g of (R)-8-hydroxy-1 -((S)-1 - (4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2- a]pyrimidin-6(2H)-one, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 370; [M-H]-: m/z 368; Tr (min) = 1 .06 OR=-96.3 +/- 1 .7 at 589nm weighed 1 .623mg ds 0.5ml DMSO

(S)-1 -[(S)-1 -(4-Methoxyphenyl)ethyl]-4-trifluoromethyl-1 ,4,5,6- tetrahydropyrimidin-2-ylamine can be prepared in the following way.

4.6 g of cyanogen bromide are added, in small amounts, at ambient temperature and under an argon atmosphere, to a solution of 1 1 g of (S)-4,4,4-trifluoro-N1 -[(S)-1 -(4-methoxyphenyl)ethyl]butane-1 ,3-diamine in 100 ml of acetonitrile. At the end of the addition, the mixture obtained is then heated at reflux for two hours in an oil bath preheated to 100°C. After cooling, the reaction mixture is evaporated to dryness under reduced pressure, so as to give 1 1 g of a brown foam. 50 ml of water and 200 ml of EtOAc are added to this foam, followed by 32% sodium hydroxide to pH = 14. After separation by settling out, the organic phase is dried over magnesium sulfate, filtered, and then concentrated under reduced pressure, so as to give a residue of 1 1 g of a thick oil.

This residue is purified on a silica column, eluent: dichloromethane/MeOH/28% NH 4 OH: 90/10/0.5 then dichloro- methane/MeOH/28% NH 4 OH : 60/40/5, so as to give 8 g of (S)-1 -[(S)-1 - (4-methoxyphenyl)ethyl]-4-trifluoromethyl-1 ,4,5,6-tetrahydropyrimidin-2- ylamine, in the form of a pale yellow foam, which will be used as it is in the next step and the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 302; Tr (min) = 0.57

(S)-4,4,4-Trifluoro-N 1 -[(S)-1 -(4-methoxyphenyl)ethyl]butane-1 ,3-diamine can be prepared in the following way.

1 1 .7 g of LiAIH are added, in small portions, at ambient temperature and under an argon atmosphere, to a solution of 15 g of (S)-3-amino-4,4,4- trifluoro-N-[(S)-1 -(4-methoxyphenyl)ethyl]butyramide in 600 ml of anhydrous ethyl ether. At the end of the addition, the reaction medium, a suspension, is stirred at ambient temperature for 72 hours. The reaction medium is cooled to 4°C in an ice bath, and then 9.7 ml of water, followed by 9.7 ml of 4N NaOH and then 19.4 ml of water, are added dropwise. The white precipitate formed is filtered off. The filtrate is dried over MgSO 4 and then concentrated under reduced pressure, so as to give 1 1 .2 g of (S)-4,4,4-trifluoro-N1 -[(S)-1 -(4-methoxyphenyl)ethyl]butane-1 ,3-diamine, in the form of a colourless oil, which is used as it is in the next step and the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 277; Tr (min) = 0.32 (S)-3-Amino-4,4,4-trifluoro-N-[(S)-1 -(4-methoxyphenyl)ethyl]butyramide and (R)-3-amino-4,4,4-trifluoro-N-[(S)-1 -(4-methoxyphenyl)ethyl]butyramide can be prepared in the following way.

32.8 g of (S)-(-)-1 -(4-methoxyphenyl)ethylamine are added in one step to a suspension of 31 g of 3-amino-4-trifluorobutyric acid in 300 ml of DMF, followed, dropwise, by 64 g of phenylsilane, said additions being carried out while maintaining the temperature of the reaction medium between 25 and 35°C. At the end of the addition, the reaction medium, a suspension, is stirred at ambient temperature for 48 hours. The reaction medium is cooled to 4°C in an ice bath, and then 200 ml of water, followed by 400 ml of ethyl acetate, are added dropwise. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is taken up with 500 ml of methanol. The white solid formed is filtered off. The filtrate is concentrated under reduced pressure. The residue obtained is purified by chromatography on silica, eluents: 90/10 dichloromethane/EtOAc, so as to give 15 g of (S)-3-amino-4,4,4- trifluoro-N-[(S)-1 -(4-methoxyphenyl)ethyl]butyramide, in the form of a white solid, the characteristics of which are the following: Mass spectrum (method A): ES+/-: [M+H]+: m/z 291 ; [M-H]-: m/z 289;

ES+ base peak: m/z 135; Tr (min) = 0.46

[a] D 25 at 589 nm = -31 .8 +/- 0.9 (DMSO)

Then eluent with 50/50 dichloromethane/EtOAc, so as to give 12 g of (R)-3- amino-4,4,4-trifluoro-N-[(S)-1 -(4-methoxyphenyl)ethyl]butyramide, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 291 ; ES+ base peak: m/z 135; Tr (min) = 0.47

[a] D 25 at 589 nm = -78 +/- 1 .5 (DMSO)

Intermediate F4: (R)-8-Chloro-7-fluoro-4-(trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2- a]pyrimidin-6(2H)-one can be prepared in the following way.

30 ml of trifluoroacetic acid are added, at ambient temperature and under an argon atmosphere, to a solution of 4 g of (R)-8-chloro-7-fluoro-1 - ((S)-1 -(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1 H- pyrimido[1 ,2-a]pyrimidin-6(2H)-one in 30 ml of 1 ,2-dichloromethane. The reaction medium is stirred at ambient temperature for 18 hours. The reaction medium turns a dark violet colour. The reaction is complete according to the verification by LC/MS. The reaction medium is concentrated to dryness under reduced pressure. The residue obtained is taken up with 100 ml of dichloromethane and 50 ml of ice-cold water. 32% sodium hydroxide is added dropwise to pH = 10. After separation by settling out, the organic phase is dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is taken up with ethyl ether and the white solid formed is filtered off, so as to give 2.1 g of the solid S1 . The filtrate is concentrated to dryness under reduced pressure and the residue obtained is purified by chromatography on silica (eluent: Ch C^/EtOAc: 97/03), so as to give 0.35 g of the solid S2. The two solids S1 and S2 are combined so as to give 2.45 g of (R)-8-chloro-7-fluoro-4-(trifluoromethyl)-3,4-dihydro-1 H- pyrimido[1 ,2-a]pyrimidin-6(2H)-one, in the form of a white solid, used as it is in the next step.

(R)-8-Chloro-7-fluoro-1 -((S)-1 -(4-methoxyphenyl)ethyl)-4- (trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2-a]pyrimidin-6(2H)-one can be prepared in the following way.

10.8 ml of phosphorus oxychloride are added, at ambient temperature and under an argon atmosphere, to a suspension of 15 g of (R)-7-fluoro-8- hydroxy-1 -((S)-1 -(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1 H- pyrimido[1 ,2-a]pyrimidin-6(2H)-one in 100 ml of 1 ,2-dichloroethane. The mixture obtained is then heated to 65°C. After 3 hours of stirring at 60°C, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 100 ml of cold water and 300 ml of ethyl acetate. 32% sodium hydroxide is added to the mixture obtained, to pH = 10. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica, eluents:

- dichloromethane/EtOAc: 98/02, so as to give 4 g of (R)-8-chloro-7- fluoro-1 -((S)-1 -(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1 H- pyrimido[1 ,2-a]pyrimidin-6(2H)-one, used in the next step.

- CH 2 CI 2 /EtOAc: 95/05, so as to give 2.5 g of (R)-8-chloro-7-fluoro-4- (trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2-a]pyrimidin-6(2H)-one, in the form of a white solid.

(R)-7-Fluoro-8-hydroxy-1 -((S)-1 -(4-methoxyphenyl)ethyl)-4- (trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2-a]pyrimidin-6(2H)-one can be prepared in the following way.

30 g of methyl fluoromalonate and 10.8 g of anhydrous sodium methoxide are added, at ambient temperature and under an argon atmosphere, to a suspension of 12 g of (S)-1 -[(S)-1 -(4-methoxyphenyl)ethyl]- 4-trifluoromethyl-1 ,4,5,6-tetrahydropyrimidin-2-ylamine in 150 ml of methanol. The mixture obtained is then heated at reflux. After one hour of stirring at reflux, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up with 100 ml of cold water. 36% HCI is added dropwise to pH = 6. The solid formed is filtered off and then washed three times with ethyl ether. The solid is oven-dried under vacuum in the presence of P2O 5 , so as to give 15 g of (R)-7-fluoro-8-hydroxy-1 -((S)-1 -(4- methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1 H-pyrimido[1 ,2- a]pyrimidin-6(2H)-one, which is used as it is in the next step.

Intermediate F5: (8S)-2-Chloro-8-methyl-8-(trifluoromethyl)-6,7,8,9-tetrahydr o-4H- pyhmido[1 ,2-a]pyrimidin-4-one and (8R)-2-chloro-8-methyl-8-(trifluoromethyl)- 6,7,8,9-tetrahydro-4H-pyrinnido[1 ,2-a]pyrimidin-4-one can be prepared in the following way.

A suspension of 410 mg (1 .645 mmol) of 2-hydroxy-8-methyl-8- (trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one in 22 ml of 1 ,2-dichloroethane is treated at ambient temperature with 0.767 ml of phosphorus trichloride. The reaction medium is heated at 65°C for 7 h 15 min. It is then evaporated to dryness under reduced pressure (2.7 kPa). The residue obtained is taken up with 3 ml of water and 30 ml of ethyl acetate, cooled in an ice bath and basified to pH 9 with 32% aqueous NaOH, and then the organic phase is separated. The aqueous phase is extracted with 20 ml of ethyl acetate. The organic phases are combined, dried over magnesium sulfate and then filtered through a sintered glass funnel, and the filtrate is evaporated to dryness under reduced pressure (2.7 kPa). The crude obtained is purified by flash chromatography on silica [eluent: dichloromethane/1 - propanol/acetonitrile (100/0/0 then 96/2/2 by volume)]. After evaporation of the fractions under reduced pressure, 217 mg of 2-chloro-8-methyl-8- (trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one are obtained, in the form of a white solid (mixture of enantiomers). Mass spectrum (method A): ES+/-: [M+H]+: m/z 268; [M-H]-: m/z 266; Tr (min) = 0.58

The mixture of enantiomers is purified by preparative chromatography on a chiral column under the following conditions:

Technique: Prochrom

Chiral stationary phase: AD 20μηη, lot CFB03

Mobile phase: 85% Heptane - 15% EtOH

Flow rate: 260 ml/min

Detection: UV 254 nm

After evaporation of the fractions under reduced pressure, 93 mg of (8R)-2-chloro-8-methyl-8-(trifluoromethyl)-6,7,8,9-tetrahydr o-4H- pyrimido[1 ,2-a]pyrimidin-4-one are obtained, in the form of a white solid.

The characteristics of this product are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 268; [M-H]-: m/z 266; Tr (min) = 0.59

Retention time by chiral phase HPLC: 6.6 minutes

Conditions used for the chiral phase HPLC:

Technique: Gilson

Chiral stationary phase: AD-H 5μηη 250x4.6 mm

Mobile phase: 85% Heptane - 15% EtOH

Flow rate: 1 ml/min

Detection: UV 254 nm After evaporation of the fractions, 104 mg of (8S)-2-chloro-8-methyl-8- (trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one are also obtained, in the form of a white solid.

The characteristics of this product are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 268; [M-H]-: m/z 266; Tr (min) = 0.59

1 H NMR spectrum (300 MHz, δ in ppm, DMSO-d6): 1 .45 (q, J=0.5 Hz, 3 H); 2.00 (m, 1 H); 2.35 (td, J=4,4 and 14.7 Hz, 1 H); 3.45 (m, 1 H); 4.1 1 (m, 1 H); 5.81 (s, 1 H); 9.16 (broad s, 1 H).

Retention time by chiral phase HPLC: 15.6 minutes

Conditions used for the chiral phase HPLC:

Technique: Gilson

Chiral stationary phase: AD-H 5μηη 250x4.6 mm

Mobile phase: 85% Heptane - 15% EtOH

Flow rate: 1 ml/min

Detection: UV 254 nm

2-Hydroxy-8-methyl-8-(trifluoromethyl)-6,7,8,9-tetrahydro -4H- pyrimido[1 ,2-a]pyrimidin-4-one can be prepared in the following way.

44 mg (1 .927 mmol) of sodium are dissolved in 4 ml of methanol under argon and then 101 mg (0.385 mmol) of 4-methyl-4- (trifluoromethyl)tetrahydropyrimidin-2(1 H)-imine hydrobromide in 2 ml of methanol are added, followed by 305 mg (2.312 mmol) of methyl malonate at ambient temperature. The reaction medium is heated at reflux for 5 h 45 min . After cooling, the reaction medium is evaporated to dryness under reduced pressure. The residue obtained is taken up in 0.5 ml of water and then, after cooling in a water-ice bath, 0.1 ml of an aqueous 8N hydrochloric acid solution is added to approximately pH = 5. The reaction medium is stirred in the cold bath for approximately 15 minutes and then, after having added approximately 3 ml of ethyl ether to the reaction medium, the latter is filtered through a sintered glass funnel . After drying under vacuum, 92 mg of 2- hydroxy-8-methyl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-p yrimido[1 ,2- a]pyrimidin-4-one are obtained, in the form of a beige solid. Mass spectrum (method A): ES+/-: [M+H]+: m/z 250; [M-H]-: m/z 248;

Tr (min) = 0.32

1 H NMR spectrum (300 MHz, δ in ppm, DMSO-d6): 1 .40 (s, 3 H); 1 .92 (m, 1 H); 2.22 (m, 1 H); 3.45 (m, 1 H); 3.95 (m, 1 H); 4.61 (broad s, 1 H); 10,30 ( broad m, 2 H). 4-Methyl-4-(trifluoromethyl)tetrahydropyrimidin-2(1 H)-imine

hydrobromide can be prepared in the following way.

A solution of 458 mg (2.933 mmol) of 2-methyl-2- (trifluoromethyl)butane-l ,4-diamine in 4 ml of acetonitrile is treated at ambient temperature with 31 1 mg (2.933 mmol) of cyanogen bromide. 12 ml of acetonitrile are then added and the solution is heated at reflux for 2 h 30 min. After evaporation to dryness under reduced pressure, 695 mg of 4-methyl-4- (trifluoromethyl)tetrahydropyrimidin-2(1 H)-imine hydrobromide are obtained in the form of a yellow solid.

Mass spectrum (method A): ES+/-: [M+H]+: m/z 182; Tr (min) (ELSD)

= 0.24 1 H NMR spectrum (300 MHz, δ in ppm, DMSO-d6): 1 .45 (s, 3 H); 1 .94

(m, 1 H); 2.17 (m, 1 H); 3.1 1 to 3.44 (partially masked m, 2 H); 6.97 (broad s, 2 H); 8.17 (broad s, 1 H); 8.60 (broad s, 1 H).

2-Methyl-2-(trifluoromethyl)butane-1 ,4-diamine can be prepared in the following way.

A suspension of 1 .17 g (4.751 mmol) of N 1 -benzyl-4,4,4-trifluoro-3- methylbutane-1 ,3-diamine and 758 mg (0.713 mmol) of palladium-on-carbon (10%) in 55 ml of ethanol and 2.090 ml (10.45 mmol) of an aqueous 5N hydrochloric acid solution is hydrogenated at 50°C under 10 bar of hydrogen for 68 h. The reaction medium is then filtered through celite and the filtrate is then evaporated to dryness. Toluene is added to the residue obtained and then the resulting product is evaporated to dryness, so as to give 1 .231 g of a yellow solid. This yellow solid is dissolved in 5 ml of water and then the solution is basified with approximately 2 ml of an aqueous 32% sodium hydroxide solution to pH = 12. The aqueous phase is extracted with ethyl ether, then the organic phases are combined, dried over magnesium sulfate and then filtered through a sintered glass funnel, and the filtrate is evaporated in a rotary evaporator under reduced pressure (the bath temperature is maintained below 25°C and the pump vacuum is maintained above 100 mbar). 469 mg of 2-methyl-2-(trifluoromethyl)butane-1 ,4-diamine are obtained, in the form of a yellow liquid. Mass spectrum (method A): ES+/-: [M+H]+: m/z 157; Tr (min) = 0.1 1

1 H NMR spectrum (300 MHz, δ in ppm, DMSO-d6): 1 .1 1 (s, 3 H); 1 .55 (m, 2 H); 1 .87 (broad m, 4 H); 2.68 (m, 2 H).

N 1 -benzyl-4,4,4-trifluoro-3-methylbutane-1 ,3-diamine can be prepared the following way.

A solution of 2.494 g (9.583 mmol) of 3-amino-N-benzyl-4,4,4-trifluoro- 3-methylbutanamide in 80 ml of ethyl ether is treated at ambient temperature, under a light argon stream, with 2.182 g (57.500 mmol) of powdered lithium aluminium hydride. The reaction medium is stirred at ambient temperature for 72 h and is then diluted with 80 ml of ethyl ether and 15 ml of THF and cooled to approximately 0°C, and 2.18 ml of water, 2.18 ml of an aqueous 15% sodium hydroxide solution and 6.54 ml of water are successively added slowly, and the mixture is filtered through a sintered glass funnel. The filtrate is dried over magnesium sulfate and then, after filtration through a sintered glass funnel, the filtrate obtained is evaporated to dryness under reduced pressure (2.7 kPa). The crude is purified by flash chromatography on silica [eluent: dichloromethane/methanol/acetonitrile (90/5/5 to 80/10/10 by volume)]. After evaporation of the fractions under reduced pressure, 1 .176 g of N 1 -benzyl-4,4,4-trifluoro-3-methylbutane-1 ,3-diamine are obtained, in the form of a yellow oil .

Mass spectrum (method B): ES+/-: [M+H]+: m/z 247; Tr (min) = 7.74 (ELSD). 1 H NMR spectrum (300 MHz, δ in ppm, DMSO-d6): 1 .10 (q, J=0.6 Hz,

3 H); 1 .52 to 1 .74 (m, 2 H); 2.02 (broad m, 3 H); 2.53 to 2.76 (m, 2 H); 3.68 (s, 2 H); 7.15 to 7.39 (m, 5 H). 3-Annino-N-benzyl-4,4,4-trifluoro-3-nnethylbutanannide can be prepared in the following way.

A suspension of 3.100 g (14.93 mmol) of 3-amino-4,4,4-trifluoro-3- methylbutanoic acid hydrochloride, 2.862 g (14.93 mmol) of N-[3- (dimethylamino)propyl]-N'-ethylcarbodiimide hydrochloride and 2.017 g (14.93 mmol) of 1 -hydroxybenzotriazole in 100 ml of methylene chloride is treated at ambient temperature with 4.363 ml (31 .350 mmol) of triethylamine and then with 1 .631 ml (14.93 mmol) of benzylamine. The reaction medium is stirred at ambient temperature for 62 h and then 3.26 ml (29.86 mmol) of benylamine are added. The reaction medium is stirred at ambient temperature for 27 h and then evaporated to dryness under reduced pressure (2.7 kPa). The crude obtained is purified by flash chromatography on silica [eluent: dichloromethane/1 -propanol/acetonitrile (96/2/2 then 90/5/5 by volume)]. After evaporation of the fractions under reduced pressure, 2.504 g of 3-amino-N- benzyl-4,4,4-trifluoro-3-methylbutanamide are obtained, in the form of a brown oil.

Mass spectrum (method A): ES+/-: [M+H]+: m/z 261 ; [M-H]-: m/z 259; Tr (min) = 0.38 1 H NMR spectrum (300 MHz, δ in ppm, DMSO-d6): 1 .23 (broad s, 3

H); 2.27 (s, 2 H); 2.31 (d, J=13.8 Hz, 1 H); 2.43 (d, J=13.8 Hz, 1 H); 4.30 (d, J=5.7 Hz, 2 H); 7.18 to 7.38 (m, 5 H); 8.53 (broad t, J=5.7 Hz, 1 H).

3-Amino-4,4,4-trifluoro-3-methylbutanoic acid hydrochloride prepared in the following way.

A mixture of 4.460 g (22.393 mmol) of ethyl 3-amino-4,4,4-trifluoro-3- methylbutanoate and 1 .776 g (9.592 mmol) of methyl 3-amino-4,4,4-trifluoro- 3-methylbutanoate is treated at ambient temperature with an aqueous 5N hydrochloric acid solution. The reaction medium is heated at 90°C for 4 h. A mixture of acetonitrile and toluene is added and then the mixture is evaporated to dryness under reduced pressure. 4.61 g of 3-amino-4,4,4- trifluoro-3-methylbutanoic acid hydrochloride are obtained, in the form of a beige solid. Mass spectrum (method A): ES+/-: [M+H]+: m/z 172; [M-H]-: m/z 170;

Tr (min) = 0.13

1 H NMR spectrum (400 MHz, δ in ppm, DMSO-d6): 1 .60 (s, 3 H); 2.93 (m, 2 H); 10.1 1 (broad m, 3 H).

Ethyl 3-amino-4,4,4-trifluoro-3-methylbutanoate and methyl 3

4,4,4-trifluoro-3-methylbutanoate can be prepared in the following way

A solution of 1 .5 g (8.235 mmol) of ethyl 3-(trifluoromethyl)crotonate in 6 ml of acetonitrile and 1 1 .76 ml (82.350 mmol) of 7N aqueous ammonia in methanol is microwave-heated at 130°C for 1 h 20 min. The reaction medium is diluted with 20 ml of methylene chloride and then evaporated to dryness under reduced pressure (the bath temperature is maintained below 25°C and the pump vacuum is maintained above 100 mbar). A mixture of 969 mg (4.865 mmol) of ethyl 3-amino-4,4,4-trifluoro-3-methylbutanoate and 386 mg (2.085 mmol) of methyl 3-amino-4,4,4-trifluoro-3-methylbutanoate (70% ethyl ester - 30% methyl ester ratio) is obtained, in the form of a yellow liquid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 200; Tr (min) = 0.32 (ethyl ester).

Mass spectrum (method A): ES+/-: [M+H]+: m/z 186; Tr (min) = 0.21 (methyl ester). 1H NMR spectrum (400 MHz, δ in ppm, DMSO-d6): 1 .19 (t, J=7.1 Hz, 3

H); 1 .28 (s, 3 H); 2.19 (broad m, 2 H); 3.17 (m, 2 H); 4.08 (q, J=7.1 Hz, 2 H) (ethyl ester).

1 H NMR spectrum (400 MHz, δ in ppm, DMSO-d6): 1 .28 (s, 3 H); 2.19 (broad m, 2 H); 3.17 (m, 2 H); 3.61 (s, 3 H) (methyl ester). Intermediate F6

2-Chloro-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin- 4-one can be prepared in the following way.

1 .7 g of 2-hydroxy-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one are placed in suspension in 24 ml of 1 ,2-dichloroethane. 2.4 ml of POCI3 are added and then the medium is heated at 65°C for 2 h. The medium is concentrated to dryness. The residue is taken up in 50 ml of ethyl acetate and 10 ml of water and then cooled in an ice bath. 32% NaOH is added to pH = 7. The aqueous phase is extracted with ethyl acetate and then the organic phase is dried over magnesium sulfate. After the solvent has been evaporated off, 0.9 g (yield = 55%) of 2-chloro-8,8-dimethyl-6,7,8,9- tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one are obtained, in the form of a brown solid, the characteristics of which are the following:

Mass spectrum (method A) ES+/-: Tr: 2.14 min, m/z = 214.

2-Hydroxy-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-

4-one can be prepared in the following way.

A mixture of 2 g of 4,4-dimethyl-1 ,4,5,6-tetrahydropyrimidin-2-amine hydrobromide, 10 ml of ethyl malonate and 2.6 g of sodium methoxide is heated to 100°C. After 4 h of heating, the reaction medium is concentrated to dryness. The oil obtained is taken up in ethyl ether. The precipitate is filtered off and then the residue is taken up in 7 ml of water and acidified with 25% HCI to pH 6. The precipitate formed is filtered off, washed with ethyl ether and oven-dried under vacuum. 1 .7 g (yield = 90%) of 2-hydroxy-8,8-dimethyl- 6,7,8,9-tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one are obtained, in the form of a beige solid, the characteristics of which are the following:

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 196; [M-H]-: m/z 194; Tr (min) = 0.22

4,4-Dimethyl-1 ,4,5,6-tetrahydropyrimidin-2-amine hydrobromide can be prepared in the following way.

1 .95 g of 3-methylbutane-1 ,3-diamine dihydrobromide are placed in suspension in 20 ml of MeOH and 1 .2 g of sodium methanolate are added. The mixture is stirred at ambient temperature for 2 h. The mixture is filtered and then evaporated to dryness. The reaction crude is solubilised in 20 ml of water, cooled with an ice bath. 0.78 g of CNBr is added and the mixture is stirred at ambient temperature for 12 h. The mixture is evaporated to dryness, and 3 g (yield = quantitative) of 4,4-dimethyl-1 ,4,5,6-tetrahydropyrimidin-2- amine hydrobromide are obtained, in the form of a translucent oil, which will subsequently be used as it is.

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 128; Tr (min) = 0.12

3-Methylbutane-1 ,3-diamine dihydrobromide can be prepared following way.

2.8 g of ethyl (3-amino-1 ,1 -dimethylpropyl)carbamate are cooled using an ice bath. 9.9 ml of HBr at 33% in acetic acid are added dropwise and then the mixture is heated at reflux for 2 h. After a return to ambient temperature, the product is precipitated with ethyl ether and filtration is carried out. The powder obtained is oven-dried at 70°C. 2.34 g (yield = 55%) of 3- methylbutane-1 ,3-diamine dihydrobromide are obtained, in the form of a white powder, the characteristics of which are the following: Mass spectrum (method A) (ES+/-) [M+H]+: m/z 103; Tr (min) = 0.12

Ethyl (3-amino-1 ,1 -dimethyl propyl )carbamate can be prepared in the following way.

5.12 g of ethyl [3-(1 ,3-dioxo-1 ,3-dihydroisoindol-2-yl)-1 ,1 -dimethylpropyl] carbamate are placed in solution in 47 ml of ethanol. 4 ml of hydrazine hydrate are added and then the mixture is heated at reflux for 30 minutes. After a return to ambient temperature, the reaction medium is filtered and then the solvent is evaporated off. 2.8 g (yield = 88%) of ethyl (3-amino-1 ,1 - dimethylpropyl)carbamate are obtained in the form of a brown gum, the characteristics of which are the following:

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 175; Tr (min) = 0.22

Ethyl [3-(1 ,3-dioxo-1 ,3-dihydroisoindol-2-yl)-1 ,1 - dimethylpropyl]carbamate can be prepared in the following way.

34.2 g of ethyl carbamate are placed in solution in toluene, 22 ml of BF 3 .Et 2 O are added and the mixture is heated for 1 h 30 min at 70°C. 1 1 g of 2-(3-methylbut-2-en-1 -yl)-1 H-isoindole-1 ,3-dione are added and the mixture is heated at reflux for 12 h. After a return to ambient temperature, the mixture is evaporated to dryness and then taken up in an H 2 O/EtOAc mixture. The organic phase is separated by settling out, washed with a saturated NaCI solution and then dried over magnesium sulfate. The crude is purified by flash chromatography on silica gel (CH 2 CI 2 /MeOH, 99/1 ). 5.12 g (yield = 31 %) of ethyl [3-(1 ,3-dioxo-1 ,3-dihydroisoindol-2-yl)-1 ,1 -dimethylpropyl]carbamate are obtained, in the form of a brown powder, the characteristics of which are the following:

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 305; Tr (min) = 0.86

2-(3-Methylbut-2-en-1 -yl)-1 H-isoindole-1 , 3-dione can be prepared in the following way.

20 g of 1 -bromo-3-methylbut-2-ene and 26.1 g of phthalimide are placed in suspension in anhydrous DMF and then the mixture is heated at reflux for 12 h. After a return to ambient temperature, the reaction medium is filtered and then taken up with a saturated aqueous NH 4 CI solution. The aqueous phase is extracted with ethyl acetate, washed with an NaCI solution, then dried over magnesium sulfate and evaporated to dryness. The solid obtained is placed in suspension in 100 ml of water and stirred. The precipitated product is filtered off, rinsed with ether and then oven-dried under vacuum at 65°C. 18.3 g (yield = 63%) of 2-(3-methylbut-2-en-1 -yl)-1 H- isoindole-1 ,3-dione are obtained, in the form of a white powder, the characteristics of which are the following:

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 216; Tr (min) = 0.99

Intermediate F7

2-Chloro-3-fluoro-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyhmido [1 ,2- a]pyrimidin-4-one can be prepared in the following way.

3.15 g of 2-hydroxy-3-fluoro-8,8-dimethyl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one are placed in suspension in 42 ml of 1 ,2- dichloroethane. 4.15 ml of POCI3 are added and then the medium is heated at 65°C for 3 h. The medium is concentrated to dryness. The residue is taken up in 150 ml of ethyl acetate and 10 ml of water and then cooled in an ice bath. Concentrated NaOH is added to pH 10. After separation by settling out, the organic phase is dried over magnesium sulfate, filtered, and then concentrated to dryness under reduced pressure. The residue obtained is triturated from ethyl ether and the solid is filtered and then dried, so as to give 2.23 g of 2-chloro-3-fluoro-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyrimid o[1 ,2- a]pyrimidin-4-one in the form of a brown solid, the characteristics of which are the following: Mass spectrum (method A) (ES+/-) [M+H]+: m/z 214; [M-H]-: m/z 212;

Tr (min) = 0.42

2-Hydroxy-3-fluoro-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyr imido[1 ,2- a]pyrimidin-4-one can be prepared in the following way.

A suspension of 5 g of 4,4-dimethyl-1 ,4,5,6-tetrahydropyrimidin-2- amine, 29 g of dimethyl fluoromalonate and 3.9 g of sodium methoxide is heated at 100°C for 3 hours. The reaction medium is concentrated to dryness under reduced pressure. The residue obtained is taken up with ethyl ether. The solid formed is filtered off and then dried. 10 ml of water are added to the solid obtained, and the resulting mixture is cooled on ice, before acidification to pH 5-6 by adding concentrated hydrochloric acid (25%). The suspension is filtered and then the solid is washed with 5 ml of water and then dried under vacuum over P2O 5 , so as to give 3.15 g of 2-Hydroxy-3-fluoro-8,8-dimethyl- 6,7,8,9-tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one, in the form of a yellow powder, the characteristics of which are the following:

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 232; [M-H]-: m/z 230; Tr (min) = 0.86

Intermediate F8: (S)-7-chloro-2-methyl-2-(trifluoromethyl)-2,3- dihydroimidazo [1 ,2-a]pyrimidin-5(1 H)-one can be prepared in the following way.

1 1 ml of phosphorus oxychloride are added, at ambient temperature and under an argon atmosphere, to a suspension of 5.6 g of (S)-7-hydroxy-2- methyl-2-(trifluoromethyl)-2,3-dihydroimidazo [1 ,2-a]pyrimidin-5(1 H)-one in 100 ml of 1 ,2-dichloroethane. The resulting mixture is then heated to 70°C. After two hours of stirring and after verification by LC/MS, the reaction is complete. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 5 ml of cold water and 200 ml of ethyl acetate. 32% sodium hydroxide is added to the mixture obtained, to pH = 6. The organic phase is then separated and then dried over magnesium sulfate, filtered and concentrated under reduced pressure, so as to give 6 g of (S)-7-chloro-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidazo [1 ,2-a]pyrimidin-5(1 H)-one, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.51

[a] D 25 at 589 nm = -64.8 +/- 1 .1 (c = 2.2 mg / 0.5 ml DMSO)

(S)-7-hydroxy-2-methyl-2-(trifluoromethyl)-2,3-dihydroimi dazo [1 ,2- a]pyrimidin-5(1 H)-one can be prepared in the following way.

8.4 g of (S)-4-methyl-4-(trifluoromethyl)imidazolidin-2-ylideneamine hydrobromide and 2.16 g of sodium methoxide are added to a mixture of 5.4 g of diethyl malonate in 50 ml of methanol. The resulting mixture is refluxed for 18 hours. After cooling, the mixture obtained is concentrated to dryness under reduced pressure. 20 ml of cold water are added to the residue obtained, so as to obtain a thick suspension, to which is added 25% hydrochloric acid to pH = 5. The resulting suspension is stirred in an ice bath for two hours and then filtered through a sintered glass funnel. The insoluble matter obtained is rinsed with water (twice 4 ml) and then dried so as to give 5.6 g of (S)-7-hydroxy-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidaz o [1 ,2- a]pyrimidin-5(1 H)-one in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 236; [M-H]-: m/z 234; Tr (min) = 0.32

[a] D 25 at 589 nm = - 5.6 +/- 0.6 (c = 1 .789 mg / 0.5 ml DMSO) (S)-4-methyl-4-(trifluoromethyl)imidazolidin-2-ylideneamine

hydrobromide can be prepared in the following way.

1 .7 g of cyanogen bromide are added, in small amounts, to a solution, cooled to 5°C, of 2.3 g of (S)-3,3,3-trifluoro-2-methylpropane-1 ,2-diamine in 10 ml of water, while maintaining the temperature between 5 and 10°C. At the end of the addition, the reaction mixture is stirred at 5°C for 30 minutes. The ice bath is then withdrawn and the mixture obtained is stirred at ambient temperature for 3 hours. The resulting mixture is then concentrated under reduced pressure. The residue obtained is taken up twice with 100 ml of ethanol and then twice with 100 ml of toluene, and evaporated to dryness each time. The solid obtained is triturated with ethyl ether and then filtered off, so as to give 4.5 g of (S)-4-methyl-4-(trifluoromethyl)imidazolidin-2- ylideneamine hydrobromide, in the form of a white solid, the characteristics of which are the following: Mass spectrum (method A), ES+/-: [M+H]+: m/z 168; Tr (min) = 0.14

[a] D 25 at 589 nm: - 5.2 +/- 0.3 (c = 4.909 mg / 0.5 ml DMSO) (S)-3,3,3-Trifluoro-2-methylpropane-1 ,2-diamine can be prepared in the following way.

4.8 g of (S)-3,3,3-trifluoro-2-methylpropane-1 ,2-diamine hydrochloride, 2.5 ml of water and 100 ml of ethyl ether are placed in a round-bottomed flask. 4.5 ml of 32% sodium hydroxide are added, dropwise, to the resulting mixture, to pH = 12. The aqueous phase is subsequently separated by settling out and then extracted with 4 times 200 ml of ethyl ether. The organic phases are combined, dried over magnesium sulfate, filtered, and then concentrated under reduced pressure (300 mbar/bath temperature = 25°C), so as to give 2.3 g of (S)-3,3,3-trifluoro-2-methylpropane-1 ,2-diamine, in the form of a pale yellow oil, the characteristics of which are the following:

Mass spectrum (method B), ES+/-: [M+H]+: m/z 143; base peak: m/z 126; Tr (min) = 0.34 [a] D 25 at 589 nm = - 4.3 +/- 0.6 (c = 1 .778 mg / 0.5 ml DMSO)

(S)-3,3,3-Trifluoro-2-methylpropane-1 ,2-diamine dihydrochloride can be prepared in the following way.

A mixture of 7 g of (2R)-2-((S)-1 -aminomethyl-2,2,2-trifluoro-1 - methylethylamino)-2-phenylethanol in 40.5 ml of methanol, 23.5 ml of 3N hydrochloric acid and 0.94 g of Pd(OH) 2 /C (20%) is hydrogenated at 22°C in an autoclave, under a hydrogen pressure of 5 bar, for 18 hours. The mixture obtained is then filtered and the filtrate is evaporated to dryness. The oil obtained is taken up with a 3N hydrochloric acid solution (50 ml). The mixture obtained is extracted with diethyl ether (3 50 ml). The aqueous phase is then evaporated to dryness, taken up with methanol, and then again evaporated to dryness. The yellowish solid obtained is dried under vacuum, so as to give 5.54 g (yield 79%) of (S)-3,3,3-trifluoro-2-methylpropane-1 ,2- diamine dihydrochloride, in the form of an off-white solid, the characteristics of which are the following: 1 H NMR spectrum (400 MHz, D 2 O): 1 .55 (s, 3 H), 3.40 (d, J = 14.6 Hz,

1 H), 3.51 (d, J = 14.6 Hz, 1 H).

19 F NMR spectrum (400 MHz, D 2 O): - 81 .08 (not calibrated with C 6 F 6 )

[a] D 25 at 589 nm = + 4.65 +/- 0.6 (c = 2.2; MeOH)

(2R)-2-((S)-1 -Aminomethyl-2,2,2-trifluoro-1 -methylethylamino)-2- phenylethanol can be prepared in the following way.

1 .6 g of lithium aluminium hydride are added, in small portions, to a solution, cooled to 4°C, of 2.5 g of (2S)-3,3,3-trifluoro-2-((R)-2-hydroxy-1 - phenylethylamino)-2-methylpropionitrile in 250 ml of anhydrous ethyl ether, in a three-necked flask under argon. Substantial evolution of gas and a temperature rise to 8°C are observed . At the end of the addition, the temperature is left to come back up to ambient temperature, and then the reaction mixture is left stirring for 18 h. The mixture obtained is cooled to 4°C, followed by very slow dropwise addition of 2 ml of water. Substantial evolution of gas and a temperature rise to 12°C are observed. 2 ml of 15% potassium hydroxide are added, dropwise and very slowly, to the resulting mixture, maintained at 4°C, followed, still dropwise and very slowly, by 4 ml of water. The white precipitate formed is filtered off and the filtrate obtained is dried over magnesium sulfate and then concentrated under reduced pressure, so as to give 2.2 g of (2R)-2-((S)-1 -aminomethyl-2,2,2-trifluoro-1 - methylethylannino)-2-phenylethanol, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 263; Tr (min) = 0.43

[a] D 25 at 589 nm = - 51 .2 +/- 1 .3 (c = 1 .576 mg / 0.5 ml DMSO) (2S)-3,3,3-Trifluoro-2-((R)-2-hydroxy-1 -phenylethylamino)-2- methylpropionitrile can be prepared in the following way.

3.4 g of trimethylsilyl cyanide are added, dropwise, to a solution, cooled to 0°C, of 5.3 g of (2R,2S)-2-methyl-4-(R)-phenyl-2- (trifluoromethyl)oxazolidine in 100 ml of dichloromethane in a three-necked flask under argon, followed by dropwise addition of 4.9 g of boron trifluoride etherate. The cold bath is then withdrawn to allow the mixture to warm up to ambient temperature. The resulting mixture is stirred at ambient temperature for 18 hours, followed by addition of a saturated sodium bicarbonate solution to pH = 8. The organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica (eluent: cyclohexane/EtOAc: 80/20), so as to give 3 g of (2R)-3,3,3-trifluoro-2-((R)-2-hydroxy-1 - phenylethylamino)-2-methylpropionitrile, in the form of a colourless oil, and 2.5 g of (2S)-3,3,3-trifluoro-2-((R)-2-hydroxy-1 -phenylethylamino)-2- methylpropionitrile, in the form of a white solid, the characteristics of which are:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 259; [M-H+HCO 2 H]-: m/z 303; Tr (min) = 0.86 [a] D 25 at 589 nm = - 89.0 +/- 1 .4 (c = 2.444 mg / 0.5 ml CHCI 3 ) [a] D ^ at 589 nm = - 77.6 +/- 1 .4 (c = 1 .818 mg / 0.5 ml DMSO)

(2R,2S)-2-Methyl-4-(R)-phenyl-2-(trifluoromethyl)oxazolid ine

prepared in the following way.

4.8 g of (R)-phenylglycinol and then, in one step, 0.8 g of pyridinium para-toluenesulfonate are added to a solution of 5 g of trifluoroacetone in 180 ml of toluene in a three-necked flask on which is mounted a Dean-Stark apparatus. The mixture obtained is then heated at reflux for 18 hours, during which time 0.3 ml of water is collected. After cooling, the reaction mixture is concentrated under reduced pressure. The residue obtained is purified by filtration on silica (eluent: dichloromethane), so as to give 5.3 g of (2R,2S)-2- methyl-4-(R)-phenyl-2-(trifluoromethyl)oxazolidine, in the form of a colourless liquid, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 232; Tr (min) = 0.96

[OC] D 25 at 589 nm = - 23.4 +/- 0.8 (c = 1 .794 mg / 0.5 ml MeOH)

Intermediate F9:

(S)- 6-Fluoro-7-chloro-2-methyl-2-(trifluoromethyl)-2,3-dihydroim idazo[1 ,2- a]pyrimidin-5(1 H)-one can be obtained in the following way.

9 ml of phosphorus oxychloride are added, at ambient temperature and under an argon atmosphere, to a suspension of 8.20 g of (S)-6-fluoro-7- hydroxy-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidazo [1 ,2-a]pyrimidin- 5(1 H)-one in 90 ml of 1 ,2-dichloroethane. The resulting mixture is then heated to 70°C. After 3 hours of stirring and after verification by LC/MS, the reaction is complete. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 50 ml of cold water and 200 ml of ethyl acetate. 32% sodium hydroxide is added to the mixture obtained, to pH = 10. The organic phase is then separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is purified by silica column chromatography (eluent: 98.5/1 .5 dichloromethane/methanol), so as to give 4 g of (S)-6-fluoro- 7-chloro-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidazo [1 ,2-a]pyrimidin- 5(1 H)-one, the characteristics of which are the following: Mass Spectrometry: Method B:

Retention time Tr (min) = 2.92, [M+H]+: m/z 272; [M-H]-: m/z 270

(S)-6-Fluoro-7-hydroxy-2-methyl-2-(trifluoromethyl)-2,3-d ihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one can be obtained in the following way.

1 1 g of (S)-4-methyl-4-(trifluoromethyl)imidazolidin-2-ylideneamine hydrobromide and 4.79 g of sodium methoxide are added to a mixture of 6.7 g of diethyl fluoromalonate in 1 10 ml of methanol. The resulting mixture is refluxed for 3 hours. After cooling, the mixture obtained is concentrated to dryness under reduced pressure. 15 ml of cold water are added to the residue obtained, so as to obtain a thick suspension, to which is added 25% hydrochloric acid to pH = 5-6. The reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up with an 80/20 dichloromethane/MeOH mixture and then filtered. The filtrate is concentrated under reduced pressure and the residue obtained is purified by chromatography on silica (eluent: 70/30 dichloromethane/MeOH), so as to give 8.14 g of (2S)-7-hydroxy-2-methyl-2-(trifluoromethyl)-2,3- dihydroimidazo[1 ,2-a]pyrimidin-5(1 H)-one, in the form of a pale orange foam, which is used as it is in the next step. able 1: Starting intermediates of type F

Experimental section: Table 2: Examples from 1 to 295, starting intermediates of type F and amount of each example isolated

890 EXAMP L E 1 EXAMP L E 1 EXAMP L E 2 EXAMP L E 21 EXAMP L E 22 -----

(S)-3-Fluoro-2-((R)-3- O

methylmorpholin-4-yl)- 9-[2-oxo-2-(tetrahydro-

R4=F; p=0;

pyran-4-yl)ethyl]-8- q=2; R2=H; 140 trifluoromethyl-6,7,8,9- R3=CF3 (S)

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2-((R)-3- methylmorpholin-4-yl)- O

9-(3-methyl- [1 ,2,4]oxadiazol-5-yl- R4=F; p=0;

methyl)-8- q=2; R2=H; 95 trifluoromethyl-6,7,8,9- R3=CF3 (S)

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-9-(2- O

methoxy-ethyl)-2-((R)- 3-methylmorpholin-4- R4=F; p=0;

yl)-8-trifluoromethyl- q=2; R2=H; 38 6,7,8,9-tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- pyrinnidin-4-one

(R)-3-Fluoro-2-((R)-3- methylmorpholin-4-yl)-

9-(5-methyl- [1 ,2,4]oxadiazol-3-yl- R4=F; p=2;

methyl)-6- q=0; R2=H; 86 trifluoromethyl-6,7,8,9- R3=CF3 (R )

tetrahydro- pyrimido[1 ,2-a]-

pyrinnidin-4-one

(S)-3-Fluoro-2-((R)-3- O

methylmorpholin-4-yl)-

9-(2-oxobutyl)-8- R4=F; p=0;

trifluoromethyl-6,7,8,9- q=2; R2=H; F F

tetrahydro- R3=CF3 (S) ° ° 62 pyrimido[1 ,2-a]- pyrinnidin-4-one

03 EXAMP L E 4 EXAMP L E 41 EXAMP L E 42 EXAMP L E 4 ----

Chiral

(S)-3-Fluoro-9-(2- 0

methoxypyridin-4-yl)- 2-((R)-3-Methyl-

R4=F; p=0;

morpholin-4-yl)-8- q=2; R2=H; 98 trifluoromethyl-6,7,8,9- R3=CF3 (S)

tetrahydro- pyrimido[1 ,2-a]- 0

pyrinnidin-4-one I

Chiral

(S)-9-(2-Chloro- 0

pyridin-4-ylmethyl)-3- fluoro-2-((R)-3-methyl-

R4=F; p=0;

morpholin-4-yl)-8- q=2; R2=H; 48 trifluoromethyl-6,7,8,9- R3=CF3 (S)

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one CI

Chiral

(S)-3-Fluoro-2-((R)-3- methylmorpholin-4-yl)- 9-oxazol-2-ylmethyl-8- R4=F; p=0;

trifluoromethyl-6,7,8,9- q=2; R2=H; 85 tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-9-(6-Cyclopropyl- 0

pyrid in-3-yl)-3-fl uoro- 2-((R)-3-methyl-

R4=F; p=0;

morpholin-4-yl)-8- q=2; R2=H; 40 trifluoromethyl-6,7,8,9- R3=CF3 (S)

tetrahydro- r F F pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(R)-9-(2-Chloro- pyridin-4-yl)-2-((R)-3- methylmorpholin-4-yl)- R4=H; p=2;

6-trifluoronnethyl- q=0; R2=H; 106 6,7,8,9-tetrahydro- R3=CF3 (R )

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(R)-9-(2-Methoxy- pyridin-4-yl)-2-((R)-3- methylmorpholin-4-yl)- R4=H; p=2;

6-trifluoronnethyl- q=0; R2=H; 208 6,7,8,9-tetrahydro- R3=CF3 (R )

pyrimido[1 ,2-a]- pyrinnidin-4-one 0 '

Chiral

(R)-2-((R)-3-Methyl- morpholin-4-yl)-9- oxazol-4-ylmethyl-6- R4=H; p=2;

trifluoromethyl-6,7,8,9- q=0; R2=H; 54 tetrahydro- R3=CF3 (R )

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-3-Fluoro-2-((R)-3-

0

methylmorpholin-4-yl)- 9-oxazol-5-ylmethyl-8- R4=F; p=0;

trifluoromethyl-6,7,8,9- q=2; R2=H; 34 tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- pyrinnidin-4-one vT

py nn n- -one Chiral

(R)-3-Fluoro-2-((R)-3- methylmorpholin-4-yl)- o

9-(3-methyl-2-oxo- f - f

R4=F; p=2;

butyl)-6- q=0; R2=H; 74 trifluoromethyl-6,7,8,9- R3=CF3 (R )

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one ύ *

Chiral

(R)-3-Fluoro-2-((R)-3- methylmorpholin-4-yl)- 9-oxazol-2-ylmethyl-6- R4=F; p=2;

trifluoromethyl-6,7,8,9- q=0; R2=H; 44 tetrahydro- R3=CF3 (R )

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(R)-2-((R)-3-Methyl- morpholin-4-yl)-9-(3- methyl-2-oxobutyl)-6- R4=H; p=2;

trifluoromethyl-6,7,8,9- q=0; R2=H; 53 tetrahydro- R3=CF3 (R )

pyrimido[1 ,2-a]- pyrinnidin-4-one

stereoisomer (S)-2-((R)-3-Methyl- Chiral

morpholin-4-yl)-9-[1 - 0

(tetrahydropyran-2- yl)methyl]-8- R4=H; p=0;

trifluoromethyl-6,7,8,9- q=2; R2=H; 74 tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- pyrinnidin-4-one, single

stereoisomer

Chiral

(S)-2-((R)-3-Methyl- morpholin-4-yl)-9-[1 - (tetrahydropyran-2- yl)methyl]-8- R4=H; p=0;

trifluoromethyl-6,7,8,9- q=2; R2=H; 94 tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- pyhmidin-4-one, single

stereoisomer

Chiral

(S)-2-((R)-3-Methyl- morpholin-4-yl)-8- trifluoromethyl-9-(5- trifluoromethyl- R4=H; p=0;

[1 ,3,4]oxadiazol-2-yl- q=2; R2=H; 33 methyl)-6,7,8,9- R3=CF3 (S)

tetrahydro- pyrimido[1 ,2-a]- pyrimidin-4-one

Chiral

(R)-2-((R)-3-Methyl- F

morpholin-4-yl)-9-(2- oxo-2-pyridin-3-yl-

R4=H; p=2;

ethyl)-6- q=0; R2=H; 86 trifluoromethyl-6,7,8,9- R3=CF3 (R )

tetrahydro- pyrimido[1 ,2-a]- pyrimidin-4-one Ό (R)-9-(3-Cyclopropyl- [1 ,2,4]oxadiazol-5-yl- Chiral q

methyl)-3-fluoro-2-

((R)-3-methyl- R4=F; p=2;

morpholin-4-yl)-6- q=0; R2=H; 78 trifluoromethyl-6,7,8,9- R3=CF3 (R )

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(R)-3-Fluoro-2-((R)-3- methylmorpholin-4-yl)-

9-(2-oxopropyl)-6- R4=F; p=2;

trifluoromethyl-6,7,8,9- q=0; R2=H; 64 tetrahydro- R3=CF3 (R )

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(R)-3-Fluoro-2-((R)-3- methylmorpholin-4-yl)-

9-(3-methyl- o Ρ ψ Ρ

[1 ,2,4]oxadiazol-5-yl- R4=F; p=2;

methyl)-6- q=0; R2=H; 36 trifluoromethyl-6,7,8,9- R3=CF3 (R )

tetrahydro- I i

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-2-(3,3-Dimethyl- 0

morpholin-4-yl)-9-(2- oxo-2-phenylethyl)-8- R4=H; p=0;

trifluoromethyl-6,7,8,9- q=2; R2=H; 26 tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-1 -(2-Cyclopropyl- 2-oxoethyl)-6-fluoro-2- 0

methyl-7-((R)-3-

R4=F; p=0;

methylmorpholin-4-yl)- q=1 ; R2=Me; 63 2-trifluoromethyl-2,3- R3=CF3 (S)

dihydro-1 H- imidazo[1 ,2-a]- pyrinnidin-5-one

Chiral

(S)-2-Methyl-7-((R)-3- methylmorpholin-4-yl)- 0

1 -(3-methyl-2-oxo-

R4=H; p=0;

butyl)-2- I ii N — I

q=1 ; R2=Me; 15 trifluoronnethyl-2,3- R3=CF3 (S)

dihydro-1 H- imidazo[1 ,2-a]- pyrinnidin-5-one

Chiral

(S)-6-Fluoro-2-methyl-

7-((R)-3-methyl- morpholin-4-yl)-1 -(2- oxo-2-pyridin-3-yl- R4=F; p=0;

ethyl)-2- q=1 ; R2=Me; 172 trifluoronnethyl-2,3- R3=CF3 (S)

dihydro-1 H- imidazo[1 ,2-a]- pyrinnidin-5-one

Chiral

(S)-2-Methyl-7-((R)-3- 0

methylmorpholin-4-yl)- 1 -[2-oxo-2-(tetrahydro-

R4=H; p=0;

pyran-4-yl)ethyl]-2- q=1 ; R2=Me; 188 trifluoronnethyl-2,3- R3=CF3 (S)

dihydro-1 H- imidazo[1 ,2-a]- pyrinnidin-5-one Chiral

(S)-9-(2-Hydroxy-2- methyl propyl )-8- 0

methyl-2-((R)-3-

R4=H; p=0;

methylmorpholin-4-yl)- q=2; R2=Me; 2 8-trifluoromethyl- f N N N 6

R3=CF3 (S)

6,7,8,9-tetrahydro- pyrimido[1 ,2-a]- OH

pyrinnidin-4-one

Chiral

(S)-9-(5-lsopropyl- [1 ,2,4]oxadiazol-3-yl- methyl)-2-((R)-3-

R4=H; p=0;

methylmorpholin-4-yl)- q=2; R2=H; 103 8-trifluoromethyl- R3=CF3 (S)

6,7,8,9-tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-9-(5-Cyclopropyl- [1 ,2,4]oxadiazol-3-yl- methyl)-2-((R)-3-

R4=H; p=0;

methylmorpholin-4-yl)- q=2; R2=H; 1 12 8-trifluoromethyl- R3=CF3 (S)

6,7,8,9-tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-9-(5-tert-Butyl- [1 ,2,4]oxadiazol-3-yl- methyl)-2-((R)-3-

R4=H; p=0;

methylmorpholin-4-yl)- q=2; R2=H;

8-trifluoromethyl- R3=CF3 (S)

6,7,8,9-tetrahydro- 0 108

F

pyrimido[1 ,2-a]- pyrinnidin-4-one 689 EXAMP L E 21 EXAMP L E 217 EXAMP L E 21 EXAMP L E 21 ----

Chiral

(S)-2-((R)-3-Methyl- morpholin-4-yl)-9- pyridin-4-ylmethyl-8- R4=H; p=0;

trifluoromethyl-6,7,8,9- q=2; R2=H; 43 tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-2-((R)-3-Methyl- morpholin-4-yl)-9- pyridin-3-ylmethyl-8- R4=H; p=0;

trifluoromethyl-6,7,8,9- q=2; R2=H; 1 10 tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-2-((R)-3-Methyl- morpholin-4-yl)-9- pyridin-2-ylmethyl-8- R4=H; p=0;

trifluoromethyl-6,7,8,9- q=2; R2=H; 1 10 tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-9-[2-(4-Fluoro- phenyl)ethyl]-2-((R)-3- methylmorpholin-4-yl)- R4=H; p=0;

8-trifluoromethyl- q=2; R2=H; 40 6,7,8,9-tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- pyrinnidin-4-one

03 EXAMP L E 22 EXAMP L E 221 EXAMP L E 222 EXAMP L E 22 ----

Chiral

(S)-2-((R)-3-Methyl- morpholin-4-yl)-9-(2- pyridin-2-ylethyl)-8- R4=H; p=0;

trifluoromethyl-6,7,8,9- q=2; R2=H; 6 tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-9-(2-Fluoropyridin- 3-ylmethyl)-2-((R)-3- methylmorpholin-4-yl)- R4=H; p=0;

8-trifluoronnethyl- q=2; R2=H; 1 10 6,7,8,9-tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

N,N-Dimethyl-2-[(S)-8-

((R)-3-methyl- morpholin-4-yl)-6-oxo-

R4=H; p=0;

2-trifluoromethyl-3,4- q=2; R2=H; 150 dihydro-2H,6H- R3=CF3 (S)

pyrimido[1 ,2-a]- pyrimidin-1 -yl]- acetamide

Chiral

N-Methyl-2-[(S)-8-((R)- 3-methylmorpholin-4- yl)-6-oxo-2-

R4=H; p=0;

trifluoronnethyl-3,4- q=2; R2=H; 90 dihydro-2H,6H- R3=CF3 (S)

pyrimido[1 ,2-a]- ° > F F

pyrimidin-1 -yl]- ^NH

acetamide Chiral

(S)-3-Fluoro-9-(3- isopropyl- 0

[1 ,2,4]oxadiazol-5-yl- methyl)-2-((R)-3- R4=F; p=0;

methylmorpholin-4-yl)- q=2; R2=H; 100 8-trifluoromethyl- R3=CF3 (S) N . if

6,7,8,9-tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-9-(3-Cyclopropyl- [1 ,2,4]oxadiazol-5-yl- methyl)-3-fluoro-2-

((R)-3-methyl- R4=F; p=0;

morpholin-4-yl)-8- q=2; R2=H; 125 trifluoromethyl-6,7,8,9- R3=CF3 (S)

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-9-(3-tert-Butyl- [1 ,2,4]oxadiazol-5-yl- 0

methyl)-3-fluoro-2-

((R)-3-methyl- R4=F; p=0;

morpholin-4-yl)-8- q=2; R2=H; 100 trifluoromethyl-6,7,8,9- R3=CF3 (S) N /Γ

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-3-Fluoro-2-((R)-3-

0

methylmorpholin-4-yl)- 8-trifluoromethyl-9-(3- trifluoromethyl- R4=F; p=0;

[1 ,2,4]oxadiazol-5-yl- q=2; R2=H; 77 methyl)-6,7,8,9- R3=CF3 (S)

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one Chiral

(S)-8-Methyl-2-((R)-3- methylmorpholin-4-yl)- 0

9-(3-methyl-2-oxo-

R4=H; p=0;

butyl)-8- q=2; R2=Me;

trifluoromethyl-6,7,8,9- Γ N N N y 35

R3=CF3 (S)

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-9-[2-(1 -Methyl- cyclopentyl)-2-oxo- ethyl]-2-((R)-3-methyl-

R4=H; p=0;

morpholin-4-yl)-8- q=2; R2=H; 165 trifluoromethyl-6,7,8,9- R3=CF3 (S)

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

[(S)-8-((R)-3-Methyl- morpholin-4-yl)-6-oxo-

2-trifluoromethyl-3,4- R4=H; p=0;

dihydro-2H,6H- q=2; R2=H; 103 pyrimido[1 ,2-a]- R3=CF3 (S)

pyrimidin-1 -yl]acetic

acid isopropyl ester

Chiral

(S)-9-(3,3-Dimethyl-2- oxobutyl)-2-((R)-3- methylmorpholin-4-yl)- R4=H; p=0;

8-trifluoromethyl- q=2; R2=H; 144 6,7,8,9-tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- °sA F F pyrinnidin-4-one Chiral

[(S)-8-((R)-3-Methyl- morpholin-4-yl)-6-oxo- 2-trifluoromethyl-3,4- R4=H; p=0;

dihydro-2H,6H- q=2; R2=H; 1 12 pyrimido[1 ,2-a]- R3=CF3 (S)

pyrimidin-1 -yl]acetic 0

acid tert-butyl ester

2-{2-[(S)-8-((R)-3- Chiral

Methylmorpholin-4-yl)- 6-0X0-2- trifluoronnethyl-3,4-

R4=H; p=0;

dihydro-2H,6H- q=2; R2=H; 137 pyrimido[1 ,2-a]- R3=CF3 (S)

pyrimidin-1 -yl]acetyl}- pyrrolidine-1 - carboxylic acid tert- butyl ester Vx

Chiral

[(S)-8-((R)-3-Methyl- morpholin-4-yl)-6-oxo- 2-trifluoromethyl-3,4- R4=H; p=0;

dihydro-2H,6H- q=2; R2=H; 100 pyrimido[1 ,2-a]- R3=CF3 (S)

pyrimidin-1 -yl]acetic

0

acid methyl ester /

Chiral

2-[(S)-8-((R)-3-Methyl- morpholin-4-yl)-6-oxo- 2-trifluoromethyl-3,4- R4=H; p=0;

dihydro-2H,6H- q=2; R2=H; 88 pyrimido[1 ,2-a]- R3=CF3 (S)

pyrimidin-1 -yl]- acetamide NH 2

C

Chiral

(S)-3-Fluoro-2-((R)-3- 0

methylmorpholin-4-yl)- 9-(4-methyl-2-oxo-

R4=F; p=0;

pentyl)-8- q=2; R2=H; 109 trifluoromethyl-6,7,8,9- R3=CF3 (S)

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-9-(3-Ethyl-2-oxo- pentyl)-2-((R)-3- methylmorpholin-4-yl)- R4=H; p=0;

8-trifluoromethyl- q=2; R2=H; 138 6,7,8,9-tetrahydro- R3=CF3 (S) °sA F F

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

(S)-9-(3-Ethyl-2-oxo- pentyl)-3-fluoro-2-((R)- 3-methylmorpholin-4- R4=F; p=0;

yl)-8-trifluoromethyl- q=2; R2=H; 144 6,7,8,9-tetrahydro- R3=CF3 (S)

pyrimido[1 ,2-a]- pyrinnidin-4-one

Chiral

[(S)-7-Fluoro-8-((R)-3- methylmorpholin-4-yl)- 0

6-0X0-2-

R4=F; p=0;

trifluoronnethyl-3,4- q=2; R2=H; 4320 dihydro-2H,6H- R3=CF3

pyrimido[1 ,2-a]- (S) °Js °y J F F pyrimidin-1 -yl]acetic /°

acid methyl ester

configuration Z or E

Experimental section: Table 3: Synthesis routes, number of steps used in the preparation of the examples claimed above

EXAMPLE Synthesis route Number of steps EXAMPLE-1 Via intermediate of type "Q" 2

EXAMPLE-2 Via intermediate of type "P" 2

EXAMPLE-3 Via intermediate of type "P" 2

EXAMPLE-4 Via intermediate of type "P" 2

EXAMPLE-5 Via intermediate of type "P" 2

EXAMPLE-6 Via intermediate of type "P" 2

EXAMPLE-7 Via intermediate of type "P" 2

EXAMPLE-8 Via intermediate of type "P" 3

EXAMPLE-9 Via intermediate of type "P" 2

EXAMPLE-10 Via intermediate of type "Q" 2

EXAMPLE-1 1 Via intermediate of type "Q" 2

EXAMPLE-12 Via intermediate of type "P" 2

EXAMPLE-13 Via intermediate of type "P" 2

EXAMPLE-14 Via intermediate of type "P" 2

EXAMPLE-15 Via intermediate of type "P" 2

EXAMPLE-16 Via intermediate of type "P" 3

EXAMPLE-17 Via intermediate of type "P" 2

EXAMPLE-18 Via intermediate of type "P" 2

EXAMPLE-19 Via intermediate of type "P" 2 EXAMPLE-20 Via intermediate of type "P" 2

EXAMPLE-21 Via intermediate of type "P" 2

EXAMPLE-22 Via intermediate of type "P" 2

EXAMPLE-23 Via intermediate of type "P" 2

EXAMPLE-24 Via intermediate of type "Q" 2

EXAMPLE-25 Via intermediate of type "P" 3

EXAMPLE-26 Via intermediate of type "P" 2

EXAMPLE-27 Via intermediate of type "P" 2

EXAMPLE-28 Via intermediate of type "Q" 2

EXAMPLE-29 Via intermediate of type "P" 2

EXAMPLE-30 Via intermediate of type "P" 2

EXAMPLE-31 Via intermediate of type "Q" 2

EXAMPLE-32 Via intermediate of type "P" 2

EXAMPLE-33 Via intermediate of type "P" 2

EXAMPLE-34 Via intermediate of type "P" 2

EXAMPLE-35 Via intermediate of type "P" 2

EXAMPLE-36 Via intermediate of type "P" 2

EXAMPLE-37 Via intermediate of type "P" 2

EXAMPLE-38 Via intermediate of type "Q" 2

EXAMPLE-39 Via intermediate of type "P" 2

EXAMPLE-40 Via intermediate of type "P" 2

EXAMPLE-41 Via intermediate of type "P" 2 EXAMPLE-42 Via intermediate of type "P" 2

EXAMPLE-43 Via intermediate of type "P" 2

EXAMPLE-44 Via intermediate of type "P" 2

EXAMPLE-45 Via intermediate of type "P" 2

EXAMPLE-46 Via intermediate of type "P" 2

EXAMPLE-47 Via intermediate of type "P" 2

EXAMPLE-48 Via intermediate of type "P" 2

EXAMPLE-49 Via intermediate of type "P" 2

EXAMPLE-50 Via intermediate of type "P" 2

EXAMPLE-51 Via intermediate of type "Q" 2

EXAMPLE-52 Via intermediate of type "Q" 2

EXAMPLE-53 Via intermediate of type "P" 2

EXAMPLE-54 Via intermediate of type "P" 2

EXAMPLE-55 Via intermediate of type "P" 2

EXAMPLE-56 Via intermediate of type "P" 2

EXAMPLE-57 Via intermediate of type "P" 2

EXAMPLE-58 Via intermediate of type "P" 2

EXAMPLE-59 Via intermediate of type "P" 3

EXAMPLE-60 Via intermediate of type "P" 3

EXAMPLE-61 Via intermediate of type "P" 3

EXAMPLE-62 Via intermediate of type "P" 2

EXAMPLE-63 Via intermediate of type "P" 3 EXAMPLE-64 Via intermediate of type "P" 2

EXAMPLE-65 Via intermediate of type "P" 2

EXAMPLE-66 Via intermediate of type "P" 2

EXAMPLE-67 Via intermediate of type "P" 3

EXAMPLE-68 Via intermediate of type "P" 3

EXAMPLE-69 Via intermediate of type "P" 2

EXAMPLE-70 Via intermediate of type "P" 3

EXAMPLE-71 Via intermediate of type "Q" 3

EXAMPLE-72 Via intermediate of type "Q" 2

EXAMPLE-73 Via intermediate of type "Q" 2

EXAMPLE-74 Via intermediate of type "Q" 2

EXAMPLE-75 Via intermediate of type "P" 2

EXAMPLE-76 Via intermediate of type "P" 2

EXAMPLE-77 Via intermediate of type "P" 2

EXAMPLE-78 Via intermediate of type "P" 2

EXAMPLE-79 Via intermediate of type "P" 2

EXAMPLE-80 Via intermediate of type "P" 2

EXAMPLE-81 Via intermediate of type "P" 2

EXAMPLE-82 Via intermediate of type "P" 2

EXAMPLE-83 Via intermediate of type "P" 2

EXAMPLE-84 Via intermediate of type "P" 2

EXAMPLE-85 Via intermediate of type "P" 2 EXAMPLE-86 Via intermediate of type "P" 2

EXAMPLE-87 Via intermediate of type "Q" 2

EXAMPLE-88 Via intermediate of type "P" 2

EXAMPLE-89 Via intermediate of type "P" 2

EXAMPLE-90 Via intermediate of type "P" 2

EXAMPLE-91 Via intermediate of type "Q" 2

EXAMPLE-92 Via intermediate of type "Q" 2

EXAMPLE-93 Via intermediate of type "Q" 2

EXAMPLE-94 Via intermediate of type "Q" 2

EXAMPLE-95 Via intermediate of type "Q" 2

EXAMPLE-96 Via intermediate of type "Q" 2

EXAMPLE-97 Via intermediate of type "P" 2

EXAMPLE-98 Via intermediate of type "P" 2

EXAMPLE-99 Via intermediate of type "P" 2

EXAMPLE-100 Via intermediate of type "Q" 2

EXAMPLE-101 Via intermediate of type "P" 2

EXAMPLE-102 Via intermediate of type "Q" 2

EXAMPLE-103 Via intermediate of type "P" 2

EXAMPLE-104 Via intermediate of type "P" 2

EXAMPLE-105 Via intermediate of type "P" 2

EXAMPLE-106 Via intermediate of type "P" 2

EXAMPLE-107 Via intermediate of type "P" 2 EXAMPLE-108 Via intermediate of type "P" 2

EXAMPLE-109 Via intermediate of type "P" 2

EXAMPLE-1 10 Via intermediate of type "Q" 2

EXAMPLE-1 1 1 Via intermediate of type "Q" 2

EXAMPLE-1 12 Via intermediate of type "P" 2

EXAMPLE-1 13 Via intermediate of type "P" 2

EXAMPLE-1 14 Via intermediate of type "P" 2

EXAMPLE-1 15 Via intermediate of type "P" 2

EXAMPLE-1 16 Via intermediate of type "P" 2

EXAMPLE-1 17 Via intermediate of type "Q" 2

EXAMPLE-1 18 Via intermediate of type "P" 2

EXAMPLE-1 19 Via intermediate of type "P" 2

EXAMPLE-120 Via intermediate of type "P" 2

EXAMPLE-121 Via intermediate of type "P" 2

EXAMPLE-122 Via intermediate of type "P" 2

EXAMPLE-123 Via intermediate of type "P" 2

EXAMPLE-124 Via intermediate of type "P" 2

EXAMPLE-125 Via intermediate of type "P" 2

EXAMPLE-126 Via intermediate of type "Q" 2

EXAMPLE-127 Via intermediate of type "P" 2

EXAMPLE-128 Via intermediate of type "P" 2

EXAMPLE-129 Via intermediate of type "P" 2 EXAMPLE-130 Via intermediate of type "Q" 2

EXAMPLE-131 Via intermediate of type "Q" 2

EXAMPLE-132 Via intermediate of type "Q" 2

EXAMPLE-133 Via intermediate of type "Q" 2

EXAMPLE-134 Via intermediate of type "P" 2

EXAMPLE-135 Via intermediate of type "Q" 2

EXAMPLE-136 Via intermediate of type "P" 2

EXAMPLE-137 Via intermediate of type "P" 2

EXAMPLE-138 Via intermediate of type "P" 2

EXAMPLE-139 Via intermediate of type "P" 2

EXAMPLE-140 Via intermediate of type "P" 2

EXAMPLE-141 Via intermediate of type "Q" 2

EXAMPLE-142 Via intermediate of type "Q" 2

EXAMPLE-143 Via intermediate of type "P" 2

EXAMPLE-144 Via intermediate of type "Q" 2

EXAMPLE-145 Via intermediate of type "Q" 2

EXAMPLE-146 Via intermediate of type "P" 2

EXAMPLE-147 Via intermediate of type "P" 2

EXAMPLE-148 Via intermediate of type "P" 2

EXAMPLE-149 Via intermediate of type "P" 2

EXAMPLE-150 Via intermediate of type "P" 2

EXAMPLE-151 Via intermediate of type "P" 2 EXAMPLE-152 Via intermediate of type "P" 2

EXAMPLE-153 Via intermediate of type "P" 2

EXAMPLE-154 Via intermediate of type "P" 2

EXAMPLE-155 Via intermediate of type "P" 2

EXAMPLE-156 Via intermediate of type "P" 2

EXAMPLE-157 Via intermediate of type "P" 2

EXAMPLE-158 Via intermediate of type "P" 2

EXAMPLE-159 Via intermediate of type "P" 2

EXAMPLE-160 Via intermediate of type "P" 2

EXAMPLE-161 Via intermediate of type "P" 2

EXAMPLE-162 Via intermediate of type "P" 2

EXAMPLE-163 Via intermediate of type "P" 2

EXAMPLE-164 Via intermediate of type "P" 2

EXAMPLE-165 Via intermediate of type "P" 2

EXAMPLE-166 Via intermediate of type "P" 2

EXAMPLE-167 Via intermediate of type "P" 2

EXAMPLE-168 Via intermediate of type "P" 2

EXAMPLE-169 Via intermediate of type "P" 2

EXAMPLE-170 Via intermediate of type "Q" 2

EXAMPLE-171 Via intermediate of type "Q" 2

EXAMPLE-172 Via intermediate of type "Q" 2

EXAMPLE-173 Via intermediate of type "Q" 2 EXAMPLE-174 Via intermediate of type "Q" 2

EXAMPLE-175 Via intermediate of type "Q" 2

EXAMPLE-176 Via intermediate of type "P" 2

EXAMPLE-177 Via intermediate of type "P" 2

EXAMPLE-178 Via intermediate of type "P" 2

EXAMPLE-179 Via intermediate of type "Q" 2

EXAMPLE-180 Via intermediate of type "Q" 2

EXAMPLE-181 Via intermediate of type "P" 2

EXAMPLE-182 Via intermediate of type "Q" 2

EXAMPLE-183 Via intermediate of type "Q" 2

EXAMPLE-184 Via intermediate of type "P" 2

EXAMPLE-185 Via intermediate of type "P" 2

EXAMPLE-186 Via intermediate of type "P" 2

EXAMPLE-187 Via intermediate of type "P" 2

EXAMPLE-188 Via intermediate of type "Q" 2

EXAMPLE-189 Via intermediate of type "Q" 2

EXAMPLE-190 Via intermediate of type "Q" 2

EXAMPLE-191 Via intermediate of type "Q" 2

EXAMPLE-192 Via intermediate of type "Q" 2

EXAMPLE-193 Via intermediate of type "Q" 2

EXAMPLE-194 Via intermediate of type "Q" 2

EXAMPLE-195 Via intermediate of type "Q" 2 EXAMPLE-196 Via intermediate of type "P" 2

EXAMPLE-197 Via intermediate of type "P" 4

EXAMPLE-198 Via intermediate of type "P" 3

EXAMPLE-199 Via intermediate of type "Q" 2

EXAMPLE-200 Via intermediate of type "P" 2

EXAMPLE-201 Via intermediate of type "P" 2

EXAMPLE-202 Via intermediate of type "P" 2

EXAMPLE-203 Via intermediate of type "P" 2

EXAMPLE-204 Via intermediate of type "Q" 2

EXAMPLE-205 Via intermediate of type "P" 3

EXAMPLE-206 Via intermediate of type "P" 2

EXAMPLE-207 Via intermediate of type "P" 2

EXAMPLE-208 Via intermediate of type "P" 2

EXAMPLE-209 Via intermediate of type "P" 2

EXAMPLE-210 Via intermediate of type "P" 2

EXAMPLE-21 1 Via intermediate of type "P" 2

EXAMPLE-212 Via intermediate of type "P" 2

EXAMPLE-213 Via intermediate of type "P" 2

EXAMPLE-214 Via intermediate of type "P" 2

EXAMPLE-215 Via intermediate of type "P" 2

EXAMPLE-216 Via intermediate of type "P" 2

EXAMPLE-217 Via intermediate of type "P" 2 EXAMPLE-218 Via intermediate of type "P" 2

EXAMPLE-219 Via intermediate of type "P" 2

EXAMPLE-220 Via intermediate of type "Q" 2

EXAMPLE-221 Via intermediate of type "P" 2

EXAMPLE-222 Via intermediate of type "P" 2

EXAMPLE-223 Via intermediate of type "P" 2

EXAMPLE-224 Via intermediate of type "P" 2

EXAMPLE-225 Via intermediate of type "P" 2

EXAMPLE-226 Via intermediate of type "P" 2

EXAMPLE-227 Via intermediate of type "P" 2

EXAMPLE-228 Via intermediate of type "P" 2

EXAMPLE-229 Via intermediate of type "P" 2

EXAMPLE-230 Via intermediate of type "P" 2

EXAMPLE-231 Via intermediate of type "P" 2

EXAMPLE-232 Via intermediate of type "P" 2

EXAMPLE-233 Via intermediate of type "P" 2

EXAMPLE-234 Via intermediate of type "P" 2

EXAMPLE-235 Via intermediate of type "P" 2

EXAMPLE-236 Via intermediate of type "P" 2

EXAMPLE-237 Via intermediate of type "P" 2

EXAMPLE-238 Via intermediate of type "P" 2

EXAMPLE-239 Via intermediate of type "P" 2 EXAMPLE-240 Via intermediate of type "P" 2

EXAMPLE-241 Via intermediate of type "P" 2

EXAMPLE-242 Via intermediate of type "Q" 2

EXAMPLE-243 Via intermediate of type "P" 2

EXAMPLE-244 Via intermediate of type "P" 2

EXAMPLE-245 Via intermediate of type "P" 2

EXAMPLE-246 Via intermediate of type "P" 2

EXAMPLE-247 Via intermediate of type "P" 2

EXAMPLE-248 Via intermediate of type "P" 2

EXAMPLE-249 Via intermediate of type "P" 2

EXAMPLE-250 Via intermediate of type "P" 2

EXAMPLE-251 Via intermediate of type "P" 2

EXAMPLE-252 Via intermediate of type "P" 2

EXAMPLE-253 Via intermediate of type "P" 2

EXAMPLE-254 Via intermediate of type "P" 2

EXAMPLE-255 Via intermediate of type "P" 2

EXAMPLE-256 Via intermediate of type "P" 2

EXAMPLE-257 Via intermediate of type "P" 2

EXAMPLE-258 Via intermediate of type "P" 2

EXAMPLE-259 Via intermediate of type "Q" 2

EXAMPLE-260 Via intermediate of type "P" 2

EXAMPLE-261 Via intermediate of type "P" 2 EXAMPLE-262 Via intermediate of type "P" 2

EXAMPLE-263 Via intermediate of type "P" 2

EXAMPLE-264 Via intermediate of type "P" 4

EXAMPLE-265 Via intermediate of type "P" 3

EXAMPLE-266 Via intermediate of type "P" 4

EXAMPLE-267 Via intermediate of type "P" 4

EXAMPLE-268 Via intermediate of type "Q" 2

EXAMPLE-269 Via intermediate of type "P" 2

EXAMPLE-270 Via intermediate of type "P" 2

EXAMPLE-271 Via intermediate of type "P" 2

EXAMPLE-272 Via intermediate of type "P" 2

EXAMPLE-273 Via intermediate of type "P" 2

EXAMPLE-274 Via intermediate of type "P" 2

EXAMPLE-275 Via intermediate of type "P" 2

EXAMPLE-276 Via intermediate of type "P" 2

EXAMPLE-277 Via intermediate of type "P" 2

EXAMPLE-278 Via intermediate of type "P" 2

EXAMPLE-279 Via intermediate of type "P" 2

EXAMPLE-280 Via intermediate of type "P" 2

EXAMPLE-281 Via intermediate of type "P" 2

EXAMPLE-282 Via intermediate of type "P" 2

EXAMPLE-283 Via intermediate of type "P" 2 EXAMPLE-284 Via intermediate of type "P" 2

EXAMPLE-285 Via intermediate of type "P" 2

EXAMPLE-286 Via intermediate of type "P" 3

EXAMPLE-287 Via intermediate of type "P" 3

EXAMPLE-288 Via intermediate of type "P" 4

EXAMPLE-289 Via intermediate of type "P" 4

EXAMPLE-290 Via intermediate of type "P" 2

EXAMPLE-291 Via intermediate of type "P" 2

EXAMPLE-292 Via intermediate of type "P" 2

EXAMPLE-293 Via intermediate of type "P" 4

EXAMPLE-294 Via intermediate of type "P" 2

EXAMPLE-295 Via intermediate of type "P" 2

EXAMPLE-296 Via intermediate of type "P" 2

EXAMPLE-297 Via intermediate of type "P" 2

EXAMPLE-298 Via intermediate of type "Q" 2

EXAMPLE-299 Via intermediate of type "P" 2

EXAMPLE-300 Via intermediate of type "P" 2

EXAMPLE-301 Via intermediate of type "P" 2

EXAMPLE-302 Via intermediate of type "P" 2

EXAMPLE-303 Via intermediate of type "Q" 2

EXAMPLE-304 Via intermediate of type "P" 3

EXAMPLE-305 Via intermediate of type "P" 3 EXAMPLE-306 Via intermediate of type "P" 3

EXAMPLE-307 Via intermediate of type "P" 3

EXAMPLE-308 Via intermediate of type "P" 3

EXAMPLE-309 Via intermediate of type "P" 3

EXAMPLE-310 Via intermediate of type "P" 3

EXAMPLE-31 1 Via intermediate of type "P" 2

EXAMPLE-312 Via intermediate of type "P" 2

EXAMPLE-313 Via intermediate of type "P" 2

EXAMPLE-314 Via intermediate of type "P" 4

EXAMPLE-315 Via intermediate of type "Q" 2

EXAMPLE-316 Via intermediate of type "P" 4

EXAMPLE-317 Via intermediate of type "P" 4

EXAMPLE-318 Via intermediate of type "P" 4

EXAMPLE-319 Via intermediate of type "P" 4

EXAMPLE-320 Via intermediate of type "P" 2

EXAMPLE-321 Via intermediate of type "P" 2

EXAMPLE-322 Via intermediate of type "P" 2

EXAMPLE-323 Via intermediate of type "P" 2

EXAMPLE-324 Via intermediate of type "P" 2

EXAMPLE-325 Via intermediate of type "P" 2

EXAMPLE-326 Via intermediate of type "P" 2

EXAMPLE-327 Via intermediate of type "Q" 2 EXAMPLE-328 Via intermediate of type 2

EXAMPLE-329 Via intermediate of type 2

EXAMPLE-330 Via intermediate of type 4

EXAMPLE-331 Via intermediate of type 2

EXAMPLE-332 iipn

Via intermediate of type 2

EXAMPLE-333 Via intermediate of type 4

Experimental section: Table 4: Description of the reaction sequences: starting from the intermediates of type F, according to the synthesis route selected (Tables 1 and 2), the intermediate is treated with the reagent specified according to the method specified

o

o

o

o

EXAMP L E 310 EXAMP L E 311 EXAMP L E 312 EXAMP L E 313 EXAMP L E 314 EXAMP L E 315 ------

(S)-8-((R)-3-Methyl- morpholino)-2-

3-(R )- (trifluoromethyl)-3,4- methyl- 1 ,1 Method 1 None

dihydro-1 H- morpholine

pyrimido[1 ,2-a]pyrimidin- 6(2H)-one

(S)-2-((R)-3-Methyl- morpholin-4-yl)-8-

3-(R )- trifluoromethyl-6,7,8,9- Methyl- 3 Method-1 None

tetrahydro- morpholine

pyrimido[1 ,2-a]pyrimidin- 4-one

(S)-8-((3R,5R)-3,5-

3-(R)-5- Dimethylmorpholino)-2-

(R)- Method-

1.7 None (trifluoromethyl)-3,4- Dimethyl- 39

dihydro-1 H-pyrimido[1 ,2- morpholine

]pyrimidin-6(2H)-one

(S)-8-((3R,5R)-3,5-

3-(R)-5- Dimethylmorpholino)-2-

(R)- Method-

1.7 None (trifluoromethyl)-3,4- Dimethyl- 39

dihydro-1 H-pyrimido[1 ,2- morpholine

]pyrimidin-6(2H)-one

(S)-3-Fluoro-2-((R)-3- methylmorpholin-4-yl)-8-

3-(R )- trifluoromethyl-6,7,8,9- Methyl- 3 Method-1 None

tetrahydro- morpholine

pyrimido[1 ,2-a]pyrimidin- 4-one

(S)-2-Chloro-9-(2- hydroxyethyl)-8-

Bromo- Method- trifluoromethyl-6,7,8,9-

1.5-2.0 None

ethanol 23 tetrahydro- pyrimido[1 ,2-a]pyrimidin- 4-one EXAMP L E 316 EXAMP L E 317 EXAMP L E 318 EXAMP L E 319 EXAMP L E 320 -----

(S)-3-Fluoro-2-((R)-3- methylmorpholin-4-yl)-8-

3-(R )- trifluoromethyl-6,7,8,9- Methyl- 3 Method-1 None

tetrahydro- morpholine

pyrimido[1 ,2-a]pyrimidin- 4-one

(S)-3-Fluoro-2-((R)-3- methylmorpholin-4-yl)-8-

3-(R )- trifluoromethyl-6,7,8,9- Methyl- 3 Method-1 None

tetrahydro- morpholine

pyrimido[1 ,2-a]pyrimidin- 4-one

(S)-2-((R)-3-Methyl- morpholin-4-yl)-8-

3-(R )- trifluoromethyl-6,7,8,9- Methyl- 3 Method-1 None

tetrahydro- morpholine

pyrimido[1 ,2-a]pyrimidin- 4-one

(S)-2-((R)-3-Methyl- morpholin-4-yl)-8-

3-(R )- trifluoromethyl-6,7,8,9- Methyl- 3 Method-1 None

tetrahydro- morpholine

pyrimido[1 ,2-a]pyrimidin- 4-one

3-(R)- (S)-2-(2-Methyl- Methyl- morpholin-4-yl)-8- morpholine trifluoromethyl-6,7,8,9- prepared tetrahydro- internally pyrimido[1 ,2-a]pyrimidin-

3 Method-1 None

and 4-one, diastereoisomer 1 contamiof undetermined nated with absolute configuration 2-methyl- on the asymmetric morpholine carbon of the morpholine EXAMP L E 321 EXAMP L E 322 EXAMP L E 323 EXAMP L E 324 EXAMP L E 325 -----

(S)-3-Fluoro-2-((R)-3- methylmorpholin-4-yl)-8-

3-(R )- trifluoromethyl-6,7,8,9- Methyl- 3 Method-1 None

tetrahydro- morpholine

pyrimido[1 ,2-a]pyrimidin- 4-one

3-(R )- (S)-2-(2-Methyl- Methyl- morpholin-4-yl)-8- morpholine trifluoromethyl-6,7,8,9- prepared tetrahydro- internally pyrimido[1 ,2-a]pyrimidin-

3 Method-1 None

and 4-one, diastereoisomer 1 contamiof undetermined nated with absolute configuration 2-methyl- on the asymmetric morpholine carbon of the morpholine

(S)-2-((R)-3-Methyl- morpholin-4-yl)-8-

3-(R )- trifluoromethyl-6,7,8,9- Methyl- 3 Method-1 None

tetrahydro- morpholine

pyrimido[1 ,2-a]pyrimidin- 4-one

(S)-2-((R)-3-Methyl- morpholin-4-yl)-8-

3-(R )- trifluoromethyl-6,7,8,9- Methyl- 3 Method-1 None

tetrahydro- morpholine

pyrimido[1 ,2-a]pyrimidin- 4-one

(S)-2-((R)-3-Methyl- morpholin-4-yl)-8-

3-(R )- trifluoromethyl-6,7,8,9- Methyl- 3 Method-1 None

tetrahydro- morpholine

pyrimido[1 ,2-a]pyrimidin- 4-one

EXAMP L E 332 EXAMP L E 333 --

(S)-3-Fluoro-2-((R)-3- methylmorpholin-4-yl)-8-

3-(R )- trifluoromethyl-6,7,8,9- Methyl- 3 Method-1 None

tetrahydro- morpholine

pyrimido[1 ,2-a]pyrimidin- 4-one

(S)-3-Fluoro-2-((R)-3- methylmorpholin-4-yl)-8-

3-(R )- trifluoromethyl-6,7,8,9- Methyl- 3 Method-1 None

tetrahydro- morpholine

pyrimido[1 ,2-a]pyrimidin- 4-one

EXAMP L E EXAMP L E 6 EXAMP L E EXAMP L E 8 EXAMP L E 957 -----

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 4-(Chloro- 8-trifluoromethyl- methyl)-2- Method-

1 .1 None None 6,7,8,9- fluoro- 10

tetrahydro- pyridine

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

2-Bromo-1 - 8-trifluoronnethyl- Method- cyclopropyl- 1 .5 None None 6,7,8,9- 10

ethanone

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

1 -Chloro- 8-trifluoromethyl- Method- propan-2- 1 .2 None None 6,7,8,9- 22

one

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- Chiral

8-trifluoromethyl- (S)-(-)- Method- Purifi- Propylene 2 None None 6,7,8,9- 18 cation- oxide

tetrahydro- 20

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-5-(R)- methyl- morpholin-4-yl)- 5-(Bromo-

Method- 8-trifluoronnethyl- methyl)- 1 .1 None None

19

6,7,8,9- isoxazole

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 10 EXAMP L E 11 EXAMP L E 12 W I P L E 13 W I P L E 14 -----

2-Chloro-9-[2-(2- chloropyridin-4- yl)-2-oxoethyl]-8- trifluoromethyl- (3R)-Methyl- Method-

3 None None 6,7,8,9- morpholine 1

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-Chloro-9- (2-oxo-2-pyridin-

3-ylethyl)-8- trifluoromethyl- (3R)-Methyl- Method-

2.6 None None 6,7,8,9- morpholine 38

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 4-Chloro- 8-trifluoromethyl- methyl-3- Method-

1 .2 None None 6,7,8,9- methyl- 10

tetrahydro- isoxazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-2-((R)-3- Methyl- morpholin-4-yl)-

2-Chloro- 6-trifluoromethyl- Method- methyl- 1 .3 None None 6,7,8,9- 10

oxazole

X tetrahydro-

LU

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

Ethyl 2- 8-trifluoromethyl- Method- bromo- 1 .1 None None 6,7,8,9- 10

acetate

X tetrahydro-

LU

pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 1 W I P L E 16 EXAMP L E 1 EXAMP L E 18 EXAMP L E 1957 -----

(S)-3-Fluoro-2- ((R)-3-methyl-

3-Chloro- morpholin-4-yl)- methyl-5- 8-trifluoronnethyl- Method- methyl- 1 .2 None None 6,7,8,9- 10

[1 ,2,4]- tetrahydro- oxadiazole

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

Ethyl- 8-trifluoromethyl- Method- Method

magnesium 1 .2 None 6,7,8,9- 1 1 -46

bromide

X tetrahydro-

LU

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-

5-(Chloro- morpholin-4-yl)- methyl)-3- 8-trifluoromethyl- Method- methyl- 1 .2 None None 6,7,8,9- 14

1 ,2,4- tetrahydro- oxadiazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 2-Bromo-1 - 8-trifluoromethyl- (tetrahydro- Method-

1 .2 None None 6,7,8,9- pyran-4-yl)- 10

tetrahydro- ethanone

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl-

5-(Chloro- morpholin-4-yl)- methyl)-3- 8-trifluoromethyl- Method- methyl- 1 .1 None None 6,7,8,9- 13

1 ,2,4- tetrahydro- oxadiazole

pyrimido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 20 EXAMP L E 21 EXAMP L E 22 EXAMP L E 23 EXAMP L E 24 -----

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 8-trifluoromethyl- 2-Bromethyl Method-

1 .2 None None 6,7,8,9- methyl ether 10

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(R)-3-Fluoro-2- ((R)-3-methyl-

3-(Chloro- morpholin-4-yl)- methyl)-5- 6-trifluoronnethyl- Method- methyl- 1 .1 None None 6,7,8,9- 19

1 ,2,4- tetrahydro- oxadiazole

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 8-trifluoromethyl- 1 -Bromo-2- Method-

1 .5 None None 6,7,8,9- butanone 10

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 2-Chloro-N- 8-trifluoromethyl- methoxy-N- Method-

1 .1 None None 6,7,8,9- methyl- 1 1

tetrahydro- acetamide

pyrinnido[1 ,2-a]- pyrinnidin-4-one

2-Chloro-9-(6- fluoropyridin-3- yl methyl )-8- trifluoromethyl- (3R)-Methyl- Method-

16.6 None None 6,7,8,9- morpholine 1

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

EXAMP L E 3 EXAMP L E 36 EXAMP L E 3 EXAMP L E 38 EXAMP L E 3957 -----

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 2-Chloro-5- 8-trifluoromethyl- chloro- Method-

1 .1 None None 6,7,8,9- methyl- 12

tetrahydro- pyridine

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

5-(Bromo- 8-trifluoronnethyl- Method- methyl)- 1 .1 None None 6,7,8,9- 12

isoxazole

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-

5-(Chloro- morpholin-4-yl)- methyl)-1 - 8-trifluoromethyl- Method- (difluoro- 1 .1 None None 6,7,8,9- 12

methyl)-1 H- tetrahydro- pyrazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-Chloro-3- fluoro-9-(2-oxo- 2-pyridin-2-yl- ethyl)-8-

(3R)-Methyl- Method- trifluoromethyl- 2 None None morpholine 42

6,7,8,9- tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

2-Fluoro-2- 8-trifluoronnethyl- phenylethyl- Chiral

6,7,8,9- Method- 4-methyl- Purifi- None None tetrahydro- 27

benzene- cation-19

pyrinnido[1 ,2-a]- sulphonate

pyrinnidin-4-one,

single

stereoisomer EXAMP L E 40 EXAMP L E 41 W I P L E 42 EXAMP L E 43 W I P L E 44 -----

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

4-Bromo-2- 8-trifluoromethyl- Method- methoxy- 1 None None 6,7,8,9- 29

pyridine

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 2-Chloro-4- 8-trifluoromethyl- (chloro- Method-

1 None None 6,7,8,9- methyl)- 12

tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

2-Bromo- 8-trifluoromethyl- Method- methyl- 1 .1 None None 6,7,8,9- 14

oxazole

X tetrahydro-

LU

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 3-Bromo-6- 8-trifluoromethyl- (cyclo- Method-

1 .1 None None 6,7,8,9- propyl)- 29

tetrahydro- pyridine

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

4-(Chloro- 8-trifluoronnethyl- Method- methyl)-1 ,3- 1 .5 None None 6,7,8,9- 12

oxazole

X tetrahydro-

LU

pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 4 W I P L E 46 EXAMP L E 4 W I P L E 48 EXAMP L E 4957 -----

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 8-trifluoromethyl- 2-Chloro-4- Method-

3 None None 6,7,8,9- iodopyridine 29

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

4-(Chloro- 8-trifluoromethyl- Method- methyl)-1 ,3- 1 .1 None None 6,7,8,9- 12

oxazole

X tetrahydro-

LU

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 8-trifluoromethyl- 3-Bromo- Method-

4 None None 6,7,8,9- pyridine 29

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl-

2-(2-Chloro- morpholin-4-yl)- ethoxy)- 8-trifluoromethyl- Method- one None 6,7,8,9- 1 ,1 ,1 - 1 .3 N

10

trifluoro-

X tetrahydro-

LU ethane

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 8-trifluoronnethyl- Isobutylene Method-

1 None None 6,7,8,9- oxide 35

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 0 EXAMP L E 1 EXAMP L E 2 EXAMP L E 3 EXAMP L E 455555 -----

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

2-Bromo-1 - 8-trifluoromethyl- Method- (pyridin-3- 1 .5 None None 6,7,8,9- 12

yl)ethanone

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-Chloro-3- fluoro-9-(6- fluoropyridin-3- yl methyl )-8-

(3R)-Methyl- Method- trifluoromethyl- 1 .2 None None morpholine 1

6,7,8,9- tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-Chloro-9- (6-chloropyridin- 3-ylmethyl)-3- fluoro-8-

(3R)-Methyl- Method- trifluoromethyl- 1 None None morpholine 1

6,7,8,9- tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 5-Bromo-2- 8-trifluoronnethyl- (difluoro- Method-

1 .5 None None 6,7,8,9- methyl)- 30

tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- 5-(tert- morpholin-4-yl)- Butyl)-3- 8-trifluoromethyl- (chloro- Method-

1 .3 None None 6,7,8,9- methyl)- 10

tetrahydro- 1 ,2,4- pyrinnido[1 ,2-a]- oxadiazole

pyrinnidin-4-one (S)-3-Fluoro-2-

LO LO ((R)-3-methyl-

LLl morpholin-4-yl)- 1

Q_ 8-trifluoromethyl- 4- Method-

Έ 1 .5 None None <r 6,7,8,9- lodopyridine 30

^ **

X tetrahydro- LU

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2-

CD

LO ((R)-3-methyl- 2-(Bromo-

LLl morpholin-4-yl)- methyl)-5- 1

Q_ 8-trifluoronnethyl- fluoro- Method-

Έ 1 .2 None None <r 6,7,8,9- pyridine 10

^* *

X tetrahydro- hydro- LU

pyrinnido[1 ,2-a]- bromide

pyrinnidin-4-one

(S)-3-Fluoro-2-

LO ((R)-3-methyl-

LU morpholin-4-yl)- 3-(Bromo- 1

Q_ 8-trifluoromethyl- methyl)-5- Method-

Έ 1 .5 None None

6,7,8,9- fluoro- 10

X tetrahydro- pyridine

LU

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2-

CO LO ((R)-3-methyl-

LU morpholin-4-yl)- 3-(Chloro- 1

Q_ 8-trifluoromethyl- methyl)-2- Method-

Έ 1 .5 None None

6,7,8,9- fluoro- 10

X tetrahydro- pyridine

LLl

pyrinnido[1 ,2-a]- pyrimidin-4-one

(S)-3-Fluoro-2- σ>

LO ((R)-3-methyl-

LU morpholin-4-yl)- 2-Chloro-N- 1

Q_ 8-trifluoromethyl- methoxy-N- Method- Method

None

<r 6,7,8,9- methyl- 1 1 -46

^* *

X tetrahydro- acetamide

LLl

pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 60 EXAMP L E 61 EXAMP L E 62 EXAMP L E 63 EXAMP L E 64 -----

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 2-Chloro-N- 8-trifluoromethyl- methoxy-N- Method- Method

None 6,7,8,9- methyl- 1 1 -46 tetrahydro- acetamide

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 2-Chloro-N- 8-trifluoronnethyl- methoxy-N- Method- Method

None 6,7,8,9- methyl- 1 1 -47 tetrahydro- acetamide

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-Methyl- morpholin-4-yl)- 4-Chloro- 8-trifluoromethyl- methyl-3- Method-

1 .2 None None 6,7,8,9- methyl- 10

tetrahydro- isoxazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 2-Chloro-N- 8-trifluoromethyl- methoxy-N- Method- Method

None 6,7,8,9- methyl- 1 1 -47 tetrahydro- acetamide

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-

2-(Chloro- morpholin-4-yl)- methyl)- 8-trifluoromethyl- Method- imidazo- 1 .5 None None 6,7,8,9- 10

[1 ,2-a]- tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrinnidin-4-one

EXAMP L E EXAMP L E 6 W I P L E EXAMP L E 8 EXAMP L E 97577777 -----

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

3-Fluoro- 8-trifluoronnethyl- Method- iodo- 3 None None 6,7,8,9- 30

benzene

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 4-Bromo- 8-trifluoromethyl- methyl-2- Method-

1 .1 None None 6,7,8,9- chloro- 1 1

tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

2-Chloro- 8-trifluoromethyl- Method- methyl- 1 1 None None 6,7,8,9- 1 1

oxazole

X tetrahydro-

LU

pyrinnido[1 ,2-a]- pyrimidin-4-one

(S)-2-((R)-3- Methyl-

4-(Chloro- morpholin-4-yl)- methyl)- 8-trifluoromethyl- Method- thiazole 1 .1 None None 6,7,8,9- 1 1

hydrotetrahydro- chloride

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 2-Chloro-4- 8-trifluoromethyl- iodo- Method-

3 None None 6,7,8,9- pyridine, 30

tetrahydro- 99%

pyrimido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 80 EXAMP L E 81 W I P L E 82 EXAMP L E 83 EXAMP L E 84 -----

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

4-lodo-2- 8-trifluoromethyl- Method- methoxy- 3 None None 6,7,8,9- 30

pyridine

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 5-Bromo-2- 8-trifluoromethyl- (trifluoro- Method-

3 None None 6,7,8,9- methyl)- 30

tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-

2-(2-Chloro- morpholin-4-yl)- ethoxy)- 8-trifluoromethyl- Method- 6,7,8,9- 1 ,1 ,1 - 3 None None

1 1

trifluoro-

X tetrahydro-

LU ethane

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

5-Bromo-2- 8-trifluoromethyl- Method- methyl- 2 None None 6,7,8,9- 30

pyridine

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 8-trifluoromethyl- Isobutylene Method- xs None None 6,7,8,9- oxide 35

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

EXAMP L E 9 EXAMP L E 96 EXAMP L E 9 EXAMP L E 98 EXAMP L E 9957 -----

(S)-2-Chloro-9- (5-chloropyridin- 3-ylmethyl)-8- trifluoromethyl- (3R)-Methyl- Method-

7 None None 6,7,8,9- morpholine 1

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

2-Chloro-9-(5- methyl- [1 ,3,4]oxadiazol- 2-ylmethyl)-8-

(3R)-Methyl- Method- trifluoromethyl- 5 None None morpholine 1

6,7,8,9- tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

1 -Chloro- 8-trifluoromethyl- Method- pinacolone, 1 .2 None None 6,7,8,9- 22

95%

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 2-Chloro-5- 8-trifluoromethyl- (chloro- Method-

1 .1 None None 6,7,8,9- methyl)- 10

tetrahydro- thiophene

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

2-Bromo- 8-trifluoronnethyl- Method- aceto- 1 .5 None None 6,7,8,9- 10

phenone

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one (S)-2-Chloro-9- o

o ((S)-2-methoxy-

LU 2-phenylethyl)-8-

_l

Q_ trifluoromethyl- (3R)-Methyl- Method-

2 None None

6,7,8,9- morpholine 42

< X tetrahydro-

LU pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- δ Methyl-

LU morpholin-4-yl)- 5-(Bromo-

_l

Q_ 8-trifluoromethyl- methyl)-3- Method-

1 .2 None None

6,7,8,9- methyl- 10

< X tetrahydro- isoxazole

LU pyrinnido[1 ,2-a]- pyrimidin-4-one

(R)-2-Chloro-9-

CNI

O (2-oxo-2-pyridin-

LU 2-ylethyl)-6-

_l

Q_ trifluoromethyl- (3R)-Methyl- 3 Method-

None None

6,7,8,9- morpholine 38

< X tetrahydro-

LU pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Oxazol-4-yl- o Methyl- methyl 4-

LU morpholin-4-yl)- methyl-

_l

Q_ 8-trifluoromethyl- benzene- Method-

None None

6,7,8,9- sulphonate 10

< X tetrahydro- (ref.

LU pyrimido[1 ,2-a]- reagent-1

pyrinnidin-4-one table)

EXAMP L E 10 EXAMP L E 1067 EXAMP L E 105 EXAMP L E 104 ----

Oxazol-4-yl- methyl-4- methyl- benzene- sulphonate

(ref.

reagent-1

table).

(S)-2-((R)-3-

EX- 104

Methyl- isolated

morpholin-4-yl)- during the

8-trifluoromethyl- Method- purification 1 .2 None None 6,7,8,9- 10

of EX-103 is

tetrahydro- a by-product

pyrimido[1 ,2-a]- obtained

pyrimidin-4-one

during the

synthesis

because of

the excess

of tosyl

chloride in

the starting

reagent

(R)-2-((R)-3- Methyl- morpholin-4-yl)-

5-(Bromo- 6-trifluoromethyl- Method- methyl)- 1 .5 None None 6,7,8,9- 10

isoxazole

tetrahydro- pyrimido[1 ,2-a]- pyrimidin-4-one

(R)-2-((R)-3- Methyl- morpholin-4-yl)-

3-Chloro- 6-trifluoromethyl- Method- methyl- 2 None None 6,7,8,9- 10

isoxazole

tetrahydro- pyrimido[1 ,2-a]- pyrimidin-4-one

(R)-2-((R)-3- Methyl- morpholin-4-yl)- 3-Bromo-6- 6-trifluoronnethyl- (cyclo- Method-

None None 6,7,8,9- propyl)- 29

tetrahydro- pyridine

pyrimido[1 ,2-a]- pyrimidin-4-one EXAMP L E 108 EXAMP L E 109 EXAMP L E 110 EXAMP L E 111 EXAMP L E 112 -----

(R)-2-((R)-3- Methyl- morpholin-4-yl)- 6-trifluoromethyl- 2-Chloro-4- Method-

1 None None 6,7,8,9- iodopyridine 29

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(R)-2-((R)-3- Methyl- morpholin-4-yl)-

4-lodo-2- 6-trifluoromethyl- Method- methoxy- 1 None None 6,7,8,9- 29

pyridine

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-2-Chloro-9- oxazol-4-yl- methyl-6- trifluoromethyl- (3R)-Methyl- Method-

4 None None 6,7,8,9- morpholine 1

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-2-Chloro-3- fluoro-9-oxazol- 5-ylmethyl-6- trifluoromethyl- (3R)-Methyl- Method-

3 None None 6,7,8,9- morpholine 1

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-2-((R)-3- Methyl- morpholin-4-yl)- 2-Chloro-4- 6-trifluoromethyl- (chloro- Method-

1 .2 None None 6,7,8,9- methyl)- 10

tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 113 EXAMP L E 114 EXAMP L E 11 EXAMP L E 116 EXAMP L E 1157 -----

(R)-2-((R)-3- Methyl- morpholin-4-yl)- 6-trifluoromethyl- Isobutylene Method-

10 None None 6,7,8,9- oxide 17

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(R)-2-((R)-3- Methyl- morpholin-4-yl)- 4-Bromo-2- 6-trifluoromethyl- (iso- Method-

1 .2 None None 6,7,8,9- propoxy)- 29

tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-2-((R)-3- Methyl- morpholin-4-yl)- 2-Chloro-5- 6-trifluoromethyl- chloro- Method-

1 .2 None None 6,7,8,9- methyl- 10

tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-2-((R)-3- Methyl- morpholin-4-yl)-

5-Bromo-2- 6-trifluoromethyl- Method- isopropoxy- 1 .2 None None 6,7,8,9- 29

pyridine

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-2-Chloro-9- oxazol-5-yl- methyl-6- trifluoromethyl- (3R)-Methyl- Method-

2 None None 6,7,8,9- morpholine 1

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 118 EXAMP L E 119 EXAMP L E 120 EXAMP L E 121 EXAMP L E 122 -----

(R)-2-((R)-3- methyl- morpholin-4-yl)-

2-Bromo-1 - 6-trifluoromethyl- Method- cyclopropyl- 1 .2 None None 6,7,8,9- 10

ethanone

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(R)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

4-lodo-2- 6-trifluoromethyl- Method- methoxy- 1 .5 None None 6,7,8,9- 29

pyridine

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

2-Bromo-1 - 6-trifluoromethyl- Method- cyclopropyl- 1 .2 None None 6,7,8,9- 10

ethanone

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 5-Bromo-2- 6-trifluoromethyl- (difluoro- Method-

1 .3 None None 6,7,8,9- methyl)- 29

tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 6-trifluoromethyl- 2-Chloro-4- Method-

1 .1 None None 6,7,8,9- iodopyridine 29

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 123 EXAMP L E 124 EXAMP L E 12 EXAMP L E 126 EXAMP L E 1257 -----

(S)-2-((R)-3- Methyl-

2-(Chloro- morpholin-4-yl)- methyl)-5- 8-trifluoromethyl- Method- methyl- 1 .1 None None 6,7,8,9- 10

1 ,3,4- tetrahydro- thiadiazole

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 5-Bromo-2- 8-trifluoromethyl- (difluoro- Method-

1 .3 None None 6,7,8,9- methoxy)- 29

tetrahydro- pyridine

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-

5-(Chloro- morpholin-4-yl)- methyl)-4- 8-trifluoromethyl- Method- methyl- 1 .2 None None 6,7,8,9- 10

1 ,2,3- tetrahydro- thiadiazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-2-Chloro-3- fluoro-9-(2-oxo- 2-pyridin-3-yl- ethyl)-6-

(3R)-Methyl- Method- trifluoromethyl- 3 None None morpholine 1

6,7,8,9- tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(R)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 5-Bromo-2- 6-trifluoronnethyl- (difluoro- Method-

12 None None 6,7,8,9- methoxy)- 29

tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 128 EXAMP L E 129 EXAMP L E 130 EXAMP L E 131 EXAMP L E 132 -----

(R)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

1 -bromo-3- 6-trifluoromethyl- Method- methyl-2- 1 .1 None None 6,7,8,9- 19

butanone

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(R)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

2-Bromo- 6-trifluoromethyl- Method- methyl- 1 .2 None None 6,7,8,9- 19

oxazole

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

2-Chloro-9-(3- methyl-2-oxo- butyl)-6- trifluoromethyl- (3R)-Methyl- Method-

3 None None 6,7,8,9- morpholine 1

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-2-Chloro-9- [2-oxo-2-(tetra- hydropyran-4- yl)ethyl]-6-

(3R)-Methyl- Method- trifluoromethyl- 2.5 None None morpholine 1

6,7,8,9- tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(R)-2-Chloro-3- fluoro-9-[2-oxo- 2-(tetrahydro- pyran-4-yl)ethyl]-

(3R)-Methyl- Method- 6-trifluoromethyl- 4 None None morpholine 1

6,7,8,9- tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 133 EXAMP L E 134 EXAMP L E 13 EXAMP L E 136 EXAMP L E 1357 -----

(S)-2-Chloro-9- oxetan-3-yl- methyl-8- trifluoromethyl- (3R)-Methyl- Method-

3 None None 6,7,8,9- morpholine 1

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 5-Bromo-2- 8-trifluoromethyl- (difluoro- Method-

1 .3 None None 6,7,8,9- methyl)- 29

tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-2-Chloro-3- fluoro-9-(2-oxo- 2-pyridin-2-yl- ethyl)-6-

(3R)-Methyl- Method- trifluoromethyl- 3 None None morpholine 1

6,7,8,9- tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

2-Bromo- 8-trifluoromethyl- Method- methyl-tetra- 1 .5 None None 6,7,8,9- 10

hydrofuran

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

2-Bromo- 8-trifluoronnethyl- Method- methyl-tetra- 1 .5 None None 6,7,8,9- 10

hydrofuran

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

AMP L E

(S)-2-((R)-3-

00

c Methyl-

LU morpholin-4-yl)- 2-(Bromo-

_l

Q_ 8-trifluoromethyl- methyl)tetra- Method-

1 .5 None None

6,7,8,9- hydro-2 h- 10

< X tetrahydro- pyran

LU pyrinnido[1 ,2-a]- pyrimidin-4-one

(S)-2-((R)-3- co Methyl-

LU morpholin-4-yl)- 2-(Bromo-

_l

Q_ 8-trifluoromethyl- methyl)tetra- Method-

1 .5 None None

6,7,8,9- hydro-2 h- 10

< X tetrahydro- pyran

LU pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3-

<· '

Methyl- 5-(Chloro-

LU morpholin-4-yl)- methyl)-2-

_l

Q_ 8-trifluoromethyl- (trifluoro- Method-

1 .1 None None

6,7,8,9- methyl)- 10

< X tetrahydro- 1 ,3,4-

LU pyrimido[1 ,2-a]- oxadiazole

pyrinnidin-4-one

(R)-2-Chloro-9-

(2-oxo-2-pyridin-

LU 3-ylethyl)-6-

_l

Q_ trifluoromethyl- (3R)-Methyl- Method-

2 None None

6,7,8,9- morpholine 1

< X tetrahydro-

LU pyrinnido[1 ,2-a]- pyrinnidin-4-one

2-Chloro-9-(5-

CM cyclopropyl-

[1 ,3,4]oxadiazol-

2-ylmethyl)-8- Chiral

(3R)-Methyl- Method- trifluoromethyl- 2.67 Purifi- None None morpholine 1

6,7,8,9- cation-5

X

LU tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 143 EXAMP L E 144 EXAMP L E 14 EXAMP L E 146 EXAMP L E 1457 -----

(R)-2-((R)-3- Methyl- morpholin-4-yl)- 4-Chloro- 6-trifluoromethyl- methyl-3- Method-

1 .2 None None 6,7,8,9- methyl- 19

tetrahydro- isoxazole

pyrimido[1 ,2-a]- pyrinnidin-4-one

(R)-2-Chloro-6- trifluoromethyl-9-

(3-trifluoro- methyl-[1 ,2,4]-

(3R)-Methyl- Method- oxadiazol-5-yl- 2.5 None None morpholine 1

methyl)-6,7,8,9- tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

2-Chloro-9-(2- oxopropyl)-6- trifluoromethyl-

(3R)-Methyl- Method- 6,7,8,9- 2 None None morpholine 1

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 4-Chloro- 6-trifluoromethyl- methyl-3- Method-

1 .1 None None 6,7,8,9- methyl- 19

tetrahydro- isoxazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(R)-3-Fluoro-2- ((R)-3-methyl-

5-(Chloro- morpholin-4-yl)- methyl)-3- 6-trifluoromethyl- Method- cyclopropyl- 1 .2 None None 6,7,8,9- 19

1 ,2,4- tetrahydro- oxadiazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 148 EXAMP L E 149 EXAMP L E 10 EXAMP L E 11 EXAMP L E 12555 -----

(R)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 6-trifluoromethyl- Chloro- Method-

1 .2 None None 6,7,8,9- acetone 19

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(R)-3-Fluoro-2- ((R)-3-methyl-

5-(Chloro- morpholin-4-yl)- methyl)-3- 6-trifluoromethyl- Method- methyl- 1 .2 None None 6,7,8,9- 19

1 ,2,4- tetrahydro- oxadiazole

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-(3,3- Dimethyl- morpholin-4-yl)-

2-Bromo- 8-trifluoromethyl- Method- aceto- 1 .2 None None 6,7,8,9- 10

phenone

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-5-(R)- methyl-

2-Chloro-5- morpholin-4-yl)- (chloro- Method- 8-trifluoromethyl- 1 .2 None None methyl)- 31

6,7,8,9- thiophene

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-5-(R)- methyl-

2-Chloro-5- morpholin-4-yl)- (chloro- Method- 8-trifluoromethyl- 1 .2 None None methyl)- 31

6,7,8,9- thiophene

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 13 EXAMP L E 14 EXAMP L E 1 EXAMP L E 16 EXAMP L E 15555557 -----

(S)-2-((R)-3- Methyl-5-(R)- methyl- morpholin-4-yl)- 2-

Method- 8-trifluoromethyl- Bromoaceto 1 .2 None None

10

6,7,8,9- phenone

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-5-(R)- methyl- 5-(Chloro- morpholin-4-yl)- methyl)-1 -

Method- 8-trifluoromethyl- (difluoro- 1 .2 None None

19

6,7,8,9- methyl)-1 h- tetrahydro- pyrazole

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-5-(R)- methyl-

5-(Bromo- morpholin-4-yl)- methyl)-3- Method- 8-trifluoromethyl- 1 .2 None None methyl- 19

6,7,8,9- isoxazole

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-5-(R)- methyl-

2-Chloro-5- morpholin-4-yl)- chloro- Method- 8-trifluoronnethyl- 1 .2 None None methyl- 19

6,7,8,9- pyridine

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-5-(R)- methyl-

2-Chloro-4- morpholin-4-yl)- (chloro- Method- 8-trifluoromethyl- 1 .4 None None methyl)- 19

6,7,8,9- pyridine

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 18 EXAMP L E 19 EXAMP L E 160 EXAMP L E 161 EXAMP L E 16255 -----

(S)-2-((R)-3- Methyl-5-(R)- methyl- morpholin-4-yl)- 2-Chloro-

Method- 8-trifluoromethyl- methyl- 1 .5 None None

19

6,7,8,9- oxazole

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-5-(R)- methyl- morpholin-4-yl)-

2-Chloro-4- Method- 8-trifluoromethyl- 1 .2 None None iodopyridine 29

6,7,8,9- tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-5-(R)- methyl- morpholin-4-yl)-

3-Bromo- Method- 8-trifluoromethyl- 1 .2 None None pyridine 29

6,7,8,9- tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-(8-Oxa-3- aza- bicyclo[3.2.1 ]oct-

3-yl)-8- 3,5-Difluoro-

Method- trifluoromethyl- iodo- 1 .5 None None

29

6,7,8,9- benzene

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-(8-Oxa-3- azabicyclo- [3.2.1 ]oct-3-yl)- 2-Chloro-5- 8-trifluoromethyl- (chloro- Method-

1 .3 None None 6,7,8,9- methyl)- 31

tetrahydro- thiophene

pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 163 EXAMP L E 164 EXAMP L E 16 EXAMP L E 166 EXAMP L E 1657 -----

(S)-2-(8-Oxa-3- azabicyclo- [3.2.1 ]oct-3-yl)-

2-Bromo- 8-trifluoromethyl- Method- aceto- 1 .2 None None 6,7,8,9- 31

phenone

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-(8-Oxa-3- azabicyclo- [3.2.1 ]oct-3-yl)-

5-(Bromo- 8-trifluoromethyl- Method- methyl)- 1 .2 None None 6,7,8,9- 10

isoxazole

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-(8-Oxa-3- azabicyclo- [3.2.1 ]oct-3-yl)- 2-Chloro-5- 8-trifluoromethyl- chloro- Method-

1 .2 None None 6,7,8,9- methyl- 10

tetrahydro- thiazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-(8-Oxa-3- azabicyclo-

5-(Chloro- [3.2.1 ]oct-3-yl)- methyl)-1 - 8-trifluoronnethyl- Method-

(difluoro- 1 .2 None None 6,7,8,9- 10

methyl)-1 h- tetrahydro- pyrazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-(8-Oxa-3- azabicyclo- 3-Oxa-8- [3.2.1 ]oct-3-yl)- azabicyclo- 8-trifluoromethyl- [3.2.1 ]- Method-

1 .2 None None 6,7,8,9- octane 10

tetrahydro- hydropyrinnido[1 ,2-a]- chloride

pyrinnidin-4-one

EXAMP L E 184 EXAMP L E 18 EXAMP L E 186 EXAMP L E 18 EXAMP L E 18857 -----

(S)-6-Fluoro-2- methyl-7-((R)-3- methyl- 2-Chloro-4- morpholin-4-yl)- (chloro- Method-

1 .2 None None 2-trifluoromethyl- methyl)- 10

2,3-dihydro-1 H- pyridine

imidazo[1 ,2-a]- pyrinnidin-5-one

(S)-6-Fluoro-2- methyl-7-((R)-3- methyl-

1 -Bromo-3- morpholin-4-yl)- Method- methyl-2- 1 .2 None None 2-trifluoromethyl- 19

butanone

2,3-dihydro-1 H- imidazo[1 ,2-a]- pyrinnidin-5-one

(S)-6-Fluoro-2- methyl-7-((R)-3- methyl- 2-Bromo-1 - morpholin-4-yl)- (tetrahydro- Method-

1 .1 None None 2-trifluoromethyl- 2h-pyran-4- 19

2,3-dihydro-1 H- yl)ethanone

imidazo[1 ,2-a]- pyrinnidin-5-one

(S)-6-Fluoro-2- methyl-7-((R)-3- methyl-

2-Bromo-1 - morpholin-4-yl)- Method- cyclopropyl- 1 None None 2-trifluoromethyl- 19

ethanone

2,3-dihydro-1 H- imidazo[1 ,2-a]- pyrinnidin-5-one

(S)-7-Chloro-2- methyl-1 -(3- methyl-2-oxo- butyl)-2- (3R)-Methyl- Method-

2 None None trifluoromethyl- morpholine 1

2,3-dihydro-1 H- imidazo[1 ,2-a]- pyrinnidin-5-one

EXAMP L E 20 EXAMP L E 205 EXAMP 4 E L E 203 XAMP L E 202 EXAMP L E 201 -----

(S)-2-((R)-3- Methyl-

3-(Chloro- morpholin-4-yl)- methyl)-5- 8-trifluoromethyl- Method- (propan-2- 1 .2 None None 6,7,8,9- 1 1

yl)-1 ,2,4- tetrahydro- oxadiazole

pyrimido[1 ,2-a]- pyrimidin-4-one

(S)-2-((R)-3- Methyl-

3-(Chloro- morpholin-4-yl)- methyl)-5- 8-trifluoromethyl- Method- cyclopropyl- 1 .2 None None 6,7,8,9- 1 1

1 ,2,4- tetrahydro- oxadiazole

pyrimido[1 ,2-a]- pyrimidin-4-one

(S)-2-((R)-3- Methyl- 5-(tert- morpholin-4-yl)- Butyl)-3- 8-trifluoromethyl- (chloro- Method-

1 .2 None None 6,7,8,9- methyl)- 1 1

tetrahydro- 1 ,2,4- pyrimido[1 ,2-a]- oxadiazole

pyrimidin-4-one

(S)-2-Chloro-3- fluoro-9-(2- hydroxyethyl)-8- trifluoromethyl- (3R)-Methyl- Method-

10 None None 6,7,8,9- morpholine 1

tetrahydro- pyrimido[1 ,2-a]- pyrimidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- (S)-(-)- 8-trifluoromethyl- Propylene Method- 6,7,8,9- oxide 12 None None

18

tetrahydro- pyrimido[1 ,2-a]- pyrimidin-4-one EXAMP L E 206 EXAMP L E 20 EXAMP L E 208 EXAMP L E 209 EXAMP L E 2107 -----

(S)-2-(8-Oxa-3- azabicyclo- (S)-2- [3.2.1 ]oct-3-yl)- methoxy-2- 8-trifluoromethyl- phenylethyl Method-

1 .2 None None 6,7,8,9- para- 28

tetrahydro- toluene- pyrimido[1 ,2-a]- sulphonate

pyrinnidin-4-one

(S)-6-Fluoro-2- methyl-7-((R)-3-

5-(Chloro- methyl- methyl)-3- morpholin-4-yl)- Method- methyl- 1 None None 2-trifluoromethyl- 10

1 ,2,4- 2,3-dihydro-1 H- oxadiazole

imidazo[1 ,2-a]- pyrinnidin-5-one

(S)-6-Fluoro-2- methyl-7-((R)-3-

5-(Chloro- methyl- methyl)-3- morpholin-4-yl)- Method- methyl- 1 None None 2-trifluoromethyl- 10

1 ,2,4- 2,3-dihydro-1 H- oxadiazole

imidazo[1 ,2-a]- pyrinnidin-5-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 8-trifluoromethyl- 3-(Oxiran-2- Method-

1 .3 None None 6,7,8,9- yl)pyridine 20

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

Chiral

8-trifluoromethyl- 3-(Oxiran-2- Method- Purifi- None None 6,7,8,9- yl)pyridine 20

cation-18

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 211 EXAMP L E 212 EXAMP L E 213 EXAMP L E 214 EXAMP L E 215 -----

(S)-8-Methyl-2- ((R)-3-methyl-

3-(Chloro- morpholin-4-yl)- methyl)-5- 8-trifluoromethyl- Method- methyl- 1 .1 None None 6,7,8,9- 23

1 ,2,4- tetrahydro- oxadiazole

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 8-trifluoromethyl- 2-(Oxiran-2- Method-

1 .2 None None 6,7,8,9- yl)pyridine, 25

tetrahydro- pyrimido[1 ,2-a]- pyrimidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 8-trifluoromethyl- 2-(Oxiran-2- Method-

1 .2 None None 6,7,8,9- yl)pyridine, 25

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-8-Methyl-2- ((R)-3-methyl-

5-(Chloro- morpholin-4-yl)- methyl)-1 - 8-trifluoromethyl- Method- (difluoro- 1 None None 6,7,8,9- 16

methyl)-1 H- tetrahydro- pyrazole

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-8-Methyl-2- ((R)-3-methyl- morpholin-4-yl)-

3-(Chloro- 8-trifluoronnethyl- Method- methyl)- 1 .2 None None 6,7,8,9- 14

isoxazole

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 216 EXAMP L E 21 EXAMP L E 218 EXAMP L E 219 EXAMP L E 2207 -----

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

4-(Chloro- 8-trifluoromethyl- Method- methyl)- 1 .2 None None 6,7,8,9- 22

pyridine

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

3-(Chloro- 8-trifluoromethyl- Method- methyl)- 1 .2 None None 6,7,8,9- 22

pyridine.HCI

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

2-(Bromo- 8-trifluoromethyl- Method- methyl)- 1 .2 None None 6,7,8,9- 22

pyridine

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 1 -(2-Chloro- 8-trifluoromethyl- ethyl)-4- Method-

1 .2 None None 6,7,8,9- fluoro- 32

tetrahydro- benzene

pyrinnido[1 ,2-a]- pyrimidin-4-one

(S)-2-Chloro-9- (2-pyridin-2-yl- ethyl)-8- trifluoromethyl- (3R)-Methyl- Method-

3 None None

6,7,8,9- morpholine 1

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 221 EXAMP L E 222 EXAMP L E 223 EXAMP L E 224 EXAMP L E 225 -----

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 3-(Chloro- 8-trifluoromethyl- methyl)-2- Method-

1 .2 None None 6,7,8,9- fluoro- 22

tetrahydro- pyridine

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 2-Chloro- 8-trifluoromethyl- N,N- Method-

1 .2 None None 6,7,8,9- dimethyl- 22

tetrahydro- acetamide

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

2-Chloro-N- 8-trifluoromethyl- Method- methyl- 1 .2 None None 6,7,8,9- 22

acetamide

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 2-Chloro- 8-trifluoromethyl- methyl-6- Method-

1 .2 None None 6,7,8,9- fluoro- 22

tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-

4-(Chloro- morpholin-4-yl)- methyl)-2- 8-trifluoromethyl- Method- (propan-2- 1 .2 None None 6,7,8,9- 22

yloxy)- tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrinnidin-4-one

EXAMP L E 230 EXAMP L E 229 E EXAMP L E 228 EXXAMP L E 22 AMP L E 2267 -----

(S)-2-((R)-3- Methyl-

5-(Chloro- morpholin-4-yl)- methyl)-3- 8-trifluoromethyl- Method- isopropyl- 1 .2 None None 6,7,8,9- 14

1 ,2,4- tetrahydro- oxadiazole

pyrimido[1 ,2-a]- pyrimidin-4-one

(S)-2-((R)-3- Methyl-

5-(Chloro- morpholin-4-yl)- methyl)-3- 8-trifluoromethyl- Method- cyclopropyl- 1 .2 None None 6,7,8,9- 14

1 ,2,4- tetrahydro- oxadiazole

pyrimido[1 ,2-a]- pyrimidin-4-one

(S)-2-((R)-3- Methyl-

3-tert-Butyl- morpholin-4-yl)- 5-(chloro- 8-trifluoromethyl- Method- methyl)- 1 .1 None None 6,7,8,9- 14

1 ,2,4- tetrahydro- oxadiazole

pyrimido[1 ,2-a]- pyrimidin-4-one

(S)-2-((R)-3- Methyl-

5-(Chloro- morpholin-4-yl)- methyl)-2- 8-trifluoromethyl- Method- (propan-2- 1 .2 None None 6,7,8,9- 22

yloxy)- tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrimidin-4-one

(S)-2-((R)-3- Methyl-

3-(Chloro- morpholin-4-yl)- methyl)-2- 8-trifluoromethyl- Method- (propan-2- 1 .2 None None 6,7,8,9- 22

yloxy)- tetrahydro- pyridine

pyrinnido[1 ,2-a]- pyrimidin-4-one EXAMP L E 231 EXAMP L E 232 EXAMP L E 233 EXAMP L E 234 EXAMP L E 235 -----

(S)-2-((R)-3- Thiazol-2-yl- Methyl- methyl 4- morpholin-4-yl)- methyl- 8-trifluoromethyl- benzene- Method-

1 .5 None None 6,7,8,9- sulphonate 10

tetrahydro- (ref.

pyrimido[1 ,2-a]- Reagent-2

pyrinnidin-4-one table)

(S)-3-Fluoro-2- Thiazol-2-yl- ((R)-3-methyl- methyl 4- morpholin-4-yl)- methyl- 8-trifluoromethyl- benzene- Method-

1 .5 None None 6,7,8,9- sulphonate 1 1

tetrahydro- (ref.

pyrimido[1 ,2-a]- Reagent-2

pyrinnidin-4-one table)

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

2-Chloro-1 - 8-trifluoromethyl- Method- piperidin-1 - 1 .2 None None 6,7,8,9- 14

ylethanone

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

4-(2-Chloro- 8-trifluoromethyl- Method- acetyl)- 1 .2 None None 6,7,8,9- 14

morpholine

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

4-(2-Chloro- 8-trifluoromethyl- Method- acetyl)- 1 .5 None None 6,7,8,9- 14

morpholine

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 236 EXAMP L E 23 EXAMP L E 238 EXAMP L E 239 EXAMP L E 240 EXAMP L E 2417 ------

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

2-Chloro-N- Chiral

8-trifluoromethyl- Method- phenyl- Purifi- None None 6,7,8,9- 22

acetamide cation-13

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

2-Chloro-1 - Chiral

8-trifluoromethyl- Method- piperidin-1 - 2 Purifi- None None 6,7,8,9- 14

ylethanone cation-14

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-

3-(Chloro- morpholin-4-yl)- methyl)-5- Chiral

8-trifluoromethyl- Method- methyl- Purifi- None None 6,7,8,9- 1 1

1 ,2,4- cation-15

tetrahydro- oxadiazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-8-Methyl-2- ((R)-3-methyl- morpholin-4-yl)-

2-Chloro- Chiral

8-trifluoromethyl- Method- methyl- Purifi- None None 6,7,8,9- 23

oxazole cation-16

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-Methyl-7- ((R)-3-methyl- 3-(Chloro- morpholin-4-yl)- methyl)-5-

Method- 2-trifluoronnethyl- methyl- 1 .2 None None

22

2,3-dihydro-1 H- 1 ,2,4- imidazo[1 ,2-a]- oxadiazole

pyrinnidin-5-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

2-Bromo-1 - 8-trifluoromethyl- Method- cyclopropyl- 1 .1 None None 6,7,8,9- 10

ethanone

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 242 EXAMP L E 243 EXAMP L E 244 EXAMP L E 24 EXAMP L E 2465 -----

2-Chloro-9-(2- oxo-2-thiazol-2- ylethyl)-8- trifluoromethyl- (3R)-Methyl- Method-

4 None None 6,7,8,9- morpholine 1

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

Cyclopentyl

8-trifluoromethyl- Method- 2-bromo- 1 .1 None None 6,7,8,9- 10

acetate

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

2-Bromo-1 - 8-trifluoromethyl- Method- cyclopentyl- 1 .1 None None 6,7,8,9- 10

ethanone

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 2-Bromo-1 - 8-trifluoromethyl- (tetrahydro- Method-

1 .1 None None 6,7,8,9- pyran-4-yl)- 10

tetrahydro- ethanone

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl-

3-(Chloro- morpholin-4-yl)- methyl)-5- 8-trifluoromethyl- Method- isopropyl- 1 .2 None None 6,7,8,9- 13

1 ,2,4- tetrahydro- oxadiazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 24 EXAMP L E 248 EXAMP L E 249 EXAMP L E 20 EXAMP L E 21755 -----

(S)-3-Fluoro-2- ((R)-3-methyl-

3-(Chloro- morpholin-4-yl)- methyl)-5- 8-trifluoromethyl- Method- cyclopropyl- 1 .1 None None 6,7,8,9- 13

1 ,2,4- tetrahydro- oxadiazole

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl-

5-(Chloro- morpholin-4-yl)- methyl)-3- 8-trifluoromethyl- Method- isopropyl- 1 .1 None None 6,7,8,9- 13

1 ,2,4- tetrahydro- oxadiazole

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl-

5-(Chloro- morpholin-4-yl)- methyl)-3- 8-trifluoromethyl- Method- cyclopropyl- 1 .1 None None 6,7,8,9- 15

1 ,2,4- tetrahydro- oxadiazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- 3-(tert- morpholin-4-yl)- Butyl)-5- 8-trifluoromethyl- (chloro- Method-

1 .1 None None 6,7,8,9- methyl)- 15

tetrahydro- 1 ,2,4- pyrinnido[1 ,2-a]- oxadiazole

pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- 5-(Chloro- morpholin-4-yl)- methyl)-3- 8-trifluoromethyl- (trifluoro- Method-

1 .5 None None 6,7,8,9- methyl)- 15

tetrahydro- 1 ,2,4- pyrinnido[1 ,2-a]- oxadiazole

pyrinnidin-4-one EXAMP L E 22 EXAMP L E 23 EXAMP L E 24 EXAMP L E 2 EXAMP L E 26555555 -----

(S)-8-Methyl-2- ((R)-3-methyl- morpholin-4-yl)-

1 -Bromo-3- 8-trifluoromethyl- Method- methyl- 1 .1 None None 6,7,8,9- 10

butan-2-one

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 2-Bromo-1 - 8-trifluoromethyl- (tetrahydro- Method-

1 .2 None None 6,7,8,9- pyran-4-yl)- 10

tetrahydro- ethanone

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

Isopropyl 2- 8-trifluoromethyl- Method- bromo- 1 .1 None None 6,7,8,9- 10

acetate

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 1 -Chloro- 8-trifluoromethyl- 3,3- Method-

1 .1 None None 6,7,8,9- dimethyl- 10

tetrahydro- butan-2-one

pyrinnido[1 ,2-a]- pyrimidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

1 -Chloro- 8-trifluoromethyl- Method- propan-2- 1 .2 None None 6,7,8,9- 10

one

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 2 EXAMP L E 28 EXAMP L E 29 EXAMP L E 260 EXAMP L E 2615755 -----

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 4-(Chloro- 8-trifluoromethyl- methyl)-2- Method-

1 .2 None None 6,7,8,9- fluoro- 10

tetrahydro- pyridine

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

2-Bromo-1 - 8-trifluoronnethyl- Method- cyclohexyl- 1 .1 None None 6,7,8,9- 10

ethanone

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-Chloro-9- pyridazin-4-yl- methyl-8- trifluoromethyl- (3R)-Methyl- Method-

3 None None 6,7,8,9- morpholine 1

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- tert-Butyl 2- 8-trifluoromethyl- Method- bromo- 1 .2 None None 6,7,8,9- 10

acetate

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- tert-Butyl 2- morpholin-4-yl)- (2-chloro- 8-trifluoromethyl- acetyl)- Method-

1 .1 None None 6,7,8,9- pyrrolidine- 10

tetrahydro- 1 - pyrinnido[1 ,2-a]- carboxylate

pyrinnidin-4-one EXAMP L E 262 EXAMP L E 263 EXAMP L E 264 EXAMP L E 26 EXAMP L E 2665 -----

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

Methyl 2- 8-trifluoromethyl- Method- bromo- 1 .1 None None 6,7,8,9- 10

acetate

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 8-trifluoromethyl- 2-Bromo- Method-

1 .2 None None 6,7,8,9- acetamide 10

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 8-trifluoromethyl- 2-Bromo- Method- Method Method- 6,7,8,9- acetamide 10 -56 51 tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- tert-Butyl 4- morpholin-4-yl)- (2-bromo- 8-trifluoromethyl- Method- acetyl)- None None 6,7,8,9- 10

piperidine-1 - tetrahydro- carboxylate

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

1 -Bromo-3- 8-trifluoromethyl- Method- Method

methyl- 1 .2 None 6,7,8,9- 10 -50

butan-2-one

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 26 EXAMP L E 268 EXAMP L E 269 EXAMP L E 20 EXAMP L E 21777 -----

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

1 -Bromo-3- 8-trifluoromethyl- Method- Method- methyl- 1 .2 None

6,7,8,9- 10 50 butan-2-one

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-Chloro-9- [2-(3-methyl- isoxazol-4-yl)-2- oxoethyl]-8-

(3R)-Methyl- Method- trifluoromethyl- 3 None None morpholine 1

6,7,8,9- tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 2-Bromo-1 - 8-trifluoromethyl- (tetrahydro- Method-

1 .2 None None 6,7,8,9- furan-3- 10

tetrahydro- yl)ethanone

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-(8-Oxa-3- azabicyclo-

3-(Chloro- [3.2.1 ]oct-3-yl)- methyl)-5- 8-trifluoromethyl- Method- methyl- 2 None None 6,7,8,9- 10

1 ,2,4- tetrahydro- oxadiazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-(8-Oxa-3- azabicyclo- [3.2.1 ]oct-3-yl)-

2-Bromo-1 - 8-trifluoromethyl- Method- cyclopropyl- 1 .2 None None 6,7,8,9- 10

ethanone

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

EXAMP L E 2 EXAMP L E 28 EXAMP L E 29 EXAMP L E 280 EXAMP L E 2817777 -----

(S)-2-('S)-3- Methyl- morpholin-4-yl)-

1 -Bromo-3- 8-trifluoromethyl- Method- methyl- 1 .5 None None 6,7,8,9- 10

butan-2-one

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- (8-oxa-3-aza- bicyclo[3.2.1 ]oct-

3-yl)-8- 1 -Bromo-3-

Method- trifluoromethyl- methyl- 1 .2 None None

10

6,7,8,9- butan-2-one

tetrahydro- pyrinnido[1 ,2-a]- pyrimidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

1 -Bromo-5- 8-trifluoromethyl- Method- methyl- 1 .1 None None 6,7,8,9- 10

hexan-2-one

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 1 -Bromo-4- 8-trifluoromethyl- methyl- Method-

1 .1 None None 6,7,8,9- pentan-2- 10

tetrahydro- one

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

1 -Bromo-3- 8-trifluoronnethyl- Method- ethylpentan- 1 .2 None None 6,7,8,9- 10

2-one

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 282 EXAMP L E 283 EXAMP L E 284 EXAMP L E 28 EXAMP L E 2865 -----

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

1 -Bromo-3- 8-trifluoromethyl- Method- ethylpentan- 1 .2 None None 6,7,8,9- 10

2-one

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

Methyl 2- 8-trifluoromethyl- Method- bromo- 1 .2 None None 6,7,8,9- 10

acetate

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

Chiral

8-trifluoromethyl- 2-Bromo- Method- PurifiNone None 6,7,8,9- butane 32

cation-^

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

Chiral

8-trifluoromethyl- 2-Bromo- Method- PurifiNone None 6,7,8,9- butane 32

cation^

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

1 -Bromo-3- Chiral

8-trifluoromethyl- Method- Method

methyl- PurifiNone 6,7,8,9- 10 -52

butan-2-one cation^

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 28 EXAMP L E 288 EXAMP L E 289 EXAMP L E 290 EXAMP L E 2917 -----

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

1 -Bromo-3- Chiral

8-trifluoromethyl- Method- Method

methyl- Purifi- None 6,7,8,9- 10 -52

butan-2-one cation-3

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

EX-286 and Chiral

8-trifluoromethyl- Method- Method Method- EX-287 not Purifi6,7,8,9- 10 -52 53 separated cation^

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

EX-286 and Chiral

8-trifluoromethyl- Method- Method Method- EX-287 not Purifi6,7,8,9- 10 -52 53 separated cation^

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

1 -Bromo-5- Chiral

8-trifluoromethyl- Method- methyl- Purifi- None None 6,7,8,9- 10

hexan-2-one cation-8

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 1 -Bromo-3-

Chiral

8-trifluoromethyl- methyl- Method- Purifi- None None 6,7,8,9- pentan-2- 10

cation-9

tetrahydro- one

pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 292 EXAMP L E 293 EXAMP L E 294 EXAMP L E 29 EXAMP L E 2965 -----

(S)-2-((R)-3- Methyl- 5-(Chloro- morpholin-4-yl)- methyl)-3- 8-trifluoromethyl- (trifluoro- Method-

1 .2 None None 6,7,8,9- methyl)- 15

tetrahydro- 1 ,2,4- pyrimido[1 ,2-a]- oxadiazole

pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

Methyl 2- 8-trifluoronnethyl- Method- Method Method- bromo- 1 .1

6,7,8,9- 10 -48 58 acetate

tetrahydro- pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- 2-Bromo-1 - ((R)-3-methyl- (5-methyl- morpholin-4-yl)- isoxazol-3- 8-trifluoromethyl- yl)ethanone Method-

2 None None 6,7,8,9- (preparation 17

tetrahydro- described,

pyrinnido[1 ,2-a]- see table

pyrinnidin-4-one Reagent-5)

(S)-2-((R)-3- Methyl-

2-Fluoro-2- morpholin-4-yl)- phenylethyl Chiral

8-trifluoromethyl- Method- 4-methyl- Purifi- None None 6,7,8,9- 27

benzene- cation-19

tetrahydro- sulphonate

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)-

3-Chloro- 8-trifluoromethyl- Method- methyl)- 1 .2 None None 6,7,8,9- 10

isoxazole

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 29 EXAMP L E 298 EXAMP L E 299 EXAMP L E 300 EXAMP L E 301 EXAMP L E 3027 ------

(S)-3-Fluoro-2- ((R)-3-methyl-

5-(Chloro- morpholin-4-yl)- methyl)-1 - 8-trifluoromethyl- Method- (difluoro- 1 .2 None None 6,7,8,9- 10

methyl)-1 H- tetrahydro- pyrazole

pyrimido[1 ,2-a]- pyrinnidin-4-one

2-Chloro-9- (lsoxazol-3-yl- methyl)-8,8- 3-(R )- Method- dimethyl-6,7,8,9- Methyl- 3 None None

1

tetrahydro- morpholine

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- morpholin-4-yl)- 5-(Bromo- 8-trifluoromethyl- methyl)-3- Method-

1 .5 None None 6,7,8,9- methyl- 10

tetrahydro- isoxazole

pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- 2- morpholin-4-yl)- Isopropoxy- 8-trifluoromethyl- ethyl-4- Method-

3 None None 6,7,8,9- methyl- 24

tetrahydro- benzene- pyrinnido[1 ,2-a]- sulphonate

pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 8-trifluoromethyl- 3-Bromo- Method-

3 None None 6,7,8,9- pyridine 29

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)- 3-Bromo-6- 8-trifluoromethyl- (cyclo- Method-

1 None None 6,7,8,9- propyl)- 29

tetrahydro- pyridine

pyrimido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 303 EXAMP L E 304 EXAMP L E 30 EXAMP L E 306 EXAMP L E 3057 -----

(S)-8-Chloro-1 -

(2-(2- chloropyridin-4-

130°C

yl)-2-oxoethyl)-2- (R)-3- Chiral

microwa

(trifluoromethyl)- Methyl- 2.5 PurifiNone None ves for 2

3,4-dihydro-1 H- morpholine cation^

hours

pyrimido[1 ,2-a]- pyrimidin-6(2H)- one

(S)-8-((R)-3-

Methyl- morpholino)-2-

2-Bromo-1 - (trifluoromethyl)- Method Method

cyclopropyl- 1 .1 None 3,4-dihydro-1 H- 10 -59

ethanone

pyrimido[1 ,2-a]- pyrimidin-6(2H)- one

(S)-8-((R)-3-

Methyl- morpholino)-2-

2-Bromo-1 - (trifluoromethyl)- Method Method

cyclopropyl- 1 .1 None 3,4-dihydro-1 H- 10 -59

ethanone

pyrinnido[1 ,2-a]- pyrimidin-6(2H)- one

(S)-8-((R)-3-

Methyl- morpholino)-2-

2-Bromo-1 - (trifluoromethyl)- Method Method

cyclopropyl- 1 .1 None 3,4-dihydro-1 H- 10 -60

ethanone

pyrinnido[1 ,2-a]- pyrimidin-6(2H)- one

(S)-8-((R)-3-

Methyl- morpholino)-2-

2-Bromo-1 - (trifluoromethyl)- Method Method

cyclopropyl- 1 .1 None 3,4-dihydro-1 H- 10 -60

ethanone

pyrinnido[1 ,2-a]- pyrimidin-6(2H)- one

EXAMP L E 323 EXAMP L E 324 EXAMP L E 32 EXAMP L E 326 EXAMP L E 3257 -----

(S)-2-((R)-3- Methyl-

2-Fluoro-3- morpholin-4-yl)- Chiral

methylbutyl

8-trifluoromethyl- Method- Purifi4-methyl- 1 .2 None None 6,7,8,9- 27 cation - benzene- tetrahydro- 27

sulphonate

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl-

2-Fluoro-3- morpholin-4-yl)- Chiral

methylbutyl

8-trifluoromethyl- Method- Purifi4-methyl- 1 .2 None None 6,7,8,9- 27 cation - benzene- tetrahydro- 27

sulphonate

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- 2- morpholin-4-yl)- Cyclopropyl- Chiral

8-trifluoromethyl- 2-fluoroethyl Method- Purifi¬

1 .2 None None 6,7,8,9- 4-methyl- 27 cation - tetrahydro- benzene- 28

pyrinnido[1 ,2-a]- sulphonate

pyrinnidin-4-one

(S)-2-((R)-3- Methyl- 2- morpholin-4-yl)- Cyclopropyl- Chiral

8-trifluoromethyl- 2-fluoroethyl Method- Purifi¬

1 .2 None None 6,7,8,9- 4-methyl- 27 cation - tetrahydro- benzene- 28

pyrinnido[1 ,2-a]- sulphonate

pyrimidin-4-one

(S)-2-Chloro-8- methyl-9-(2- oxopropyl)-8- trifluoromethyl- 3-(R )- Method- Methyl- 5 None None 6,7,8,9- 1

morpholine

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one EXAMP L E 328 EXAMP L E 329 EXAMP L E 330 EXAMP L E 331 EXAMP L E 332 -----

(S)-3-Fluoro-2- Chiral

((R)-3-methyl- Purifi¬

2-Fluoro-3- morpholin-4-yl)- cation - methylbutyl

8-trifluoromethyl- Method- 29

4-methyl- 1 .2 None None 6,7,8,9- 27

benzene- tetrahydro- sulphonate

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- Chiral

((R)-3-methyl- Purifi¬

2-Fluoro-3- morpholin-4-yl)- cation - methylbutyl

8-trifluoromethyl- Method- 29

4-methyl- 1 .2 None None 6,7,8,9- 27

benzene- tetrahydro- sulphonate

pyrimido[1 ,2-a]- pyrinnidin-4-one

(S)-2-((R)-3- Methyl- morpholin-4-yl)-

Methyl 2- 8-trifluoromethyl- Method- Method Method- bromo- 1 .1

6,7,8,9- 10 -48 58 acetate

tetrahydro- pyrinnido[1 ,2-a]- pyrinnidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- 2- morpholin-4-yl)- Cyclopropyl- Chiral

8-trifluoromethyl- 2-fluoroethyl Method- Purifi¬

1 .3 None None 6,7,8,9- 4-methyl- 27 cation - tetrahydro- benzene 30

pyrinnido[1 ,2-a]- sulphonate

pyrimidin-4-one

(S)-3-Fluoro-2- ((R)-3-methyl- 2- morpholin-4-yl)- Cyclopropyl- Chiral

8-trifluoromethyl- 2-fluoroethyl Method- Purifi¬

1 .3 None None 6,7,8,9- 4-methyl- 27 cation - tetrahydro- benzene- 30

pyrinnido[1 ,2-a]- sulphonate

pyrinnidin-4-one (S)-3-Fluoro-2- c ((R)-3-methyl- co

LLl morpholin-4-yl)-

Methyl 2- 8-trifluoromethyl- Method- Method Method- bromo- 1 .1

6,7,8,9- 10 -48 58

< acetate

X tetrahydro- LU pyrinnido[1 ,2-a]- pyrinnidin-4-one

Experimental section: Table 6: Methods used (Method-1 to Method-45 mentioned

in Tables 4 and 5)

In a suitable reactor, the chosen intermediate of type F is reacted with the selected reagent (see Tables 1 to 5) in the presence or absence of solvent or of cosolvent.

The mixture is tree ted under the conditions specified below.

Method reference Conditions:

Method-1 No Sol vent /100°C

Method-2 No Sol vent /120°C

Method-3 No Sol vent /130°C

Method-4 No Sol vent /150°C/microwaves

Method-5 No Sol vent /170°C/microwaves

Method-6 No Sol vent /210°C

Method-7 No Sol vent /240°C

Method-8 CH3C1 ^/140°C

Method-9 CH3C1 sl/200°C/microwaves

Method-10 CH3C1 ^/Cs2CO3/20°C

Method-1 1 CH3C1 ^/Cs2CO3/80°C

Method-12 CH3C1 ^/Cs2CO3/50°C

Method-13 CH3C1 ^/Cs2CO3/75°C

Method-14 CH3C1 ^/Cs2CO3/100°C

Method-15 CH3C1 sl/Cs2CO3/100°C/ microwaves

Method-16 CH3C1 sl/Cs2CO3/150°C/ microwaves

Method-17 CH3C1 sl/K3PO4/100°C / microwaves

Method-18 CH3C1 ^/K3PO4/120°C (autoclave)

Method-19 CH3C1 ^/DMF/Cs2C03/20°C

Method-20 CH3C1 sl/DMF/Cs2C03/150°C/microwaves

Method-21 DIEA/1 80°C

Method-22 DMF/C ;s2CO3/20°C

Method-23 DMF/C ;s2CO3/80-90°C

Method-24 DMF/C ;s2CO3/120°C

Method-25 DMF/C ;s2CO3/120°C/microwaves

Method-26 DMF/C ;s2CO3/150°C

Method-27 DMF/C ;s2CO3/140°C/microwaves Method-28 DMF/Cs2CO3/150°C/microwaves

Method-29 DMF/K3PO4/Cul/ 150-160°C

Method-30 DMF/K3PO4/160°C

Method-31 DMF/NaH/0°C then 20°C

Method-32 DMF/NaH/0°C then 50°C

Method-33 DMF/Na2CO3/160°C/microwaves

Method-34 DMSO/TEA/20°C

Method-35 DMSO/K3PO4/60°C

Method-36 Me2C0/water/NaOH

Method-37 NMP/180°C

Method-38 NMP/TEA/170°C

Method-39 NMP/DIEA/170-220°C

Method-40 TEA/DMSO/80°C

Method-41 TEA/160°C

Method-42 TEA/185°C

Method-43 THF/Cs2CO3/20°C

Method-44 THF/DEAD/PPh3/20°C

Method-45 THF/DEAD/sup. PPh3/20°C

Methods used for carrying out the conversions required for obtaining the examples from the intermediates of tvoe I

EX-16: In a 25 ml three-necked reactor, under static argon pressure, equipped with an internal thermometer, the intermediate obtained in the previous step (amount and number of equivalents indicated in the table of the examples) is introduced into THF (5 ml). The solution is cooled to -20°C in a dry ice/isopropanol bath. Ethylmagnesium bromide (amount and number of equivalents indicated in the table of the Examples) is

Method- 46 added. After 10 minutes of stirring at -20°C, the cooling bath is withdrawn and the reaction mixture is stirred at ambient temperature for 3 hours. 5 ml of a saturated NH CI solution and 10 ml of EtOAc are added. After separation by settling out, the organic phase is dried over MgSO 4 , filtered, and then concentrated under reduced pressure. The expected compound is isolated. Methods used for carrying out the conversions required for obtaining the examples from the intermediates of tvDe 1

EX-25, 59 & 60: In a dry 10 ml round-bottomed flask, under static argon pressure, the halogenated derivative (amount and number of equivalents indicated in the table of the Examples) is introduced into 2 ml of dry THF and the mixture is cooled to -78°C, then isopropylmagnesium bromide (amount and number of equivalents indicated in the table of the examples) at 2.9 M/THF is added dropwise.

The mixture is left to stir at this temperature for 30 min and then the intermediate (see Table 5) is added, portionwise, and the mixture is left to warm up to AT over a period of 18 h. The reaction mixture is cold- hydrolysed by adding saturated NH 4 CI solution, extracted with EtOAc, dried over MgSO 4 , filtered and evaporated. The compound obtained is purified on a 12 g Varian silica column, elution being carried out with 8 CH 2 CI 2 /2 solution B (38 CH 2 CI 2 /17 MeOH/2 20% NH 4 OH), at a flow rate of 40 ml/min with manual collection. The fractions containing the product are concentrated under reduced pressure. The expected compounds are isolated (see table of the Examples).

THF (2 ml) and the isopropyl magnesium chloride-lithium chloride complex (number of equivalents, see table of the Examples) are introduced into a 10 ml round-bottomed flask, under static argon pressure, and then the mixture is cooled to -15°C and the halogenated derivative (number of equivalents, see table of the Examples) is added dropwise. The reaction mixture is stirred for 30 minutes at -10°C. The intermediate

Method- obtained in the previous step (number of equivalents, see table of the 47

examples) is then added portionwise and the mixture is left to warm up to AT over a period of 18 h. The reaction mixture is cold-hydrolysed by adding saturated NH CI solution, extracted with EtOAc, dried over MgSO 4 , filtered and evaporated. Where appropriate, the compound is purified on chiral phase (Example-70, Chiral Purif ref., see Examples table) or else on a 12 g silica column, elution being carried out with 8 CH2CI2/2 solution B Methods used for carrying out the conversions required for obtaining the examples from the intermediates of tvDe 1

(38 CH 2 CI 2 /17 MeOH/2 20% NH OH), at a flow rate of 40 ml/min with manual collection. The fractions containing the product are concentrated under reduced pressure. The expected compounds are isolated (see table of the Examples) (Example-61 , 63, 67, 68).

The alkyl carboxylate derivative is placed in solution in methanol and then treated with a sodium hydroxide solution until the ester has disappeared.

Method- 48 Subsequent acid-base treatment makes it possible to isolate the acid intermediate which is used in the subsequent step.

The intermediate obtained via the previous reaction (1 eq) is placed in solution in dioxane and a solution of hydrochloric acid in dioxane (4M, 10 eq) is added to the reaction mixture. The reaction mixture is stirred at 20°C until the protective group has been eliminated. The reaction mixture

Method- 49 is poured into water, separated by settling out, and extracted with ethyl acetate. The organic extracts are combined, washed with a saturated sodium chloride solution, dried over magnesium sulphate, filtered, and evaporated under reduced pressure. The expected compound is isolated.

Diethylaminosulphur trifluoro (1 eq) is added to a solution of the intermediate obtained during the previous reaction (200 mg, 1 eq) in dichloromethane at -78°C. After returning to 20°C, the reaction mixture is poured into a solution of NaHCO3, extracted with dichloromethane, dried over magnesium sulphate, and then evaporated to dryness. The

Method- compound obtained is chromatographed on a 15 g (15-40 m) Merck 50

column at a flow rate of 20 ml/min, elution being carried out with isopropyl ether (1 min) and then isopropyl ether/MeOH at 99/01 (2 min), 98/02 (2 min), 95/05 (5 min) and 90/10 (for 10 min). The fractions containing the fluorination compound (Example-266) and also the elimination compound (Example-267) are brought to dryness in a rotary evaporator.

The intermediate obtained by the previous reaction (1 eq, 150 mg) is

Method- 51 treated with hydrazine hydrate (number of equivalents, see table of the Methods used for carrying out the conversions required for obtaining the examples from the intermediates of tvDe 1

Examples) in the presence of acetic acid at 90°C for 2 h. After returning to 20°C, the reaction mixture is brought to dryness; a white solid is obtained, water is added, filtration is carried out, and washing is carried out with a 10% sodium bicarbonate solution and twice with water, drying is carried out under vacuum for 1 h, then washing is carried out with diisopropyl ether, rinsing is carried out once and twice with pentane, and drying is carried out under vacuum overnight. The expected compound is isolated.

The carbonylated derivative is placed in solution in cold methanol, and then sodium borohydride (3 eq) is added. The progression of the reduction is monitored by TLC. After treatment, the mixture of the two

Method- 52 diastereoisomers is obtained, which is separated by chiral-phase chromatography (Example-286 & Example-287) or which is kept as it is and which is used in the next step (see Examples table).

The hydroxylated derivative is placed in solution in THF at 20°C, then treated with sodium hydride (4 eq). After 30 min at ambient temperature,

Method- iodomethane (4 eq) is added. After treatment, a mixture of the 53

diastereoisomers is obtained, and separated by chiral-phase chromatography (Example-288 & Example-289, see Examples table).

In a 25 ml three-necked reactor, the synthesis intermediate previously obtained (number of equivalents, see table of the Examples) is introduced into ethanol and then palladium (number of equivalents, see table of the Examples) is added. The reaction medium is heated to 65°C and then

Method- hydrazine hydrate (number of equivalents, see table of the Examples) is 54

added dropwise. The mixture is kept at this temperature for 30 minutes. After returning to 20°C, the compound obtained is purified by silica chromatography, elution being carried out with 96/04 dichloromethane/MeOH. The expected compound is obtained.

In a 50 ml three-necked reactor, with stirring, 2-chloro-4,6-dimethoxy-

Method- 1 ,3,5-triazine (number of equivalents, see table of the Examples) and the 55

intermediate obtained in the previous step (number of equivalents, see Methods used for carrying out the conversions required for obtaining the examples from the intermediates of tvDe 1

table of the Examples) and also O-methylhydroxylamine hydrochloride (number of equivalents, see table of the Examples) are introduced into acetonitrile (10 ml) and N-methylmorpholine (number of equivalents, see table of the Examples). The suspension is stirred at ambient temperature for 18 hours. 2 ml of water and 20 ml of EtOAc are added. After separation by settling out, the organic phase is dried over MgSO 4 , filtered, and then concentrated under reduced pressure.

The intermediate obtained in the previous reaction (150 mg, 1 eq) is treated with an excess of Ν,Ν-dimethylformamide dimethyl acetal at 1 10°C for 3 hours.

Method- After returning to 20°C, the reaction mixture is poured into 15 ml of water 56 and extracted with 3 χ 15 ml of ethyl acetate. The organic extracts are combined, washed with a saturated sodium chloride solution, dried over magnesium sulphate, filtered, and evaporated under reduced pressure. The expected compound is isolated and is used in the next step.

The intermediate obtained during the previous reaction (1 eq) is placed in solution in dichloromethane and then stirred for 3 h at 20°C. The reaction mixture is poured into a saturated NaHCO3 solution, separated by settling

Method- out and extracted with dichloromethane, and then washed with an 57

Na 2 S 2 O 3 solution. The organic extracts are dried over magnesium sulphate, filtered and evaporated. The expected compound is obtained and is used in the next step.

The carboxylated intermediate is placed in solution in DMF in the presence of 2.2 eq of the amino derivative to be coupled (see table

Method- reference), of hydroxybenzotriazole (2.4 eq), of EDCI (2.4 eq) and of 58

DIPEA (6 eq). The reaction mixture is stirred at 20°C. After treatment, the caboxyamide derivative is isolated. Methods used for carrying out the conversions required for obtaining the examples from the intermediates of tvDe 1

The intermediate obtained during the previous reaction (1 eq) is placed in solution in ethanol in the presence of hydroxylamine hydrochloride (3 eq)

Method- 59 and of triethylamine, and then stirred at 60°C.

Chiral purification -23

The intermediate obtained during the previous reaction (1 eq) is placed in solution in pyridine in the presence of O-methylhydroxyamine

Method- hydrochloride (4 eq) and of triethylamine, and then stirred at 100°C for 60

4 h.

Chiral purification -24

The intermediate obtained during the previous reaction (1 eq) is treated with trimethylsulphoxonium iodide (4 eq) suspended in a mixture of tBuOH

Method- 61 (15 ml) and tBuOK (4 eq) at 50°C for 48 h.

Chiral purification -25

Experimental section: Table 8: Specific preparations of Reagent-1 to Reagent-5 cited in Tables 4 and/or 5

Preparation of sp scific rsagents used in th e syr thesis pathways described above

O> cazol-4-ylmethanol (325 mg,

3.: 18 mmol) is introduced into 10 ml of

Ch H 2 Cl2, the colourless solution is

CO oled to -20°C, and TEA (0.55 ml,

3.< 30 mmol) and p-toluenesulphonyl ch loride (664 mg, 3.41 mmol) are

Reagent-1 pxazol-4-ylmethyl para- gd ded. The cooling bath is withdrawn, a toluene sulphonate ^

5 temperature is allowed to return to

Al and the colourless solution is sti rred for 1 h 00. The reaction rru sdium is concentrated. The int ermediate is used as it is in the ne xt reaction.

1 ( sq of thiazol-2-ylmethanol

Reagent-2 Thiazol-2-ylmethyl para- 58-87-1 ] is treated with 1 .5 eq of a toluenesulphonate j Qe

>yl chloride [98-59-9] in the dichloromethane.

The 2-cyclopropyl-2-fluoroethyl 4- methylbenzenesulphonate is prepared from a solution of 2-cyclopropyl-2-fluoroethanol

(532 mg, 5.1 1 mmol) (prepared as in Bioorganic and Medicinal Chemistry Letters 201 1 , Vol. 21 , 276-279) and p-toluenesulphonyl chloride (1 .25 g, 6.49 mmol) in dichloromethane (15 ml) which is cooled to -10°C in an ice/acetone bath and then treated with triethylamine (907.72 μΙ,

2-Cyclopropyl-2- 6.49 mmol). After 5 min, the cold bath fluoroethyl 4- is removed and the reaction medium

Reagent-9

methylbenzene- is stirred at 20°C for 17 h. The sulphonate reaction medium is diluted with dichloromethane and then the organic phase is washed with water (20 ml) and then dried on a Chromoptic 1ST hydrophobic column. The filtrate is evaporated to dryness. The crude is purified by flash chromatography on a silica gel column (70 g), elution being carried out with 20-80 to 80-20 by volume dichloromethane-pentane. After evaporation of the solvents to dryness, 1 .164 g (88%) of a colourless oil are thus obtained.

Experimental section: Table 9: Chiral-phase purification methods used and cited in

Tables 4 and 5

Prep Colunnn: Cellulose

HPLC 4 5 μηη di=30 mm

x L=250 mm

The 225 mg are

Chiral solubilized in

Purification - 21 ml of mobile EtOH 20-

1=254 nm 45 ml/min 29 (EX-328, phase. 7 injections TEA 0.1

329) in total. 5 I of

solvents.

Prep cell 4

Chiral Prep Column: Chiralpak

Purification - HPLC IC 20 pm Heptane 60 300

1=240 nm

30 (EX-331 , Size: EtOH 40 ml/min

332) 350x76.5 mm

Experimental section: Table 10: Physicochemical characteristics of the examples (RT = retention time, expressed in

minutes)

CL

o

CD

CL

CL

LU

co

00

CL

CL

CL

LU o

Conditions a: the spectra were obtained on a Waters UPLC-SQD apparatus

Ionization: positive and/or negative mode electrospray (ES+/-)

- Chromatographic conditions:

- Column: ACQUITY BEH C18 - 1 .7 Mm - 2.1 x 50 mm

- Solvents: A: H 2 0 (0.1 % formic acid) B: CH 3 CN (0.1 % formic acid)

- Column temperature: 50°C

- Flow rate: 1 ml/min

- Gradient (2 min): from 5% to 50% of B in 0.8 min; 1 .2 min: 100% of B; 1 .85 min: 100% of B; 1 .95: 5% of B

Conditions b: the spectra were obtained on a Waters UPLC-SQD apparatus

Ionization: positive and/or negative mode electrospray (ES+/-)

Chromatographic conditions:

- Column: ACQUITY BEH C18 - 1 .7 Mm - 2.1 x 50 mm

- Solvents: A: H 2 0 (0.1 % formic acid) B: CH 3 CN (0.1 % formic acid)

- Column temperature: 50°C

- Flow rate: 0.8 ml/min

- Gradient (2.5 min): from 5% to 100% of B in 1 .8 min; 2.40 min: 100% of B; 2.45 min: 100% of B; from 100 to 5% of B in 0.05 min

Conditions c: the spectra were obtained on a Waters ZQ apparatus

Ionization: positive and/or negative mode electrospray (ES+/-)

Chromatographic conditions:

- Column: XBridge C18 - 2.5 Mm - 3 x 50 mm

- Solvents: A: H 2 0 (0.1 % formic acid) B: CH 3 CN (0.1 % formic acid)

- Column temperature: 70°C

- Flow rate: 0.9 ml/min

- Gradient (7 min): from 5% to 100% of B in 5.3 min; 5.5 min: 100% of B; 6.3 min: 5% of B Conditions k: the spectra were obtained on a Waters ZQ apparatus

Ionization: positive and/or negative mode electrospray (ES+/-)

Chromatographic conditions:

- Column: XSelect CSH C18 - 3.5 Mm - 3 x 50 mm

- Solvents: A: H 2 0 (0.1 % formic acid) B: CH 3 CN (0.1 % formic acid)

- Column temperature: 55°C

- Flow rate: 1 .3 ml/min

- Gradient (5 min): from 4% to 98% of B in 3.2 min; 3.5 min: 98% of B; 3.8 to 5 min: 4% of B

Conditions I: the spectra were obtained on a Waters XeVo - QTof apparatus

Ionization: positive mode electrospray (ES+)

Chromatographic conditions:

- Column: ACQUITY BEH C8 - 1.7 pm - 2.1 x 100 mm

- Solvents: A: H 2 0 (0.1 % formic acid) B: CH 3 CN (0.1 % formic acid)

- Column temperature: 70°C

- Flow rate: 0.55 ml/min

- Gradient (1 1 min): from 5% to 97% of B in 8.3 min; 8.6 min: 97% of B; 9 min: 5% of B; 1 1 min: 5% of B

Example 334: Pharmaceutical composition

Tablets corresponding to the following formula were prepared:

Product of Example 42 0.2 g Excipient for a tablet with a final weight of 1 g

(details of the excipient: lactose, talc, starch, magnesium stearate).

Example 42 is taken by way of example of a pharmaceutical

preparation, it being possible for this preparation to be carried out, if desired, with other products in examples in the present application.

Pharmacological section: Experimental protocols

Study of the phosphorylation of phosphatidylinositol (PI) by Vps34 in vitro

This test is based on the detection of the ADP produced during the phosphorylation of PI by Vps34 in the presence of ATP. The ADP is detected by TR-FRET (Time resolved - Fluorescence Resonance Energy transfer) using the Transcreener kit sold by Cisbio (HTRF® Transcreener® ADP, reference 62ADPPEB).

The molecules are diluted 3-fold in pure dimethyl sulfoxide (DMSO, Sigma Fluka 41647), and then diluted, in a second step, in 10% DMSO in water. 2 μΙ of molecules are added to 96-well plates (Corning Costar 3694), followed by 8 μΙ of a PI (Sigma P5766) / recombinant Vps34 (Invitrogen PV5126 or produced by Sanofi) mixture in buffer A: 50 mM Hepes, 5 mM MnCI 2 , 0.1 % CHAPS, 2 mM TCEP, pH 7.1 . The reaction is initiated with 10 μΙ of a solution of ATP (Sigma A7699) in buffer A and lasts 1 hour at ambient temperature. The concentrations during the reaction are 1 % DMSO, 10 μΜ ATP, 55 g/ml PI, approximately 3 nM of Vps34 and between 0.51 nM and 10 μΜ for the molecules. The amount of enzyme is adapted to each batch so as to form approximately 2 μΜ of ADP during the reaction. In parallel, a range of ADP and of ATP for calibrating the results is prepared according to the indications of the kit. Controls not containing enzyme (negative control) or not containing molecules (positive control) are also prepared in parallel. The reaction is then blocked and visualised with the transcreener kit using 10 μΙ of each of the two reagents and according to the indications of the kit. The fluorescence emission is detected on a Rubystar instrument at 620 and 665 nm. The signal ratio is calculated by dividing the 665 nm signal by the 620 nm signal and then multiplying by 10 000. The signal ratios are converted into ADP concentration using the calibration range and according to the instructions of the kit. The percentages of inhibition by the molecules are calculated relative to the positive controls according to the formula (1 - signal ratio of the molecule/signal ratio of the positive control) 100. The absolute IC50s (inhibitory concentration which gives 50% inhibition) are calculated according to a 4-parameter logistical model. Two independent experiments make it possible to calculate the mean of the IC50s. The IC50 results, in nM, obtained for the products in examples of the present invention are given in the table below.

Table of pharmacological results obtained by means of the above test